FedInvent™ Patent Applications

Application Details for Thursday, September 01, 2022 

This page was updated on Thursday, September 01, 2022 at 06:09 AM GMT

Department of Health and Human Services (HHS) 

US 20220273184 CLARK et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
APPLICANT(S) Terran Biosciences, Inc. (New York, New York);  The Trustees of Columbia University in the City of New York (New York, New York);  The Research Foundation for Mental Hygiene, Inc. (Menands, New York)
ASSIGNEE(S)
INVENTOR(S) Samuel CLARK (New York, New York);  Guillermo HORGA HERNANDEZ (Brooklyn, New York);  Clifford Mills CASSIDY (Ottawa, Canada);  Kenneth WENGLER (New York, New York)
ABSTRACT A neuromelanin sensitive magnetic resonance imaging (“MRI”) technique, method and computer-accessible medium for measuring the extent of, providing a diagnosis of, monitoring the treatment of, assessing novel treatments for, or determining a prognosis related to Parkinson's disease.
FILED Monday, August 17, 2020
APPL NO 17/636018
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/055 (20130101) Original (OR) Class
A61B 5/4082 (20130101)
A61B 5/4842 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6896 (20130101)
G01N 2800/50 (20130101)

Measuring Electric Variables; Measuring Magnetic Variables
G01R 33/5608 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273187 Rutkove et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Science Foundation (NSF)
APPLICANT(S) Myolex Inc. (Brookline, Massachusetts)
ASSIGNEE(S) Myolex Inc. (Brookline, Massachusetts)
INVENTOR(S) Seward Rutkove (Brookline, Massachusetts);  Elmer C. Lupton (Charlestown, Massachusetts);  Jose L. Bohorquez (Burlingame, California);  Haydn Taylor (Windham, New Hampshire);  Gonzalo Cespedes (Daly City, California);  Cary Liberman (Oakland, California);  Dmitri Khrebtukov (San Francisco, California);  Claudio Cassina (Hollywood, Florida);  Yensy Hall (Pembroke Pines, Florida);  Stanislava Daraskevich (San Francisco, California);  Juan Jaramillo (San Francisco, California)
ABSTRACT A portable device for measuring a bioimpedance-related property of tissue includes a plurality of electrodes arranged in a pattern on a surface and associated software for measuring bio-impedance related data of localized regions of tissue and calculate health-related parameters based on the measured data. These calculated parameters may be representative of muscular health of the localized tissue region.
FILED Sunday, February 13, 2022
APPL NO 17/670478
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/0004 (20130101)
A61B 5/486 (20130101)
A61B 5/0537 (20130101) Original (OR) Class
A61B 5/742 (20130101)
A61B 5/4519 (20130101)
A61B 5/4872 (20130101)
A61B 5/7278 (20130101)
A61B 2560/0425 (20130101)
A61B 2562/043 (20130101)
A61B 2562/0214 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273216 Chen
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORA (Indianapolis, Indiana)
ASSIGNEE(S)
INVENTOR(S) Peng-Sheng Chen (Indianapolis, Indiana)
ABSTRACT System and methods for monitoring and/or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.
FILED Wednesday, May 18, 2022
APPL NO 17/747081
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/05 (20130101)
A61B 5/24 (20210101) Original (OR) Class
A61B 5/725 (20130101)
A61B 5/4029 (20130101)
A61B 5/6877 (20130101)

Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 1/0456 (20130101)
A61N 1/0476 (20130101)
A61N 1/0504 (20130101)
A61N 1/0551 (20130101)
A61N 1/3627 (20130101)
A61N 1/36017 (20130101)
A61N 1/36053 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273253 BOONE et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) John M. BOONE (Folsom, California);  Thomas R. YELLEN-NELSON (Del Mar, California)
ABSTRACT A device and methods for performing a simulated CT biopsy on a region of interest on a patient. The device comprises a gantry (22) configured to mount an x-ray emitter (24) and CT detector (26) on opposing sides of the gantry, a motor (28) rotatably coupled to the gantry such that the gantry rotates horizontally about the region of interest, and a high resolution x-ray detector (172) positioned adjacent the CT detector in between the CT detector and the x-ray emitter.
FILED Tuesday, May 17, 2022
APPL NO 17/746264
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 6/06 (20130101)
A61B 6/12 (20130101)
A61B 6/037 (20130101)
A61B 6/0435 (20130101)
A61B 6/482 (20130101) Original (OR) Class
A61B 6/488 (20130101)
A61B 6/502 (20130101)
A61B 6/584 (20130101)
A61B 6/4417 (20130101)
A61B 8/0825 (20130101)
A61B 8/4416 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273365 Rege et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Arizona Board of Regents on behalf of Arizona State University (Scottsdale, Arizona);  MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (Rochester, Minnesota)
ASSIGNEE(S)
INVENTOR(S) Kaushal Rege (Chandler, Arizona);  Inam Ridha (Tempe, Arizona);  Russell Urie (Tempe, Arizona);  Pelagia Kouloumberis (Paradise Valley, Arizona);  Shelley Noland (Scottsdale, Arizona)
ABSTRACT The present invention provides a method of nerve repair using localized delivery of heat. The method involves localized induction of hyperthermia for end-to-end attachment of severed peripheral nerves by delivering stimulus responsive materials and exposing them to an excitation source under conditions wherein they emit heat. The generation of heat effects the joining of the nerve ends.
FILED Thursday, August 27, 2020
APPL NO 17/637484
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 18/20 (20130101) Original (OR) Class
A61B 2018/00434 (20130101)

Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 24/001 (20130101)
A61L 24/02 (20130101)
A61L 24/0015 (20130101)
A61L 24/0042 (20130101)
A61L 27/047 (20130101)
A61L 27/50 (20130101)
A61L 27/54 (20130101)
A61L 27/58 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273440 BERTASSONI et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Dental and Craniofacial Research (NIDCR)
APPLICANT(S) OREGON HEALTH and SCIENCE UNIVERSITY (Portland, Oregon)
ASSIGNEE(S)
INVENTOR(S) Luiz E. BERTASSONI (Portland, Oregon);  Avathamsa ATHIRASALA (Portland, Oregon);  Anthony TAHAYERI (Portland, Oregon)
ABSTRACT A synthetic tissue-graft scaffold (10) includes one or more nominally identical scaffold cages (12) that are configured to facilitate regrowth of tissue of an organism in and around the scaffold cages. Each scaffold cage comprises a volumetric enclosure (14) bounded by a perforated wall structure (30) that has an interior surface (32) and an exterior surface (34). A first annular inlet (22) and second annular inlet (24) positioned at opposite ends of the enclosure form, respectively, a first conjoining surface (54) and a second conjoining surface (56) that are configured so that confronting conjoining surfaces form complementary surfaces to each other. A perforated platform (60) is bounded by the interior surface of the enclosure and provides passageways (62) within the interior chamber. Corridors (40) extend through the perforated wall structure and communicate with the passageways to enable migration of material within and out of the cage.
FILED Thursday, January 30, 2020
APPL NO 17/597818
CURRENT CPC
Filters Implantable into Blood Vessels; Prostheses; Devices Providing Patency To, or Preventing Collapsing Of, Tubular Structures of the Body, e.g Stents; Orthopaedic, Nursing or Contraceptive Devices; Fomentation; Treatment or Protection of Eyes or Ears; Bandages, Dressings or Absorbent Pads; First-aid Kits
A61F 2/2846 (20130101) Original (OR) Class
A61F 2002/30985 (20130101)

Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 27/12 (20130101)
A61L 27/52 (20130101)
A61L 27/54 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273586 KIM et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Nursing Research (NINR)
APPLICANT(S) KENT STATE UNIVERSITY (Kent, Ohio)
ASSIGNEE(S)
INVENTOR(S) Min-Ho KIM (Hudson, Ohio);  Songping D. HUANG (KENT, Ohio);  Ronghui SONG (Pittsburgh, Pennsylvania);  Bing YU (Chesterbrook, Pennsylvania)
ABSTRACT Naphthoquinone derivatives of Lawsone have been found to be effective against Staphylococcus aureus and methicillin resistant Staphylococcus aureus (MRSA). Such compounds generally contain a substituent group at the 3-position of a specific naphthoquinone compound, i.e. 2-hydroxy-1,4-naphthoquinone. One of these derivatives referred to as compound 6c in the series exhibits potent antimicrobial activity that is comparable to that of the two commercial antibiotics ofloxacin and ciprofloxacin against the two strains of methicillin sensitive Staphylococcus aureus (MSSA; ATCC 29213 and ATCC 6538). In the case of two strains of MRSA (ATCC BAA-44 and ATCC BAA-1717) that have developed drug resistance to both ofloxacin and ciprofloxacin, the antimicrobial activity of 6c can almost rival that of vancomycin and daptomycin. Furthermore, 6c is also effective against vancomycin-intermediate and daptomycin non-susceptible strain of MRSA (ATCC 700699). Besides the efficacy, 6c has a much improved drug resistance profile in comparison with the conventional antibiotics.
FILED Wednesday, August 26, 2020
APPL NO 17/637581
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/122 (20130101) Original (OR) Class
A61K 31/431 (20130101)
A61K 31/496 (20130101)
A61K 31/5383 (20130101)
A61K 38/14 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/04 (20180101)

Acyclic or Carbocyclic Compounds
C07C 45/74 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273589 Richmond et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
APPLICANT(S) University of Massachusetts (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Jillian M. Richmond (Dayville, Connecticut);  John E. Harris (Sterling, Massachusetts);  James Pennock Strassner (Worcester, Massachusetts)
ABSTRACT Methods of diagnosing and treating vitiligo.
FILED Wednesday, February 09, 2022
APPL NO 17/667699
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/137 (20130101) Original (OR) Class
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 17/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273599 Kaplan
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
APPLICANT(S) UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Daniel H. Kaplan (Pittsburgh, Pennsylvania)
ABSTRACT Provided herein are methods of treating conditions associated with activation or over-activation of mast cells is acute or chronic urticaria, mastocytosis or any subtype of mastocytosis, pseudo-allergy, any form of dermatitis, such as contact or atopic dermatitis, wound healing, rosacea, acne, or psoriasis, food allergy, or irritable bowel syndrome. The method comprises administering a MRGPRD agonist, such as beta alanine, GABA, β-AIBA, or 5-oxoETE to a patient to treat the condition. Topical, enteric, delayed-release, or aerosol dosage forms comprising beta-alanine also are provided.
FILED Thursday, August 27, 2020
APPL NO 17/637951
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/198 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 17/02 (20180101)
A61P 17/04 (20180101)
A61P 17/06 (20180101)
A61P 17/10 (20180101)
A61P 29/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273606 Song et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Emory University (Atlanta, Georgia)
ASSIGNEE(S)
INVENTOR(S) Jie Song (Atlanta, Georgia);  Shuming Nie (Atlanta, Georgia);  Craig Hill (Atlanta, Georgia)
ABSTRACT The disclosure relates polyoxometalate complexes and uses in the management, treatment, or prevention of cancer. In certain embodiments, the polyoxometalate complexes comprise polydentate oxygen bridging ligands such as those of the following formula: [POM{(OCH2)3CX}2], [M6O13{(OCH2)3CX}2], [V6O13{(OCH2)3CX}2], salts, or derivatives thereof wherein POM is a polyoxometalate, M is a metal, and X is defined herein. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising polyoxometalate complexes disclosed herein.
FILED Friday, May 13, 2022
APPL NO 17/744369
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/28 (20130101) Original (OR) Class
A61K 31/282 (20130101)
A61K 33/243 (20190101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form
B32B 21/02 (20130101)

Acyclic or Carbocyclic Compounds
C07C 229/00 (20130101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 5/02 (20130101)
C09D 5/08 (20130101)
C09D 7/65 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273608 Stains et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) Joseph Stains (Laurel, Maryland);  Christopher Ward (Baltimore, Maryland);  James Lyons (York, Pennsylvania)
ASSIGNEE(S) University of Maryland, Baltimore (Baltimore, Maryland)
INVENTOR(S) Joseph Stains (Laurel, Maryland);  Christopher Ward (Baltimore, Maryland);  James Lyons (York, Pennsylvania)
ABSTRACT Provided herein are methods for treating a bone-related disorder in a subject. At least one of a microtubule altering drug, for example, a microtubule disrupting drug or a microtubule stabilizing drug, a TRPV4 agonist or a NOX2 activator is administered to the subject. Also provided are related methods for treating a bone-related disorder in the subject by further administering at least one of an anti-sclerostin agent, a parathyroid hormone agonist, a bisphosphonate, an estrogen mimic, or a selective estrogen receptor modulator with the at least one of a microtubule altering drug, a TRPV4 agonist or a NOX2 activator.
FILED Monday, May 16, 2022
APPL NO 17/745556
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/165 (20130101)
A61K 31/337 (20130101) Original (OR) Class
A61K 39/3955 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 19/08 (20180101)

Peptides
C07K 16/22 (20130101)
C07K 2317/24 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273625 HAASS-KOFFLER
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
APPLICANT(S) Brown University (Providence, Rhode Island)
ASSIGNEE(S)
INVENTOR(S) Carolina L. HAASS-KOFFLER (Providence, Rhode Island)
ABSTRACT Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP (10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP (27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP (10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF, a cell-based assay was miniaturized, wherein CRFBP (10 kD) was fused as a chimera with CRF, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules. This resulted in the identification of negative allosteric modulators (NAMs) of the CRFBP (10 kD)-CRF2 complex that blunt CRF-induced potentiation of N-Methyl-D-aspartic acid receptor (NMDAR)-mediated synaptic transmission in dopamine neurons in the ventral tegmental area (VTA). These results provide the first evidence of specific roles for CRF2 and CRFBP in the modulation of neuronal activity and suggest that NMDARs in the VTA may be a target for the treatment of stress and substance abuse disorders such as alcohol use disorder.
FILED Friday, March 18, 2022
APPL NO 17/698814
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/517 (20130101)
A61K 31/4245 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273661 MEZZAROMA et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) PTC Therapeutics MP, Inc. (South Plainfield, New Jersey);  Virginia Commonwealth University (Richmond, Virginia)
ASSIGNEE(S)
INVENTOR(S) Eleonora MEZZAROMA (Glen Allen, Virginia);  Christopher RABENDER (Chesterfield, Virginia);  Ross MIKKELSEN (Richmond, Virginia);  Vasily YAKOVLEV (Richmond, Virginia);  Neil SMITH (Cary, North Carolina)
ABSTRACT The invention provides methods for treating radiation exposure in a subject by administering sepiapterin, tetrahydrobiopterin, or dihydrobiopterin.
FILED Wednesday, August 05, 2020
APPL NO 17/631995
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/519 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 39/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273665 MCGOVERN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) CEDARS-SINAI MEDICAL CENTER (Los Angeles, California)
ASSIGNEE(S)
INVENTOR(S) Dermot MCGOVERN (Los Angeles, California);  Dalin LI (Los Angeles, California);  Janine BILSBOROUGH (Los Angeles, California)
ABSTRACT Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis in a subject, with an antagonist of RIPK2 activity or expression. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with the antagonist to RIPK2 activity or expression, as described herein.
FILED Thursday, June 24, 2021
APPL NO 17/357625
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/44 (20130101)
A61K 31/517 (20130101)
A61K 31/5025 (20130101)
A61K 31/5377 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 1/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273674 DORMER et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Deafness and Other Communication Disorders (NIDCD)
APPLICANT(S) Adare Pharmaceuticals USA Inc. (Lawrenceville, New Jersey)
ASSIGNEE(S)
INVENTOR(S) Nathan DORMER (Mission, Kansas);  Cory BERKLAND (Lawrence, Kansas)
ABSTRACT An extended-release drug delivery composition and method of administering the same is provided. The composition comprises microspheres loaded with a biologically-active agent and suspended in a soluble polymer capable of forming a film upon injection onto a biological surface.
FILED Monday, May 16, 2022
APPL NO 17/744932
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/10 (20130101)
A61K 9/0019 (20130101)
A61K 9/0046 (20130101)
A61K 9/1635 (20130101)
A61K 9/1647 (20130101)
A61K 31/43 (20130101)
A61K 31/573 (20130101) Original (OR) Class
A61K 31/711 (20130101)
A61K 31/713 (20130101)
A61K 38/38 (20130101)
A61K 47/10 (20130101)
A61K 47/26 (20130101)
A61K 47/32 (20130101)
A61K 47/38 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273679 Lu et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of General Medical Sciences (NIGMS)
NIH Office of the Director (NIHOD)
APPLICANT(S) New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special S (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Theresa T. Lu (New York, New York);  Carl Blobel (Eastchester, New York)
ABSTRACT A method and/or composition for treating or suppressing ultraviolet radiation sensitivity in a subject in need thereof. The method involves in one embodiment, administering a therapeutically effective amount of an agent which activates or increases the expression or activity of ADAM 17, or activates or increase the release of EGFR ligands, or increases epidermal EGFR in the subject's Langerhans cells. Compositions can include topical ointments, sunscreens, creams and sprays for topical application to the skin. These methods and compositions are useful particularly for patients with systemic lupus erythematosus, among other inflammatory skin conditions.
FILED Friday, July 31, 2020
APPL NO 17/631793
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0014 (20130101)
A61K 31/661 (20130101) Original (OR) Class
A61K 38/191 (20130101)
A61K 38/465 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 17/16 (20180101)

Enzymes
C12Y 301/01032 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273680 Scott
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
APPLICANT(S) Thompson Scott (Baltimore, Maryland)
ASSIGNEE(S) University of Maryland, Baltimore (Baltimore, Maryland)
INVENTOR(S) Thompson Scott (Baltimore, Maryland)
ABSTRACT Provided herein are methods for preventing or treating a psychological disorder. A serotonin agonist or an agonist of serotonin receptors is administered separately, sequentially or simultaneously in combination with a serotonin receptor 2A antagonist.
FILED Thursday, August 13, 2020
APPL NO 17/634729
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/36 (20130101)
A61K 31/517 (20130101)
A61K 31/675 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273681 VOELKER
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) National Jewish Health (Denver, Colorado)
ASSIGNEE(S)
INVENTOR(S) Dennis R. VOELKER (Littleton, Colorado)
ABSTRACT The invention generally relates to methods to prevent and/or inhibit viral infection as well as to inhibit inflammation and/or pathogen infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual.
FILED Thursday, February 10, 2022
APPL NO 17/669107
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0043 (20130101)
A61K 31/683 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/14 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273684 Attardi et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Board of Trustees of the Leland Stanford Junior University (Stanford, California)
ASSIGNEE(S) The Board of Trustees of the Leland Stanford Junior University (Stanford, California)
INVENTOR(S) Laura D. Attardi (Stanford, California);  Christina Curtis (Stanford, California);  Brittany M. Flowers (Stanford, California);  Hang Xu (Stanford, California);  Jose A. Seoane Fernandez (L'Hospitalet de Llobregat, Spain)
ABSTRACT Embodiments herein describe systems and methods to identify and treat pancreatic ductal adenocarcinoma (PDAC) based on cell of origin. Various embodiments comprise assessing transcriptomic data to identify gene expression profiles for the cancer. Based on type of cancer, additional embodiments treat individuals for PDAC. Further embodiments identify possible treatments for a PDAC tumor, by screening effective treatments, including drugs.
FILED Tuesday, March 01, 2022
APPL NO 17/653114
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/433 (20130101)
A61K 31/519 (20130101)
A61K 31/7004 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0693 (20130101)
C12N 2503/02 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6874 (20130101)
C12Q 1/6886 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5008 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273694 GONZALEZ et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Eye Institute (NEI)
APPLICANT(S) Duke University (Durham, North Carolina)
ASSIGNEE(S) Duke University (Durham, North Carolina)
INVENTOR(S) Pedro GONZALEZ (Durham, North Carolina);  Coralia C. LUNA (Durham, North Carolina)
ABSTRACT Provided herein are methods and compositions for decreasing intraocular pressure in a subject. Also provided are methods and compositions for treating or preventing glaucoma.
FILED Friday, August 07, 2020
APPL NO 17/633024
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/711 (20130101)
A61K 31/7105 (20130101) Original (OR) Class
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 27/02 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101)
C12N 2310/113 (20130101)
C12N 2310/141 (20130101)
C12N 2320/32 (20130101)
C12N 2710/10343 (20130101)
C12N 2740/16043 (20130101)
C12N 2750/14143 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273697 Machielse et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) Mandos LLC (West Hollywood, California)
ASSIGNEE(S)
INVENTOR(S) Bernardus Nicolaas Machielse (North Potomac, Maryland);  Allan Darling (North Potomac, Maryland)
ABSTRACT This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
FILED Monday, May 16, 2022
APPL NO 17/745470
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/08 (20130101)
A61K 9/0019 (20130101)
A61K 9/0085 (20130101)
A61K 31/724 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273703 Schopfer et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) University Of Pittsburgh-Of The Commonwealth System Of Higher Education (Pittsburgh, Pennsylvania)
ASSIGNEE(S) University Of Pittsburgh-Of The Commonwealth System Of Higher Education (Pittsburgh, Pennsylvania)
INVENTOR(S) Francisco J. Schopfer (Pittsburgh, Pennsylvania);  Dario A. Vitturi Iglesias (Pittsburgh, Pennsylvania);  Soma Jobbagy (Boston, Massachusetts)
ABSTRACT Disclosed is a method for treating or preventing nephrogenic diabetes insipidus (NDI) in a subject that includes administering to the subject a therapeutically effective amount of a Nuclear factor-erythroid 2-related factor 2 (Nrf2) inducer, thereby treating or preventing the NDI in the subject. The Nrf2 inducer may be a fumarate, a nitro fatty acid, a bardoxolone or sulforaphane. Also disclosed is a pharmaceutical composition comprising (i) a Nuclear factor-crythroid 2-related factor 2 (Nrf2) inducer and (ii) lithium or a lithium salt.
FILED Wednesday, July 22, 2020
APPL NO 17/628695
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 33/14 (20130101) Original (OR) Class
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 7/12 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273711 BOYKEN et al.
FUNDED BY
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) University of Washington (Seattle, Washington)
ASSIGNEE(S)
INVENTOR(S) Scott BOYKEN (Seattle, Washington);  Marc Joseph LAJOIE (Seattle, Washington);  Robert A. LANGAN (Seattle, Washington);  David BAKER (Seattle, Washington);  Jilliane Ruth BRUFFEY (Seattle, Washington)
ABSTRACT Disclosed am protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called die key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain only when the protein switch components are co-localized when bound to their targets, components of such protein switches, and their use.
FILED Monday, May 18, 2020
APPL NO 17/609972
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101) Original (OR) Class

Peptides
C07K 16/18 (20130101)
C07K 2319/00 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/62 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273714 OKADA et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Hideho OKADA (Oakland, California);  Diego A. CARRERA (Oakland, California);  Hirokazu OGINO (Oakland, California)
ABSTRACT The present disclosure relates to T-cell receptors (TCRs) and related antigen-binding constructs that selectively target a tumor-specific isoform of human RAD54 Homolog B (RAD 54B). Further disclosed are the antigen-binding constructs specific for binding the peptide in a peptide/MHC complex, as well as the sequences of complementary determining regions of the TCRs.
FILED Friday, July 17, 2020
APPL NO 17/628383
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Peptides
C07K 14/7051 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273724 MOSKOWITZ et al.
FUNDED BY
Department of Health and Human Services (HHS)
Assistant Secretary for Preparedness and Response (ASPR)
Biomedical Advanced Research and Development Authority (BARDA)
APPLICANT(S) CELLPHIRE INC. (Rockville, Maryland)
ASSIGNEE(S) CELLPHIRE INC. (Rockville, Maryland)
INVENTOR(S) Keith Andrew MOSKOWITZ (Westfield, Indiana);  Braden Carl ISHLER (Gaithersburg, Maryland);  William Matthew DICKERSON (Washington, District of Columbia);  Narendra Nath TANDON (Gaithersburg, Maryland);  Amber Nicole LEE (Rockville, Maryland);  Stephon Edward AMOS (Buckeystown, Maryland);  Rafael JORDA (Merignac, France);  Michael Alexander MATHEWS (Arlington, Virginia)
ABSTRACT Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
FILED Thursday, February 17, 2022
APPL NO 17/674770
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/19 (20130101)
A61K 35/19 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 7/04 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273728 GOLDMAN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) UNIVERSITY OF ROCHESTER (Rochester, New York)
ASSIGNEE(S)
INVENTOR(S) Steven GOLDMAN (Webster, New York);  Fraser J. SIM (Buffalo, New York)
ABSTRACT The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.
FILED Monday, May 09, 2022
APPL NO 17/740126
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/12 (20130101)
A61K 35/30 (20130101) Original (OR) Class

Peptides
C07K 14/70596 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0622 (20130101)
C12N 5/0623 (20130101)
C12N 9/1276 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5058 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273729 Marban et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) Cedars-Sinai Medical Center (Los Angeles, California)
ASSIGNEE(S)
INVENTOR(S) Eduardo Marban (Santa Monica, California);  Eugenio Cingolani (Marina Del Rey, California);  James Dawkins (Los Angeles, California)
ABSTRACT Described herein are compositions and methods related to use of exosomes, including cardiosphere derived cell (CDC)-derived exosomes for treatment and prevention of heart related disease and conditions, such as ventral arrhythmias, such as tachycardias. CDC-derived exosomes delivered by endocardial injection can diminish the total amount of isolated late potentials associated with an isthmus of slow conduction, while reducing the isoelectric interval between late abnormal ventricular activity and decreasing the incidence of inducible ventricular arrhythmias, thereby providing a biological treatment for arrhythmias which otherwise requires therapeutic interventions with adverse effects.
FILED Thursday, May 19, 2022
APPL NO 17/748992
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0019 (20130101)
A61K 35/12 (20130101)
A61K 35/34 (20130101) Original (OR) Class

Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 1/3956 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 9/06 (20180101)
A61P 9/10 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273732 MAZMANIAN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
APPLICANT(S) California Institute of Technology (Pasadena, California)
ASSIGNEE(S)
INVENTOR(S) Sarkis K MAZMANIAN (Pasadena, California);  Wen-Li WU (Pasadena, California);  Mark D ADAME (Pasadena, California);  Brittany NEEDHAM (Pasadena, California)
ABSTRACT Some embodiments include bacterial species for use in treatment of social behavioral deficit symptoms in a subject in need thereof. The bacterial species can include Enterococcus faecalis. Upon treatment, one or more symptoms of behavioral deficit can be improved in the subject.
FILED Thursday, February 24, 2022
APPL NO 17/652464
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/14546 (20130101)

Preparations for Medical, Dental, or Toilet Purposes
A61K 31/567 (20130101)
A61K 35/744 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273740 Borad et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Mayo Foundation for Medical Education and Research (Rochester, Minnesota)
ASSIGNEE(S)
INVENTOR(S) Mitesh J. Borad (85281-5063, Arizona);  Bolni M. Nagalo (Tempe, Arizona)
ABSTRACT The disclosure provides methods and materials for treating cancer. Specifically, the disclosure provides a chimeric vesiculovirus comprising: (a) a first genomic fragment of a first vesiculovirus species; and (b) a second genomic fragment of a second vesiculovirus species different from said first vesiculovirus species; wherein the vesiculovirus species comprising vesicular stomatitis viruses (VSVs) and morreton Virus (MorV). Further disclosed are methods of using chimeric vesiculoviruses as oncolytic agents for treating cancer.
FILED Friday, August 14, 2020
APPL NO 17/635161
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/766 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 2760/20221 (20130101)
C12N 2760/20232 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273742 LI
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) JUN LI (MIAMI, Florida)
ASSIGNEE(S) THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (MIAMI, Florida)
INVENTOR(S) JUN LI (MIAMI, Florida)
ABSTRACT The subject invention provides fungal extracts, fungal metabolites, pharmaceutical compositions comprising the fungal extracts, and/or fungal metabolites, methods of preparation, and therapeutic uses thereof. The subject invention also provides a bioactive agent and a composition comprising the bioactive agent, and therapeutic uses thereof. The subject invention further provides methods for treating, inhibiting and/or preventing malaria infection and transmission by using the fungal extracts, fungal metabolites, bioactive agents, and pharmaceutical compositions comprising the fungal extracts, fungal metabolites, and/or bioactive agent.
FILED Thursday, February 24, 2022
APPL NO 17/679355
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/366 (20130101)
A61K 36/062 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 33/06 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273768 MENDELOWITZ et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) The George Washington University (Washington, District of Columbia);  Johns Hopkins University, School of Medicine (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) David MENDELOWITZ (Vienna, Virginia);  Vsevolod POLOTSKY (Pikesville, Maryland);  Carla FREIRE (Baltimore, Maryland)
ABSTRACT The present disclosure generally relates to compositions and methods of treating opioid-induced respiratory depression in a subject in need thereof, the method comprising administering leptin.
FILED Wednesday, May 18, 2022
APPL NO 17/747905
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/2264 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 11/00 (20180101)
A61P 25/04 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273778 Miller et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) NORTHWESTERN UNIVERSITY (Evanston, Illinois);  MYELIN REPAIR FOUNDATION, INC. (Saratoga, California)
ASSIGNEE(S)
INVENTOR(S) Stephen D. Miller (Evanston, Illinois);  Michael A. Pleiss (Sunnyvale, California);  Daniel R. Getts (Northbrook, Illinois);  Aaron Martin (Evanston, Illinois)
ABSTRACT The present invention provides compositions and methods for inducing antigen-specific tolerance in a subject. In one embodiment, the present invention provides a composition comprising an apoptotic body and an epitope of an antigen. Also provided herein are methods of preparing and administering the composition. The composition and methods provided herein can induce antigen-specific tolerance in a subject.
FILED Monday, November 22, 2021
APPL NO 17/532688
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/1709 (20130101)
A61K 38/1761 (20130101)
A61K 38/1841 (20130101)
A61K 38/2013 (20130101)
A61K 38/2066 (20130101)
A61K 39/001 (20130101) Original (OR) Class
A61K 39/0008 (20130101)
A61K 39/35 (20130101)
A61K 47/646 (20170801)
A61K 47/6901 (20170801)
A61K 47/6933 (20170801)
A61K 47/6937 (20170801)
A61K 2035/122 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0006 (20130101)
C12N 5/0648 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273810 Lu et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) IMCARE BIOTECH, LLC (Doylestown, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Xuanyong Lu (Horsham, Pennsylvania);  Felix Lu (Burbank, California)
ABSTRACT Anti-AS-SPIK antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to diagnose and/or treat disorders characterized by the expression of AS-SPIK (e.g., liver cancer). Diagnostic methods and kits comprising the anti-AS-SPIK antibodies are also disclosed.
FILED Wednesday, July 08, 2020
APPL NO 17/625693
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/542 (20170801)
A61K 47/6817 (20170801)
A61K 47/6843 (20170801) Original (OR) Class

Peptides
C07K 16/38 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6893 (20130101)
G01N 2333/811 (20130101)
G01N 2800/50 (20130101)
G01N 2800/085 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273824 Ahrens et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Eric T. Ahrens (Encinitas, California);  Dina Hingorani (San Diego, California);  Stephen Adams (Poway, California)
ABSTRACT This disclosure provides compositions of fluorinated nanoemulsions and associated methods for producing cellular labels for tracking cells by magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and related methods.
FILED Thursday, August 06, 2020
APPL NO 17/630286
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 6/032 (20130101)
A61B 6/5235 (20130101)

Preparations for Medical, Dental, or Toilet Purposes
A61K 49/0032 (20130101)
A61K 49/0078 (20130101) Original (OR) Class
A61K 49/1806 (20130101)

Peptides
C07K 14/16 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273828 Frank et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) IGL Pharma Inc. (Angleton, Texas)
ASSIGNEE(S) IGL Pharma Inc. (Angelton, Texas)
INVENTOR(S) R. Keith Frank (Lake Jackson, Texas);  Jaime Simon (Angleton, Texas);  Kelli R. Jay (Brazoria, Texas)
ABSTRACT This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.
FILED Saturday, May 21, 2022
APPL NO 17/750333
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/19 (20130101)
A61K 47/02 (20130101)
A61K 51/0482 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273829 Hammoud et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland)
ASSIGNEE(S) THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland)
INVENTOR(S) Dima A. Hammoud (Bethesda, Maryland);  Rolf Eric Swenson (Rockville, Maryland);  Xiang Zhang (Bethesda, Maryland);  Swati Shah (Bethesda, Maryland);  Peter R. Williamson (Bethesda, Maryland);  Zhen-Dan Shi (Rockville, Maryland)
ABSTRACT Disclosed herein are compounds having a structure according to Formula I and optionally Formula IV. The compounds may be radiolabeled compounds useful for diagnosis and/or imaging fungal infections. In such embodiments, at least one substituent is a radionuclide, such as 18F. Also disclosed are precursor compounds according to Formula I and/or IV that are useful for making the radiolabeled compounds. In such embodiments, the precursor compound comprises at least one leaving group suitable for introducing a radionuclide, such as 18F, at a desired position. Also disclosed are methods for making and using the compounds, including embodiments of a method for imaging and/or diagnosing a fungal infection in a subject.
FILED Friday, July 31, 2020
APPL NO 17/631600
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 51/0491 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/10 (20180101)

General Methods of Organic Chemistry; Apparatus Therefor
C07B 59/005 (20130101)
C07B 2200/05 (20130101)

Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids
C07H 5/02 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273834 Atreya et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) The United States of America, as represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland);  The University of Strathclyde (Glasgow, United Kingdom)
ASSIGNEE(S) The United States of America, as represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland);  The University of Strathclyde (Glasgow, United Kingdom)
INVENTOR(S) Chintamani Atreya (Bethesda, Maryland);  Michelle Maclean (Renfrewshire, United Kingdom);  John G. Anderson (Glasgow, United Kingdom);  Scott J. MacGregor (Glasgow, United Kingdom)
ABSTRACT Disclosed herein are methods and devices for the inactivation of pathogens (e.g., bacteria, viruses, etc.) in ex vivo stored blood products, such as plasma and/or platelets, by means of directing visible light radiation from an illuminating device into blood product storage containers in order to achieve effective pathogen inactivation without the presence of an added photosensitising agent in the blood product. An exemplary apparatus includes a control unit that operates a light source that emits light in the wavelength region of about 380-500 nm which is directed onto blood product storage bags at sufficient intensity to penetrate the bag material and the opaque blood product therein in order to inactivate pathogens in the blood product but at dose levels that cause no significant detrimental effects on the blood product.
FILED Friday, May 20, 2022
APPL NO 17/750108
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 2/0052 (20130101) Original (OR) Class
A61L 2/084 (20130101)
A61L 2202/22 (20130101)
A61L 2202/122 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273874 BRETON et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
National Center for Research Resources (NCRR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) University of Virginia Patent Foundation (Charlottesville, Virginia)
ASSIGNEE(S)
INVENTOR(S) Marc D. BRETON (Charlottesville, Virginia);  Patricio COLMEGNA (Charlottesville, Virginia)
ABSTRACT Provided are a method, system and computer-readable storage medium for fully-automated artificial pancreas (AP) control aimed at minimizing and/or preventing occurrence of hyperglycemia following an unannounced meal. Such control is modulated relative to a utilized insulin, the absorption level of which is basis for the control's aggressiveness in administering insulin. In this way, the control can, for increasing levels of absorption, be increasingly aggressive and thus avoid instances of hyperglycemia and hypoglycemia.
FILED Thursday, February 24, 2022
APPL NO 17/679265
CURRENT CPC
Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 5/1723 (20130101) Original (OR) Class
A61M 2230/201 (20130101)

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 20/17 (20180101)
G16H 40/63 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273929 Konofagou
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, New York)
ASSIGNEE(S) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, New York)
INVENTOR(S) Elisa E. Konofagou (New York, New York)
ABSTRACT The present subject matter relates to techniques for opening target tissue. The disclosed system can include a navigation guidance device configured to locate and/or monitor the target tissue, a single-element transducer for stimulating the target tissue with focused ultrasound (FUS), and a processor configured to determine a cavitation mode. The navigation guidance device can include a cavitation detector and an arm. The single-element transducer can be attached to the arm and be configured to induce the FUS with a predetermined parameter to open the target tissue.
FILED Thursday, April 21, 2022
APPL NO 17/726193
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 8/481 (20130101)

Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 37/0092 (20130101) Original (OR) Class

Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 2007/0039 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274101 Lasalde-Dominicci et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) UNIVERSITY OF PUERTO RICO (San Juan, Puerto Rico)
ASSIGNEE(S)
INVENTOR(S) Jose Lasalde-Dominicci (San Juan, Puerto Rico);  Orestes Quesada-Gonzalez (Canovanas, Puerto Rico);  Josue Rodriguez-Cordero (Carolina, Puerto Rico);  Carlos Baez-Pagan (Carolina, Puerto Rico);  Martin MONTOYA-ZAVALA (San Juan, Puerto Rico)
ABSTRACT The invention is a high-throughput voltage screening crystallographic device and methodology that uses multiple micro wells and electric circuits capable of assaying different crystallization condition for the same or different proteins of interest at the same of different voltages under a humidity and temperature controlled environment. The protein is solubilized in a lipid matrix similar to the lipid composition of the protein in the native environment to ensure stability of the protein during crystallization. The invention provides a system and method where the protein is transferred to a lipid matrix that holds a resting membrane potential, which reduces the degree of conformational freedom of the protein. The invention overcomes the majority of the difficulties associated with vapor diffusion techniques and essentially reconstitutes the protein in its native lipid environment under “cuasi” physiological conditions.
FILED Wednesday, May 11, 2022
APPL NO 17/741595
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 19/0046 (20130101)
B01J 19/1893 (20130101)
B01J 2219/00317 (20130101)
B01J 2219/00522 (20130101)
B01J 2219/00585 (20130101)
B01J 2219/00639 (20130101)
B01J 2219/00725 (20130101)
B01J 2219/00745 (20130101)
B01J 2219/00756 (20130101)

Chemical or Physical Laboratory Apparatus for General Use
B01L 3/06 (20130101) Original (OR) Class
B01L 3/5085 (20130101)
B01L 2300/069 (20130101)

Peptides
C07K 1/306 (20130101)

Single-crystal-growth; Unidirectional Solidification of Eutectic Material or Unidirectional Demixing of Eutectoid Material; Refining by Zone-melting of Material; Production of a Homogeneous Polycrystalline Material With Defined Structure; Single Crystals or Homogeneous Polycrystalline Material With Defined Structure; After-treatment of Single Crystals or a Homogeneous Polycrystalline Material With Defined Structure; Apparatus Therefor
C30B 7/12 (20130101)
C30B 29/58 (20130101)

Combinatorial Chemistry; Libraries, e.g Chemical Libraries
C40B 40/10 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274265 Bomsztyk et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Human Genome Research Institute (NHGRI)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) Matchstick Technologies, Inc. (Kirkland, Washington);  University of Washington (Seattle, Washington)
ASSIGNEE(S)
INVENTOR(S) Karol Bomsztyk (Mercer Island, Washington);  Gregory P. Darlington (Snohomish, Washington);  Daniel S. Mar (Seattle, Washington);  Gregory T. Wing (Bellevue, Washington)
ABSTRACT Disclosed embodiments include illustrative devices for hand-indirect handling of analytical and culture vessels and illustrative methods for hand-indirect handling of analytical and culture vessels. A plate handling device includes a base having a first and second base member configured to hold a plate, wherein the base is adapted to expand and contract to secure the plate to the plate handling device. A handle having an upper end and a lower end, wherein the handle is adapted to actuate the expanding and contracting of the base to secure and hold the plate. An outer handle member fixedly attached to the first base member. A user interface member fixedly attached to the second base member, wherein the user interface member is pivotably attached to the lower end of the handle and pivotably receivable in portions of the outer handle member.
FILED Friday, February 25, 2022
APPL NO 17/680417
CURRENT CPC
Manipulators; Chambers Provided With Manipulation Devices
B25J 11/008 (20130101)
B25J 15/0014 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274381 Singamaneni et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
APPLICANT(S) Washington University (St. Louis, Missouri)
ASSIGNEE(S)
INVENTOR(S) Srikanth Singamaneni (St. Louis, Missouri);  Jingyi Luan (St. Louis, Missouri);  Jeremiah Morrissey (St. Louis, Missouri);  Evan Kharasch (St. Louis, Missouri)
ABSTRACT Fluorescence-based techniques are the cornerstone of modern biomedical optics with applications ranging from bioimaging at various scales (organelle to organism) to detection and quantification of a wide variety of biological species of interest. However, feeble fluorescence signal remains a persistent challenge in meeting the ever-increasing demand to image, detect and quantify biological species of low abundance. Disclosed herein are simple and universal methods based on a flexible and conformal elastomeric film adsorbed with plasmonic nanostructures, referred to as “plasmonic skin” or “plasmonic patch”, that provide large and uniform enhancement of fluorescence on a variety of surfaces, through an “add-on-top” process. The novel fluorescence enhancement approach presented here represents a disease-, biomarker-, and application-agnostic ubiquitously-applicable fundamental and enabling technology to improve the sensitivity of existing analytical methodologies in an easy-to-handle and cost-effective manner, without changing and/or minimally altering the original procedures of the existing techniques.
FILED Friday, May 06, 2022
APPL NO 17/662293
CURRENT CPC
Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form
B32B 27/06 (20130101) Original (OR) Class
B32B 2307/422 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274921 Dewji
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
APPLICANT(S) Cura Therapeutics, LLC (La Jolla, California)
ASSIGNEE(S)
INVENTOR(S) Nazneen Dewji (San Diego, California)
ABSTRACT Provided herein are compounds, for example, a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition.
FILED Friday, July 10, 2020
APPL NO 17/625698
CURRENT CPC
Acyclic or Carbocyclic Compounds
C07C 311/21 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274922 Dewji et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
APPLICANT(S) Cura Therapeutics, LLC (La Jolla, California)
ASSIGNEE(S)
INVENTOR(S) Nazneen Dewji (San Diego, California);  Darryl Rideout (Milford, Pennsylvania);  Gerard Rosse (Poway, California)
ABSTRACT Provided herein are sulfone compounds, for example, a compound of Formula A, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition.
FILED Friday, July 10, 2020
APPL NO 17/625704
CURRENT CPC
Acyclic or Carbocyclic Compounds
C07C 311/21 (20130101) Original (OR) Class
C07C 317/44 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274927 Cheung et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) Trustees of Dartmouth College (Hanover, New Hampshire);  Regents of the University of Minnesota (Minneapolis, Minnesota)
ASSIGNEE(S) Trustees of Dartmouth College (Hanover, New Hampshire);  Regents of the University of Minnesota (Minneapolis, Minnesota)
INVENTOR(S) Ambrose Cheung (Hanover, New Hampshire);  Courtney Aldrich (Minneapolis, Minnesota);  John Schultz (Minneapolis, Minnesota)
ABSTRACT In an embodiment, the present disclosure pertains to methods of inhibiting bacterial growth. Generally, the methods include exposing bacteria to an anti-bacterial compound as disclosed herein. In some embodiments, the exposing occurs in vivo in a subject in order to treat or prevent a bacterial infection. In additional embodiments, the present disclosure pertains to anti-bacterial compounds that are suitable for inhibiting bacterial growth.
FILED Monday, August 31, 2020
APPL NO 17/638987
CURRENT CPC
Heterocyclic Compounds
C07D 215/44 (20130101)
C07D 215/233 (20130101) Original (OR) Class
C07D 237/28 (20130101)
C07D 239/94 (20130101)
C07D 401/04 (20130101)
C07D 401/12 (20130101)
C07D 417/12 (20130101)
C07D 471/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274928 Agarwal et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) Children`s Medical Center Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Suneet Agarwal (Lexington, Massachusetts);  John J. Piwinski (Lebanon, New Jersey);  Patricia C. Weber (Yardley, Pennsylvania);  Neha Nagpal (Boston, Massachusetts)
ABSTRACT The present application provides compounds that are PAPD5 inhibitors and are useful in treating a variety of conditions such as cancer, telomere diseases, and aging-related and other degenerative disorders.
FILED Thursday, April 23, 2020
APPL NO 17/605763
CURRENT CPC
Heterocyclic Compounds
C07D 215/42 (20130101) Original (OR) Class
C07D 215/44 (20130101)
C07D 215/54 (20130101)
C07D 401/04 (20130101)
C07D 401/06 (20130101)
C07D 401/12 (20130101)
C07D 405/04 (20130101)
C07D 405/12 (20130101)
C07D 413/04 (20130101)
C07D 413/06 (20130101)
C07D 413/12 (20130101)
C07D 413/14 (20130101)
C07D 417/12 (20130101)
C07D 471/04 (20130101)
C07D 471/14 (20130101)
C07D 471/16 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274929 Radu et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Caius G. Radu (Los Angeles, California);  Michael E. Jung (Los Angeles, California);  Daniel Sun (Los Angeles, California);  Nagichettiar Satyamurthy (Los Angeles, None);  Juno Van Valkenburgh (Los Angeles, None);  Roy Pan (Los Angeles, None);  Soumya Poddar (Los Angeles, California)
ABSTRACT Provided, inter alia, are thiosemicarbazone compounds, metal complexes of thiosemicarbazone compounds, pharmaceutical compositions, and methods for treating cancer.
FILED Friday, February 21, 2020
APPL NO 17/429722
CURRENT CPC
Heterocyclic Compounds
C07D 217/14 (20130101) Original (OR) Class

Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium
C07F 1/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274940 Ramsden et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human (Bethesda, Maryland)
ASSIGNEE(S) THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human (Bethesda, Maryland)
INVENTOR(S) Christopher Ramsden (Bethesda, Maryland);  Gregory Keyes (Timonium, Maryland)
ABSTRACT This disclosure concerns fatty acid derivatives, pharmaceutical compositions comprising the fatty acid derivatives, and methods of using the fatty acid derivatives, for example, to treat inflammation, chronic itch, chronic pain, an autoimmune disorder, atherosclerosis, a skin disorder, arthritis, a neurodegenerative disorder, or a psychiatric disorder in a subject. In some embodiments, the fatty acid derivative is a compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having a structure according to: wherein X is from 1-16 carbons in length, Z is aliphatic from 1-16 carbons in length, or is not present, Y is selected from: R1, R2, and R3 are independently hydrogen or lower alkyl, R4 is lower alkyl, hydroxyl, carboxyl, or amine, R5 is hydrogen, lower alkyl, or halide, R6 is hydroxyl or substituted thiol, and each R7 is independently hydrogen or fluoride or is not present and the adjacent carbons form alkyne.
FILED Tuesday, April 12, 2022
APPL NO 17/718965
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 3/06 (20180101)
A61P 17/00 (20180101)
A61P 25/00 (20180101)

Acyclic or Carbocyclic Compounds
C07C 59/42 (20130101)

Heterocyclic Compounds
C07D 303/42 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/92 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274949 Looper et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) Curza Global, LLC (Provo, Utah);  University of Utah Research Foundation (Salt Lake City, Utah)
ASSIGNEE(S) Curza Global, LLC (Provo, Utah);  University of Utah Research Foundation (Salt Lake City, Utah)
INVENTOR(S) Ryan E. Looper (Salt Lake City, Utah);  Justin M. Salvant (Salt Lake City, Utah);  Emily K. Kirkeby (Salt Lake City, Utah);  Wenxing Guo (Salt Lake City, Utah);  Katrin P. Guillen (Salt Lake City, Utah);  Bryan E. Welm (Salt Lake City, Utah)
ABSTRACT The present invention presents 2-(acylamino)imidazoles with therapeutic activity, including selective activity against cancer cells, and compositions comprising them. Methods of using and preparing the 2-(acylamino)imidazoles are also presented.
FILED Tuesday, May 10, 2022
APPL NO 17/741366
CURRENT CPC
Heterocyclic Compounds
C07D 233/88 (20130101)
C07D 401/04 (20130101) Original (OR) Class
C07D 405/04 (20130101)
C07D 487/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274963 Huang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Lan Huang (Irvine, California);  Scott D. Rychnovsky (Irvine, California)
ABSTRACT The disclosure provides for mass spectrometry (MS)-cleavable heterobifunctional photoactivated cross-linkers. The MS-cleavable heterobifunctional photoactivated cross-linkers can be used in mass spectrometry to facilitate structural analysis of intra-protein interactions in proteins and inter-protein interactions in protein complexes.
FILED Thursday, February 24, 2022
APPL NO 17/680236
CURRENT CPC
Heterocyclic Compounds
C07D 403/12 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 30/7233 (20130101)
G01N 33/6845 (20130101)
G01N 33/6848 (20130101)
G01N 2030/027 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274974 Babich et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
APPLICANT(S) Cornell University (Ithaca, New York)
ASSIGNEE(S) Cornell University (Ithaca, New York)
INVENTOR(S) John W. Babich (New York, New York);  Justin Wilson (Ithaca, New York);  Nikki Thiele (Brooktondale, New York);  James Kelly (New York, New York);  Shashikanth Ponnala (Ithaca, New York)
ABSTRACT The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutical y acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof,
wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
FILED Wednesday, February 23, 2022
APPL NO 17/678803
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 51/0463 (20130101)
A61K 51/0482 (20130101)
A61K 51/1072 (20130101)

General Methods of Organic Chemistry; Apparatus Therefor
C07B 59/002 (20130101)

Heterocyclic Compounds
C07D 413/14 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274978 Boateng
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
APPLICANT(S) HIGH POINT UNIVERSITY (High Point, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Comfort Ahenkan Boateng (High Point, North Carolina)
ABSTRACT The disclosure provides compounds which exhibit dopamine receptor antagonist activity and which may be useful as therapeutic agents for the treatment of diseases and disorders associated with dopamine receptors. Also provided are methods for the preparation of such compounds, pharmaceutical compositions comprising the disclosed compounds, and methods for treating diseases or disorders with such compounds or pharmaceutical compositions.
FILED Friday, February 18, 2022
APPL NO 17/675696
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/30 (20180101)

Heterocyclic Compounds
C07D 417/06 (20130101)
C07D 417/14 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274980 Erb et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) The Scripps Research Institute (La Jolla, California)
ASSIGNEE(S)
INVENTOR(S) Michael A. Erb (San Diego, California);  Dennis Wolan (La Jolla, California);  Seiya Kitamura (San Diego, California);  Arnab Chatterjee (San Diego, California)
ABSTRACT Provided herein are compounds, pharmaceutical compositions, and methods for inhibiting the ENL YEATS domain. Further, provided herein are compounds, pharmaceutical compositions, and methods for the treatment of leukemia.
FILED Wednesday, July 29, 2020
APPL NO 17/630335
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/04 (20180101)

Heterocyclic Compounds
C07D 471/04 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274996 Mekonnen et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
APPLICANT(S) AGENEBIO, INC. (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) Belew Mekonnen (Gilbertsville, Pennsylvania);  John A. Butera (Clarksburg, New Jersey);  Jianxing Huang (Bethlehem, Pennsylvania)
ABSTRACT This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.
FILED Friday, February 04, 2022
APPL NO 17/592679
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/13 (20130101)
A61K 31/27 (20130101)
A61K 31/55 (20130101)
A61K 31/445 (20130101)
A61K 31/496 (20130101)
A61K 31/551 (20130101)
A61K 31/5517 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/00 (20180101)

Heterocyclic Compounds
C07D 487/14 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275001 Davis et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) University of Utah Research Foundation (Salt Lake City, Utah)
ASSIGNEE(S)
INVENTOR(S) Darrell Davis (Salt Lake City, Utah);  Shuanghu Liu (Salt Lake City, Utah)
ABSTRACT The present disclosure is concerned with benzimidazole compounds and methods of using these compounds for the treatment of hepatitis (e.g., hepatitis C), RNA virus infections (e.g., Zika virus, dengue virus, Powassan virus, Chikungunya virus, Enterovirus, respiratory syntactical virus (RSV), Rift Valley fever, Influenza virus, Tacaribe virus, Mayaro virus, West Nile virus, yellow fever virus, and coronavirus), and disorders of uncontrolled cellular proliferation (e.g., cancer). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
FILED Thursday, April 28, 2022
APPL NO 17/732447
CURRENT CPC
Heterocyclic Compounds
C07D 235/30 (20130101)
C07D 487/04 (20130101)
C07D 491/048 (20130101)
C07D 491/052 (20130101)
C07D 491/147 (20130101) Original (OR) Class
C07D 495/14 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275016 Li et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (Atlanta, Georgia)
ASSIGNEE(S)
INVENTOR(S) Lei Li (Alpharetta, Georgia);  George Peng Wang (Johns Creek, Georgia);  Madhusudhan Reddy Gadi (Atlanta, Georgia);  Jun Yin (Atlanta, Georgia)
ABSTRACT The present disclosure is concerned with compounds, compositions, and methods for synthesizing sphingosines and glycolipids including glycosphingolipids, such as but not limited to lactosyl sphingosine.
FILED Tuesday, February 22, 2022
APPL NO 17/677227
CURRENT CPC
Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids
C07H 15/10 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275017 GIN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) MEMORIAL SLOAN-KETTERING CANCER CENTER (New York City, New York)
ASSIGNEE(S)
INVENTOR(S) David Y. GIN (New York, New York);  Eric K. CHEA (Flushing, New York);  Alberto FERNANDEZ-TEJADA (New York, New York);  Derek S. TAN (New York, New York);  Jason S. LEWIS (New York, New York);  Jeffrey R. GARDNER (New York, New York);  NagaVaraKishore PILLARSETTY (Jackson Heights, New York)
ABSTRACT Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.
FILED Monday, March 14, 2022
APPL NO 17/694180
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/704 (20130101)
A61K 31/7024 (20130101)
A61K 39/39 (20130101)
A61K 45/06 (20130101)
A61K 2039/55577 (20130101)

Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids
C07H 15/18 (20130101)
C07H 15/24 (20130101)
C07H 15/256 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275027 MUIR et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Research Resources (NCRR)
National Institute of General Medical Sciences (NIGMS)
NIH Office of the Director (NIHOD)
APPLICANT(S) TRUSTEES OF PRINCETON UNIVERSITY (Princeton, New Jersey);  ALBERT EINSTEIN COLLEGE OF MEDICINE (Bronx, New York)
ASSIGNEE(S)
INVENTOR(S) TOM W. MUIR (Princeton, New Jersey);  ADAM STEVENS (Princeton, New Jersey);  JOSEF GRAMESPACHER (Princeton, New Jersey);  DAVID COWBURN (Bronx, New York);  GIRIDHAR SEKAR (Bronx, New York)
ABSTRACT The present disclosure relates to atypical split N- and C-inteins and variants thereof. This disclosure also relates to complexes comprising the split N- or C-inteins of this disclosure and a compound of interest and compositions comprising said complexes. In addition, this disclosure relates to methods of using the atypical split N- and C-inteins.
FILED Wednesday, August 28, 2019
APPL NO 17/753299
CURRENT CPC
Peptides
C07K 1/026 (20130101)
C07K 14/001 (20130101) Original (OR) Class
C07K 2319/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275034 WONG et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) THE JOHNS HOPKINS UNIVERSITY (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) Philip C. WONG (Baltimore, Maryland);  Aneesh DONDE (Baltimore, Maryland);  Jonathan P. LING (Baltimore, Maryland);  Liam CHEN (Baltimore, Maryland);  Mingkuan SUN (Baltimore, Maryland)
ABSTRACT An adenovirus or adenoviral vector is described that includes a non-native nucleotide sequence capable of expressing a chimeric protein comprising an N-terminal nucleotide binding domain of transactivation response element DNA-binding protein (TDP-43), a C-terminal domain derived from a splicing repressor, and an autoregulatory element. Methods of using the adenovirus or adenoviral vector to treat degenerative diseases such as inclusion body myocytosis, amyotrophic lateral sclerosis, and frontotemporal dementia are also described.
FILED Monday, November 04, 2019
APPL NO 17/287730
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Peptides
C07K 14/47 (20130101)
C07K 14/4702 (20130101) Original (OR) Class

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/86 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6883 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275035 Ulrichts et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) ARGENX BV (Zwijnaarde, Belgium);  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas)
ASSIGNEE(S)
INVENTOR(S) Peter Ulrichts (Destelbergen, Belgium);  Christophe Blanchetot (Destelbergen, Belgium);  Torsten Dreier (Sint Martens Latem, Belgium);  Johannes de Haard (NA Oudelande, Netherlands);  E. Sally Ward Ober (Dallas, Texas);  Nicolas G. H. Ongenae (Gent, Belgium)
ABSTRACT Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
FILED Tuesday, February 15, 2022
APPL NO 17/672346
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)
A61K 38/1709 (20130101)
A61K 45/06 (20130101)

Peptides
C07K 14/4703 (20130101) Original (OR) Class
C07K 2317/41 (20130101)
C07K 2317/52 (20130101)
C07K 2317/94 (20130101)
C07K 2317/524 (20130101)
C07K 2317/526 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275064 Goodman et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Deafness and Other Communication Disorders (NIDCD)
APPLICANT(S) RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (Columbus, Ohio)
ASSIGNEE(S)
INVENTOR(S) Steven D. Goodman (Columbus, Ohio);  Lauren O. Bakaletz (Columbus, Ohio)
ABSTRACT Provided herein are methods and compositions for disrupting bio films in vitro and in vivo. Also disclosed are antibodies comprising a specified heavy chain (HC) immunoglobulin variable domain sequence and/or a specified light chain (LC) immunoglobulin variable domain sequence.
FILED Tuesday, July 07, 2020
APPL NO 17/625715
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/04 (20180101)

Peptides
C07K 16/12 (20130101) Original (OR) Class
C07K 16/1018 (20130101)
C07K 2317/21 (20130101)
C07K 2317/24 (20130101)
C07K 2317/41 (20130101)
C07K 2317/52 (20130101)
C07K 2317/54 (20130101)
C07K 2317/55 (20130101)
C07K 2317/565 (20130101)
C07K 2317/567 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275084 Wernig et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) The Board of Trustees of the Leland Stanford Junior University (Stanford, California)
ASSIGNEE(S)
INVENTOR(S) Gerlinde Wernig (Stanford, California);  Irving L. Weissman (Stanford, California)
ABSTRACT Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition.
FILED Wednesday, February 09, 2022
APPL NO 17/668068
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/1774 (20130101)
A61K 39/3955 (20130101)
A61K 45/06 (20130101)
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 1/16 (20180101)
A61P 11/00 (20180101)

Peptides
C07K 16/2803 (20130101) Original (OR) Class
C07K 16/2896 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/53 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275085 Majeti et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Board of Trustees of the Leland Stanford Junior University (Stanford, California)
ASSIGNEE(S)
INVENTOR(S) Ravindra Majeti (Palo Alto, California);  Irving L. Weissman (Stanford, California);  Siddhartha Jaiswal (San Francisco, California);  Mark P. Chao (Mountain View, California)
ABSTRACT Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
FILED Wednesday, May 04, 2022
APPL NO 17/736847
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/02 (20180101)

Peptides
C07K 16/28 (20130101)
C07K 16/30 (20130101)
C07K 16/2803 (20130101) Original (OR) Class
C07K 16/2896 (20130101)
C07K 2317/73 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0093 (20130101)
C12N 5/0694 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6886 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5011 (20130101)
G01N 33/57426 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275086 Diaz et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Johns Hopkins University (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) Luis Diaz (Ellicot City, Maryland);  Bert Vogelstein (Baltimore, Maryland);  Kenneth W. Kinzler (Baltimore, Maryland);  Nickolas Papadopoulos (Towson, Maryland);  Dung Le (Lutherville, Maryland);  Drew M. Pardoll (Brookville, Maryland);  Suzanne L. Topalian (Brookville, Maryland)
ABSTRACT Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
FILED Monday, May 09, 2022
APPL NO 17/739274
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Peptides
C07K 16/30 (20130101)
C07K 16/40 (20130101)
C07K 16/2803 (20130101) Original (OR) Class
C07K 16/2818 (20130101)
C07K 16/2827 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6886 (20130101)
C12Q 2600/106 (20130101)
C12Q 2600/156 (20130101)

Enzymes
C12Y 113/11052 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275330 Rao et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Child Health and Human Development (NICHD)
APPLICANT(S) North Carolina State University (Raleigh, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Balaji Rao (Raleigh, North Carolina);  Adam Mischler (Raleigh, North Carolina)
ABSTRACT The present disclosure provides compositions and methods related to the derivation of trophoblast stem cells. In particular, the present disclosure provides novel formulations and methods for deriving and maintaining trophoblast stem cells from human pluripotent stem cells, which can be used for basic research purposes as well as for developing treatments for pregnancy-associated pathologies such as preeclampsia, recurrent loss of pregnancy, placenta accreta, and intrauterine growth restriction.
FILED Friday, August 28, 2020
APPL NO 17/638015
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0606 (20130101) Original (OR) Class
C12N 2501/11 (20130101)
C12N 2501/16 (20130101)
C12N 2501/117 (20130101)
C12N 2501/119 (20130101)
C12N 2501/155 (20130101)
C12N 2506/02 (20130101)
C12N 2506/025 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6869 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275341 Zorn et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Child Health and Human Development (NICHD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) CHILDREN'S HOSPITAL MEDICAL CENTER (Cincinnati, Ohio);  RIKEN (Wako, Saitama, Japan)
ASSIGNEE(S)
INVENTOR(S) Aaron M. Zorn (Cincinnati, Ohio);  Lu Han (Charleston, South Carolina);  Keishi Kishimoto (Wako, Saitama, Japan);  Mitsuru Morimoto (Wako, Saitama, Japan)
ABSTRACT Disclosed herein are in vitro methods of making splanchnic mesoderm cell types and subtypes thereof from pluripotent cells. These methods can be used to produced improved foregut- and hindgut-derived organoids containing enriched mesenchyme, which enhances organoid viability, growth, and maturation, both in in vitro culture and in vivo transplantation.
FILED Tuesday, August 25, 2020
APPL NO 17/638753
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0652 (20130101)
C12N 5/0679 (20130101) Original (OR) Class
C12N 2501/15 (20130101)
C12N 2501/115 (20130101)
C12N 2501/155 (20130101)
C12N 2501/415 (20130101)
C12N 2501/999 (20130101)
C12N 2506/02 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275356 Joung et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Human Genome Research Institute (NHGRI)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) The General Hospital Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) J. Keith Joung (Winchester, Massachusetts);  Jason Michael Gehrke (Cambridge, Massachusetts)
ABSTRACT Methods and compositions for improving the genome-wide specificities of targeted base editing technologies.
FILED Monday, May 09, 2022
APPL NO 17/739418
CURRENT CPC
Peptides
C07K 14/435 (20130101)
C07K 14/4703 (20130101)
C07K 2319/70 (20130101)
C07K 2319/80 (20130101)
C07K 2319/81 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0647 (20130101)
C12N 9/22 (20130101)
C12N 9/78 (20130101) Original (OR) Class
C12N 15/63 (20130101)
C12N 15/90 (20130101)
C12N 15/102 (20130101)
C12N 2310/20 (20170501)

Enzymes
C12Y 305/04001 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275364 Knouse et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
NIH Office of the Director (NIHOD)
APPLICANT(S) Whitehead Institute for Biomedical Research (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Kristin Knouse (Boston, Massachusetts);  Heather R. Keys (Quincy, Massachusetts)
ABSTRACT Disclosed herein are methods and non-human mammals for in vivo functional genomic screens.
FILED Friday, January 28, 2022
APPL NO 17/588038
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 49/0004 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 15/11 (20130101) Original (OR) Class
C12N 15/86 (20130101)
C12N 15/907 (20130101)
C12N 15/1065 (20130101)
C12N 2310/20 (20170501)
C12N 2320/11 (20130101)
C12N 2740/15043 (20130101)
C12N 2800/80 (20130101)
C12N 2840/002 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5088 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275371 Moses et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Children's Medical Center Corporation (Boston, Massachusetts)
ASSIGNEE(S) Children's Medical Center Corporation (Boston, Massachusetts)
INVENTOR(S) Marsha A. Moses (Brookline, Massachusetts);  Golnaz Morad (Boston, Massachusetts)
ABSTRACT Provided herein are compositions and methods for delivery an agent (e.g., diagnostic agent or therapeutic agent) to the brain using an extracellular vesicle comprising the agent and a Rab7 inhibitor. Methods of diagnosing or treating a brain disease are also provided.
FILED Thursday, April 23, 2020
APPL NO 17/605799
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/127 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1137 (20130101) Original (OR) Class
C12N 2310/14 (20130101)
C12N 2310/141 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6886 (20130101)
C12Q 2600/158 (20130101)
C12Q 2600/178 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275376 KIMMELMAN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) New York University (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Alec C. KIMMELMAN (Larchmont, New York);  Seth J. PARKER (New York, New York)
ABSTRACT The present disclosure provides compositions and methods for interfering with uptake of neutral amino acids (e.g., alanine) in pancreatic cells. Alanine uptake can be inhibited by inhibiting the function and/or expression of SLC38A2 and/or SLC1A4.
FILED Thursday, August 20, 2020
APPL NO 17/637427
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/15 (20130101)
A61K 31/55 (20130101)
A61K 31/135 (20130101)
A61K 31/138 (20130101)
A61K 31/4525 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1138 (20130101) Original (OR) Class
C12N 2310/14 (20130101)
C12N 2310/531 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/57438 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275402 Peranteau et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) THE CHILDREN'S HOSPITAL OF PHILADELPHIA (Philadelphia, Pennsylvania);  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, Pennsylvania)
ASSIGNEE(S) THE CHILDREN'S HOSPITAL OF PHILADELPHIA (Philadelphia, Pennsylvania);  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, Pennsylvania)
INVENTOR(S) William H. Peranteau (Philadelphia, Pennsylvania);  Edward E. Morrisey (Newtown Square, Pennsylvania);  Michael F. Beers (Philadelphia, Pennsylvania);  Kiran Musunuru (Philadelphia, Pennsylvania)
ABSTRACT Compositions and methods for in utero gene editing in mammalian lung cells are disclosed.
FILED Monday, April 06, 2020
APPL NO 17/601581
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/007 (20130101)
A61K 9/0019 (20130101)

Peptides
C07K 14/705 (20130101)
C07K 14/8121 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 15/907 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275403 Kay et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) The Board of Trustees of the Leland Stanford Junior University (Stanford, California)
ASSIGNEE(S)
INVENTOR(S) Mark A. Kay (Los Altos, California);  Shinnosuke Tsuji (Redwood City, California)
ABSTRACT The present disclosure provides methods and compositions for facilitating efficient adeno-associated virus (AAV)-based homologous recombination (HR). Subject methods include a step of contacting a cell (e.g., a population of cells) with a ribonucleotide reductase inhibitor, which provides for increased HR efficiency compared to performing HR in the absence of the inhibitor. The cell is also contacted with a recombinant adeno-associated vims (rAAV) that includes a donor DNA having a sequence cassette (i.e., a nucleotide sequence of interest) flanked by homology arms that facilitate integration of the sequence cassette into a target genomic locus via HR.
FILED Monday, August 17, 2020
APPL NO 17/636010
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/17 (20130101)
A61K 31/7068 (20130101)
A61K 31/7076 (20130101)
A61K 48/0008 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/86 (20130101)
C12N 15/907 (20130101) Original (OR) Class
C12N 15/1137 (20130101)
C12N 2310/14 (20130101)
C12N 2750/14143 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275437 STAPLETON et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) METABIOTECH CORPORATION (San Jose, California)
ASSIGNEE(S)
INVENTOR(S) James A. STAPLETON (Eugene, Oregon);  Timothy WHITEHEAD (East Grand Rapids, Michigan)
ABSTRACT The disclosure relates to methods for obtaining nucleic acid sequence information by constructing a nucleic acid library and reconstructing longer nucleic acid sequences by assembling a series of shorter nucleic acid sequences.
FILED Tuesday, October 12, 2021
APPL NO 17/499265
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6806 (20130101)
C12Q 1/6869 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275461 KIM et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, Florida)
ASSIGNEE(S)
INVENTOR(S) Sungjune KIM (Tampa, Florida);  Anders BERGLUND (Tampa, Florida)
ABSTRACT Disclosed are methods for using the methylation status of a cancerous tissue to assess the susceptibility of a cancer to immunotherapy and determine new treatment regimens. Disclosed are methods related to producing an immunotherapeutic regimen based on the amount of methylation in co-stimulatory genes and/or immune checkpoint genes, as well as, methods of treating an immunogenic cancer based on the same.
FILED Friday, August 21, 2020
APPL NO 17/636532
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/706 (20130101)
A61K 31/7068 (20130101)
A61K 39/3955 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6886 (20130101) Original (OR) Class
C12Q 2600/106 (20130101)
C12Q 2600/154 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276226 STATSYUK et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) University of Houston System (Houston, Texas)
ASSIGNEE(S) University of Houston System (Houston, Texas)
INVENTOR(S) Alexander STATSYUK (Houston, Texas);  Sandipan Roy CHOWDHURY (Houston, Texas)
ABSTRACT Multikinase degraders described herein contain on one end a Von Hippel-Lindau (VHL) E3 ligase ligand or cereblon E3 ligase recruiter moiety, which bind to the VHL or cereblon E3 ubiquitin ligase (defined as a ubiquitin ligand binding moiety or ULM group), respectively, and on the other end a promiscuous kinase ligand that binds a target protein kinase (defined as a protein/polypeptide targeting moiety or PTM group), such that the target protein is in close proximity to the ubiquitin ligase. This leads to the ubiquitination and subsequent degradation (and inhibition) of the target protein. Specific present multikinase degraders as shown bind about 360 out of 400 tested kinases, showing that they are much more general kinase binders and degraders than any previously reported.
FILED Tuesday, July 28, 2020
APPL NO 17/631003
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/54 (20170801)
A61K 47/55 (20170801)
A61K 47/545 (20170801)

Heterocyclic Compounds
C07D 401/14 (20130101)
C07D 417/14 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5011 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276237 Lin et al.
FUNDED BY
Department of Health and Human Services (HHS)
Centers for Disease Control and Prevention (CDC)
National Institute for Occupational Safety and Health (NIOSH)
APPLICANT(S) Washington State University (Pullman, Washington)
ASSIGNEE(S) Washington State University (Pullman, Washington)
INVENTOR(S) Yuehe Lin (Pullman, Washington);  Dan Du (Pullman, Washington);  Yang Song (Pullman, Washington);  Ranfeng Ye (Pullman, Washington)
ABSTRACT The disclosure relates to antigen detection reagents and related methods, systems, and kits. The reagents comprise an antigen-binding molecule conjugated to an inorganic component. In some embodiments, the inorganic component possesses catalytic functionality to provide a detectable signal. In some embodiments, the catalytic inorganic component is or comprises a bimetallic nanoparticle. In other embodiments, the inorganic component is a nanoflowers that provides a physical scaffold onto which the antigen-binding component and a reporter component can be loaded, resulting in augmented antigen-binding and reporting capabilities.
FILED Monday, March 14, 2022
APPL NO 17/693798
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/00 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/553 (20130101)
G01N 33/581 (20130101)
G01N 33/587 (20130101)
G01N 33/54346 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276258 Bettoun et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) Larimar Therapeutics, Inc. (Bala Cynwyd, Pennsylvania);  The United States of America, as represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland)
ASSIGNEE(S)
INVENTOR(S) Joan David Bettoun (Elkins Park, Pennsylvania);  Erik Johan Wagner (Sterling, Virginia);  Xin Xu (Potomac, Maryland);  Jean-Nicholas Mess (Laval, Canada);  Amy Qiu Wang (Poolesville, Maryland)
ABSTRACT The present disclosure provides methods for determining the amount of FXN or FXN fusion protein in a sample, e.g, a tissue sample, by using mass spectrometry.
FILED Wednesday, July 29, 2020
APPL NO 17/631414
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6848 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276264 Sierks et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (Scottsdale, Arizona)
ASSIGNEE(S)
INVENTOR(S) Michael Sierks (Ft. McDowell, Arizona);  Stephanie Williams (Phoenix, Arizona)
ABSTRACT Disclosed are diagnostics kits and compositions for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.
FILED Friday, March 04, 2022
APPL NO 17/687587
CURRENT CPC
Peptides
C07K 14/4711 (20130101)
C07K 2318/00 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6896 (20130101) Original (OR) Class
G01N 2800/2821 (20130101)
G01N 2800/2835 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276265 Kim
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Hyesook Kim (Bloomfield Hills, Michigan)
ASSIGNEE(S) Detroit R and D, Inc. (Bloomfield Hills, Michigan)
INVENTOR(S) Hyesook Kim (Bloomfield Hills, Michigan)
ABSTRACT This invention discloses diagnosis of risk of chemotherapy-induced cardiotoxicity by measurement of increased expression of soluble epoxide hydrolase in vitro and in vivo in cells, tissues or animals including measurement of increased levels of soluble epoxide hydrolase metabolites, e.g., 14,15-DHET and 11,12-DHET, in biological fluids. This invention also includes diagnosis of risk of chemotherapy-induced cardiotoxicity by measuring increased levels of oxidative stress in cells, tissues or animals including measurement of increased levels of oxidative stress biomarkers, e.g., 8-isoprostane, in biological fluids. Fatty acid and protein biomarkers to diagnose the risk of chemotherapy-induced cardiotoxicity are detected using various detection methods including mass spectrometry and immunoassay such as ELISA, Western blot analysis or label-free microwell and nanowell technologies. This invention discloses targeted medical intervention for a subject who is at risk or with chemotherapy-induced cardiotoxicity by treating with soluble epoxide hydrolase inhibitor(s) with or without antioxidants to prevent or ameliorate the chemotherapy-induced cardiotoxicity.
FILED Monday, January 28, 2019
APPL NO 16/259499
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/92 (20130101) Original (OR) Class
G01N 33/573 (20130101)
G01N 33/6887 (20130101)
G01N 2405/00 (20130101)
G01N 2560/00 (20130101)
G01N 2800/32 (20130101)
G01N 2800/42 (20130101)
G01N 2800/50 (20130101)
G01N 2800/52 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276266 Carey et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S) The Regents of the University of California (Oakland, California)
INVENTOR(S) Thomas Robert Carey (Berkeley, California);  Molly Aliza Kozminsky (Berkeley, California);  Lydia L. Sohn (Berkeley, California)
ABSTRACT Lipid bilayer particles, such as extracellular vesicles (EVs), are labeled with lipid-tagged single-stranded DNA (ssDNA), which is amplified by polymerase chain reaction (PCR) to quantify particles captured via surface marker interactions or complementary oligonucleotide hybridization.
FILED Friday, May 20, 2022
APPL NO 17/749163
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6851 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/92 (20130101) Original (OR) Class
G01N 2458/10 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276480 XU et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) SCANOGEN INC. (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) ZHIGUANG XU (Malvern, Pennsylvania);  ALFREDO ANDRES CELEDON (Columbia, Maryland)
ABSTRACT An imaging system is described for measuring the position or movement of a particle having a size of less than about 20 microns. The system comprises an optional sample holder configured to hold a sample with a particle, an optional illumination source configured to illuminate the sample, a lens having a magnification ratio from about 1:5 to about 5:1 and configured to generate the image of the sample, an image sensor having a pixel size of up to about 20 microns and configured to sense the image of the sample, and an image processor operatively connected to the image sensor to process the image of the particle in order to determine the position or movement of the particle. The dimension of the image of each particle is at least about 1.5 times the dimension of the particle multiplied by the magnification ratio of the lens, and the image of each particle is distributed on at least two pixels of the sensor. The imaged area of the sample is at least about one millimeter squared.
FILED Thursday, May 12, 2022
APPL NO 17/743166
CURRENT CPC
Measuring Length, Thickness or Similar Linear Dimensions; Measuring Angles; Measuring Areas; Measuring Irregularities of Surfaces or Contours
G01B 9/04 (20130101)

Optical Elements, Systems, or Apparatus
G02B 21/06 (20130101)
G02B 21/16 (20130101)
G02B 21/361 (20130101) Original (OR) Class
G02B 21/365 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277427 Bromberg et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas)
ASSIGNEE(S)
INVENTOR(S) Raquel Bromberg (Dallas, Texas);  Zbyszek Otwinowski (Dallas, Texas);  Dominika Borek (Dallas, Texas)
ABSTRACT Methods for correcting one or more image aberrations in an electron microscopy image, including cryo-EM images, are provided. The method includes obtaining a plurality of electron microscope (EM) images of an internal reference grid sample having one or more known properties, the plurality of electron microscope images obtained for a plurality of optical conditions and for a plurality of coordinated beam-image shifts. The method may also include, among other features, determining an aberration correction function that predicts aberrations for every point in the imaged area using kernel canonical correlation analysis (KCCA).
FILED Monday, August 10, 2020
APPL NO 17/633133
CURRENT CPC
Image Data Processing or Generation, in General
G06T 5/006 (20130101) Original (OR) Class
G06T 2207/10061 (20130101)

Electric Discharge Tubes or Discharge Lamps
H01J 37/222 (20130101)
H01J 2237/223 (20130101)
H01J 2237/2826 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277804 WEI et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
APPLICANT(S) BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (East Lansing, Michigan)
ASSIGNEE(S)
INVENTOR(S) Guowei WEI (Haslett, Michigan);  Zixuan CANG (Irvine, California);  Jiahui CHEN (Dallas, Texas);  Weihua GENG (Dallas, Texas)
ABSTRACT Systems and methods are described relating to a Poisson Boltzmann machine learning model, which may be executed to predict electrostatic solvation free energy for molecular compounds, such as proteins. Feature data input to the Poisson Boltzmann machine learning model may include multi-weighted colored subgraph centralities, which may be calculated based on edge definitions of pairwise atomic interactions between atoms of a given protein using a generalized exponential function and/or a generalized Lorentz function, either or both of which may be weighted based on atomic rigidity or atomic charge. Predictions of electrostatic solvation free energy performed by the Poisson Boltzmann machine learning model may be used as a basis for ranking candidate compounds for a defined target clinical application.
FILED Tuesday, May 05, 2020
APPL NO 17/637440
CURRENT CPC
Electric Digital Data Processing
G06F 17/13 (20130101)

Computer Systems Based on Specific Computational Models
G06N 7/08 (20130101)

Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology
G16B 15/30 (20190201) Original (OR) Class
G16B 40/00 (20190201)
G16B 45/00 (20190201)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220278498 Wise et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Cornell University (Ithaca, New York)
ASSIGNEE(S)
INVENTOR(S) Frank Wise (Ithaca, New York);  Pavel Sidorenko (Ithaca, New York);  Walter Fu (Ithaca, New York)
ABSTRACT Disclosed is a pulsed laser apparatus and method of generating a laser pulse. The apparatus includes an input coupler configured to receive pumping light from a pumping light source and a seed pulse from a seed pulse generator. The apparatus further includes a doped fiber-optic cable with an input port at a first end configured to receive the pumping light and the seed pulse. The doped fiber-optic cable amplifies the seed pulse to generate an output pulse. Along a first length of the doped fiber optic cable, the pulse spectrum broadens rapidly owing to nonlinearity. Beyond the first length in an extended portion, the output pulse shifts towards longer wavelengths and broadens in both spectral and temporal domains The apparatus also includes an output port at a second end of the doped fiber-optic cable, wherein the output pulse exits the doped fiber-optic cable at the output port.
FILED Thursday, July 09, 2020
APPL NO 17/597501
CURRENT CPC
Devices Using the Process of Light Amplification by Stimulated Emission of Radiation [LASER] to Amplify or Generate Light; Devices Using Stimulated Emission of Electromagnetic Radiation in Wave Ranges Other Than Optical
H01S 3/1618 (20130101)
H01S 3/06716 (20130101)
H01S 3/06725 (20130101) Original (OR) Class
H01S 2301/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220279119 Alshurafa et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Science Foundation (NSF)
Directorate for Computer and Information Science and Engineering (CISE)
Division of Computer and Network Systems (CNS)
APPLICANT(S) Northwestern University (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Nabil I. Alshurafa (Chicago, Illinois);  Josiah D. Hester (Evanston, Illinois)
ABSTRACT A camera system includes a camera configured to capture first video of a scene in the form of first image frames. The camera system also includes an infrared sensor configured to capture second video of the scene in the form of second image frames. The system also includes a processor in communication with the camera and the infrared sensor. The processor is configured to obfuscate one or more portions of the scene.
FILED Wednesday, April 27, 2022
APPL NO 17/730858
CURRENT CPC
Image Data Processing or Generation, in General
G06T 5/003 (20130101)
G06T 5/50 (20130101)
G06T 7/194 (20170101)
G06T 2207/10024 (20130101)
G06T 2207/10048 (20130101)
G06T 2207/20221 (20130101)

Pictorial Communication, e.g Television
H04N 5/76 (20130101)
H04N 5/247 (20130101)
H04N 5/272 (20130101)
H04N 5/2252 (20130101)
H04N 5/2253 (20130101)
H04N 5/23229 (20130101) Original (OR) Class
H04N 7/18 (20130101)
H04N 9/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Defense (DOD) 

US 20220273488 Myers et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
APPLICANT(S) Vivonics, Inc. (Bedford, Massachusetts)
ASSIGNEE(S) Liberating Technologies, Inc. (Holliston, Massachusetts)
INVENTOR(S) Ryan Myers (North Andover, Massachusetts);  Kristen LeRoy (Waltham, Massachusetts);  Ian Cohen (Boulder, Colorado);  Gordon B. Hirschman (Cohoes, New York);  Thane R. Hunt (Colchester, Connecticut);  Kevin E. Keough (Sharon, Massachusetts);  Carlos Martinez Luna (Boylston, Massachusetts);  Todd R. Farrell (Waltham, Massachusetts);  Jennifer L. Johansson (Wayland, Massachusetts);  Brendan LaBrecque (Middleton, Massachusetts)
ABSTRACT A prosthetic socket cooling system and method includes a thermally conductive heat spreader including a curved shaped portion configured to maximize contact with a residual limb of a user. A heat extraction subsystem is coupled through a wall of the prosthetic socket and to the thermally conductive heat spreader and is configured to maintain a desired temperature inside the prosthetic socket.
FILED Thursday, May 19, 2022
APPL NO 17/748581
CURRENT CPC
Filters Implantable into Blood Vessels; Prostheses; Devices Providing Patency To, or Preventing Collapsing Of, Tubular Structures of the Body, e.g Stents; Orthopaedic, Nursing or Contraceptive Devices; Fomentation; Treatment or Protection of Eyes or Ears; Bandages, Dressings or Absorbent Pads; First-aid Kits
A61F 2/60 (20130101)
A61F 2/80 (20130101)
A61F 2/7812 (20130101)
A61F 7/00 (20130101) Original (OR) Class
A61F 2007/0067 (20130101)
A61F 2007/0075 (20130101)
A61F 2007/0228 (20130101)

Details of Heat-exchange and Heat-transfer Apparatus, of General Application
F28F 2230/00 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 35/30 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273573 Kaytor et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
APPLICANT(S) Humanetics Corporation (Minneapolis, Minnesota)
ASSIGNEE(S)
INVENTOR(S) Michael D. Kaytor (Maplewood, Minnesota);  Adam J. Harvey (Blaine, Minnesota);  John C. Dykstra (Edina, Minnesota);  Samuel Elliott Kennedy (Bend, Oregon);  April Naab (Bend, Oregon);  Michael Edward Grass (Bend, Oregon)
ABSTRACT The present invention is directed to solid dispersion formulations comprising genistein and one or more pharmaceutically acceptable excipients. In particular embodiments, the one or more pharmaceutically acceptable excipients include polyvinylpyrrolidone. Various techniques can be used to form the solid dispersions, including spray drying and extrusion techniques.
FILED Wednesday, May 18, 2022
APPL NO 17/664015
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/1635 (20130101) Original (OR) Class
A61K 31/352 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273711 BOYKEN et al.
FUNDED BY
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) University of Washington (Seattle, Washington)
ASSIGNEE(S)
INVENTOR(S) Scott BOYKEN (Seattle, Washington);  Marc Joseph LAJOIE (Seattle, Washington);  Robert A. LANGAN (Seattle, Washington);  David BAKER (Seattle, Washington);  Jilliane Ruth BRUFFEY (Seattle, Washington)
ABSTRACT Disclosed am protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called die key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain only when the protein switch components are co-localized when bound to their targets, components of such protein switches, and their use.
FILED Monday, May 18, 2020
APPL NO 17/609972
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101) Original (OR) Class

Peptides
C07K 16/18 (20130101)
C07K 2319/00 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/62 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273752 Cubillos Ruiz et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
APPLICANT(S) Cornell University (Ithaca, New York)
ASSIGNEE(S)
INVENTOR(S) Juan Rodrigo Cubillos Ruiz (New York, New York);  Chang-Suk Chae (New York, New York)
ABSTRACT Described herein are compositions and methods that include use of PERK inhibitors, inhibitors of enzymes that can synthesize lysophosphatidic acid (LPA), inhibitors of LPA signaling, such as LPA receptor antagonists, deletion/mutation knockout/knock-down) or PERK or LPA receptors, or combinations thereof. Such compositions and methods can increase production of interferon by dendritic cells in subjects suffering from cancer and improve the survival of those subjects.
FILED Thursday, July 02, 2020
APPL NO 17/622634
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/42 (20130101)
A61K 31/47 (20130101)
A61K 31/496 (20130101)
A61K 38/005 (20130101) Original (OR) Class
A61K 41/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/04 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273877 Kamen et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Contracting Command (ACC)
Aberdeen Proving Ground (APG)
Combat Capabilities Development Command (CCDC)
Army Research Laboratory (CCDC ARL)
APPLICANT(S) DEKA Products Limited Partnership (Manchester, New Hampshire)
ASSIGNEE(S)
INVENTOR(S) Dean Kamen (Bedford, New Hampshire);  Richard J. Lanigan (Concord, New Hampshire)
ABSTRACT An example agent administration device may comprise a housing. The device may further comprise a sharp assembly including a delivery sharp. The sharp assembly may be reciprocally displaceable along a guide channel of the housing. The device may further comprise an access port in fluid communication with the delivery sharp. The device may further comprise an actuation assembly configured drive the sharp assembly, via urging of a single bias member, from a storage state in which the delivery sharp is within the housing, through a first extended position in which the delivery sharp extends a maximum distance from the housing and to a partially retracted position in which the delivery sharp extends a lesser distance from the housing.
FILED Friday, December 31, 2021
APPL NO 17/566818
CURRENT CPC
Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 5/2425 (20130101) Original (OR) Class
A61M 5/2455 (20130101)
A61M 2005/247 (20130101)
A61M 2005/2477 (20130101)
A61M 2202/0007 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273906 Benkoski et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Office of Naval Research (ONR)
APPLICANT(S) The Johns Hopkins University (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) Jason J. Benkoski (Catonsville, Maryland);  Paul J. Biermann (Columbia, Maryland);  William L. Luedeman (New Market, Maryland);  Jeffrey M. Paulson (Columbia, Maryland);  Steven M. Storck (Timonium, Maryland);  Melanie L. Morris (Odenton, Maryland);  Evan D. Jacque (Columbia, Maryland);  Michael H. Jin (Ellicott City, Maryland);  Reginald Beach (Arlington, Virginia)
ABSTRACT Regenerable carbon dioxide scrubbers are provided. The regenerable carbon dioxide scrubbers include at least a first housing compartment including an inlet, an outlet, and an interior region. A sorbent material is located within the interior region of the first housing compartment, in which the sorbent material (a) attracts and/or retains carbon dioxide from an air supply passing through the sorbent material at an operating temperature below about 100° C., and (b) releases carbon dioxide at a regenerating temperature above about 150° C. Rebreathers including the regenerable carbon dioxide scrubbers and methods of scrubbing carbon dioxide from a user's exhaled air are also provided.
FILED Monday, March 01, 2021
APPL NO 17/188411
CURRENT CPC
Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 16/22 (20130101) Original (OR) Class

Separation
B01D 53/0438 (20130101)
B01D 2257/504 (20130101)
B01D 2259/4541 (20130101)
B01D 2259/40088 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273923 Zeira et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Contracting Command (ACC)
Aberdeen Proving Ground (APG)
Combat Capabilities Development Command (CCDC)
Army Research Laboratory (CCDC ARL)
APPLICANT(S) DEKA Products Limited Partnership (Manchester, New Hampshire)
ASSIGNEE(S)
INVENTOR(S) Eitan C. Zeira (Hollis, New Hampshire);  Jason A. Demers (Manchester, New Hampshire);  Dean Kamen (Bedford, New Hampshire)
ABSTRACT A medical agent delivery device may comprise a collapsible reservoir and a base portion including at least one microneedle on a first face and on an opposing second face. Each microneedle on the first face may fluidically communicate with a microneedle on the second face. The device may further comprise an elastomeric housing attached to the first face. The reservoir and the at least one microneedle on the first face of the base portion may be within the elastomeric housing. The device may further comprise a displaceable spacer having a first position in which the spacer supports the reservoir in spaced relation to the at least one microneedle on the first side of the base portion. When the spacer is in a second position, the elastomeric housing may be configured to press the reservoir into the at least one microneedle on the first side of the base portion.
FILED Monday, March 01, 2021
APPL NO 17/188301
CURRENT CPC
Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 37/0015 (20130101) Original (OR) Class
A61M 2037/003 (20130101)
A61M 2037/0023 (20130101)
A61M 2202/0007 (20130101)
A61M 2205/36 (20130101)
A61M 2205/3368 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273924 Kamen et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Contracting Command (ACC)
Aberdeen Proving Ground (APG)
Combat Capabilities Development Command (CCDC)
Army Research Laboratory (CCDC ARL)
APPLICANT(S) DEKA Products Limited Partnership (Manchester, New Hampshire);  Applied Materials, INC. (Santa Clara, California)
ASSIGNEE(S)
INVENTOR(S) Dean Kamen (Bedford, New Hampshire);  Eitan C. Zeira (Hollis, New Hampshire);  Jason A. Demers (Manchester, New Hampshire);  Brian D. Tracey (Litchfield, New Hampshire);  Michel A. Rosa (Mountain View, California);  Jack MacLeod (Nashua, New Hampshire)
ABSTRACT A medical agent delivery device may comprise a laminate of a number of layers coupled together. The device may further comprise a collapsible reservoir within the laminate. The device may further comprise a sharp bearing body having at least one microneedle. The device may further comprise a collar element attached to the sharp bearing body. The device may further comprise a removable cover assembly including a microneedle encasing body coupled to the sharp bearing body and to a release liner. The microneedle encasing body may be attached more weakly to the sharp bearing body than to the release liner.
FILED Monday, March 01, 2021
APPL NO 17/188364
CURRENT CPC
Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 37/0015 (20130101) Original (OR) Class
A61M 2037/003 (20130101)
A61M 2037/0023 (20130101)
A61M 2037/0053 (20130101)
A61M 2202/0007 (20130101)
A61M 2202/30 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273925 Zeira et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Contracting Command (ACC)
Aberdeen Proving Ground (APG)
Combat Capabilities Development Command (CCDC)
Army Research Laboratory (CCDC ARL)
APPLICANT(S) DEKA Products Limited Partnership (Manchester, New Hampshire)
ASSIGNEE(S)
INVENTOR(S) Eitan C. Zeira (Hollis, New Hampshire);  Lee A. Batchelder (Auburn, New Hampshire);  Hans E. Johnson (Salem, New Hampshire);  Dean Kamen (Bedford, New Hampshire);  Travis G. Bibeau (Chester, New Hampshire)
ABSTRACT A delivery device may comprise a main body. The main body may comprise a peripheral region. The main body may further comprise a central region extending proud of the peripheral region. The peripheral region may have a top surface and a base. The peripheral region may include a number of bodies spaced apart by slits which extend from the periphery of the peripheral region toward the central region. The delivery device may further comprise an adhesive coupled to at least a part of the main body. The delivery device may further comprise a collapsible reservoir coupled to the main body and to at least one delivery sharp.
FILED Friday, December 31, 2021
APPL NO 17/566823
CURRENT CPC
Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 5/155 (20130101)
A61M 5/162 (20130101)
A61M 5/14248 (20130101)
A61M 37/0015 (20130101) Original (OR) Class
A61M 2005/14204 (20130101)
A61M 2005/14252 (20130101)
A61M 2037/0023 (20130101)
A61M 2037/0061 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274138 DIAZ ACEVEDO et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) Drexel University (Philadelphia, Pennsylvania)
ASSIGNEE(S) Drexel University (Philadelphia, Pennsylvania)
INVENTOR(S) Maria Mercedes DIAZ ACEVEDO (Philadelphia, Pennsylvania);  Simge UZUN (Philadelphia, Pennsylvania);  Nicolas Javier ALVAREZ (Drexel Hill, Pennsylvania);  Giuseppe Rafaello PALMESE (Hainesport, New Jersey)
ABSTRACT The present invention is an apparatus and method of using the apparatus for separating individual particles from a collection of clumps (or bundles or aggregates) of particles. The apparatus has n number of separation columns, wherein each separation column is connected at an upper portion thereof to at least one fluid connection, and a particle collector. A pressurized fluid flows through the apparatus and 1) suspends a portion of the clumps within the separation column and/or the at least one fluid connection thereby separating at least some clumps into smaller clumps and/or individual particles; and 2) conveys a portion of the clumps and/or individual particles to the next separation column in the series of separation columns, or, in the case of the nth separation column conveys individual particles to the particle collector.
FILED Friday, July 31, 2020
APPL NO 17/631556
CURRENT CPC
Separating Solids From Solids by Sieving, Screening, Sifting or by Using Gas Currents; Separating by Other Dry Methods Applicable to Bulk Material, e.g Loose Articles Fit to be Handled Like Bulk Material
B07B 7/01 (20130101)
B07B 7/06 (20130101)
B07B 9/02 (20130101) Original (OR) Class

Preliminary Treatment of Fibres, e.g for Spinning
D01G 5/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274369 Hicks et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
APPLICANT(S) Government of the United States, as represented by the Secretary of the Air Force (Wright-Patterson AFB, Ohio)
ASSIGNEE(S)
INVENTOR(S) Adam S. Hicks (Huber Heights, Ohio);  Jared W. Speltz (Washington Township, Ohio);  Andrea K. Helbach (Dayton, Ohio);  Kara M. Storage (Beavercreek, Ohio);  Tara M. Storage (Beavercreek, Ohio);  Michael Anthony Pratt, JR. (Dayton, Ohio)
ABSTRACT The present invention discloses cured composites having improved surfaces and processes of making and methods of using same. Such processes use ultra-short pulse lasers, for example, a femto-second laser to ablate material without the detrimental heat affected zones of other laser processes. Such process can not only increases surface roughness and clean contaminates, but can also selectively remove the matrix material and expose the surface fibers of cured composites. The treated cured composites have improved thermal and electrical pathways that can dissipate unwanted heat and electricity when two or more prepregs and/or cured composites are bonded or cured to form a single article.
FILED Monday, February 28, 2022
APPL NO 17/681949
CURRENT CPC
Soldering or Unsoldering; Welding; Cladding or Plating by Soldering or Welding; Cutting by Applying Heat Locally, e.g Flame Cutting; Working by Laser Beam
B23K 26/402 (20130101)
B23K 26/0624 (20151001)
B23K 26/3584 (20180801)

Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form
B32B 3/266 (20130101) Original (OR) Class
B32B 5/024 (20130101)
B32B 7/12 (20130101)
B32B 27/12 (20130101)
B32B 2262/103 (20130101)
B32B 2262/106 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274692 HALDEMAN et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Contracting Command (ACC)
Redstone Arsenal (REDSTONE)
APPLICANT(S) Bell Textron Inc. (Fort Worth, Texas)
ASSIGNEE(S) Bell Textron Inc. (Fort Worth, Texas)
INVENTOR(S) Andrew Paul HALDEMAN (Fort Worth, Texas);  Paul Wayne WOOLBRIGHT (Euless, Texas);  Timothy McClellan MOSIG (Richland Hills, Texas);  George Matthew THOMPSON (Lewisville, Texas)
ABSTRACT A spherical bearing centrifugal force retention link includes an inboard spherical bearing to attach to a rotor hub and an outboard spherical bearing to attach to a rotor blade. In use, the inboard spherical bearing and the outboard spherical bearing react centrifugal force radially and a torsional moment of the centrifugal force link is substantially constant throughout the rotor blade pitch range.
FILED Monday, March 01, 2021
APPL NO 17/188785
CURRENT CPC
Aeroplanes; Helicopters
B64C 27/35 (20130101) Original (OR) Class
B64C 27/48 (20130101)
B64C 27/82 (20130101)
B64C 2027/8254 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274698 Deng et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Office of Scientific Research (AFOSR)
National Science Foundation (NSF)
APPLICANT(S) PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana)
ASSIGNEE(S) PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana)
INVENTOR(S) Xinyan Deng (Lafayette, Indiana);  Jian Zhang (Lafayette, Indiana)
ABSTRACT Disclosed herein is a voice coil actuator direct-drive resonant flapper system for flapping wing micro air vehicles and flapping fin autonomous underwater vehicles.
FILED Monday, January 11, 2021
APPL NO 17/145398
CURRENT CPC
Aeroplanes; Helicopters
B64C 33/02 (20130101) Original (OR) Class
B64C 2201/025 (20130101)
B64C 2201/042 (20130101)

Dynamo-electric Machines
H02K 7/003 (20130101)
H02K 41/0354 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275148 Kriley et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Combat Capabilities Development Command (CCDC)
APPLICANT(S) PPG Industries Ohio, Inc. (Cleveland, Ohio)
ASSIGNEE(S) PPG Industries Ohio, Inc. (Cleveland, Ohio)
INVENTOR(S) Joseph P. Kriley (Valencia, Pennsylvania);  Marvin M. Pollum, Jr. (Pittsburgh, Pennsylvania);  David J. Fortman (Pittsburgh, Pennsylvania);  Brian K. Rearick (Allison Park, Pennsylvania);  Masayuki Nakajima (Wexford, Pennsylvania);  Maria S. French (Canfield, Ohio)
ABSTRACT Disclosed is an epoxide-functional adduct (E2) and an amine-functional adduct (A3) and coating compositions including these adducts. The epoxide-functional adduct (E2) comprises a reaction product of a reaction mixture comprising (a) an epoxy-containing compound (E1) and (b) a diamine comprising a cyclic ring and/or a polyamine comprising a cyclic ring (A1). The amine-functional adduct comprises a reaction product of a reaction mixture comprising the epoxy-functional adduct (E2) and a monoamine, diamine, and/or polyamine (A2), wherein the monoamine, diamine, and/or polyamine (A2) are different than the diamine comprising a cyclic ring and/or the polyamine comprising a cyclic ring (A1). The present invention is also directed to methods of making the compositions, methods of coating a substrate, and coated substrates.
FILED Tuesday, June 23, 2020
APPL NO 17/753180
CURRENT CPC
Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 80/00 (20141201)

Lime, Magnesia; Slag; Cements; Compositions Thereof, e.g Mortars, Concrete or Like Building Materials; Artificial Stone; Ceramics; Refractories; Treatment of Natural Stone
C04B 37/028 (20130101)
C04B 2237/02 (20130101)
C04B 2237/402 (20130101)

Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds
C08G 59/245 (20130101)
C08G 59/5033 (20130101) Original (OR) Class

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 7/65 (20180101)
C09D 163/00 (20130101)

Adhesives; Non-mechanical Aspects of Adhesive Processes in General; Adhesive Processes Not Provided for Elsewhere; Use of Materials as Adhesives
C09J 11/08 (20130101)
C09J 163/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276095 Yetzbacher et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Naval Research Laboratory (NRL)
APPLICANT(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S)
INVENTOR(S) Michael K. Yetzbacher (Burke, Virginia);  Samuel D. Park (North Bethesda, Maryland);  Vasanthi Sivaprakasam (Silver Spring, Maryland)
ABSTRACT Systems and methods for remote sensing in a plurality of dimensions simultaneously are provided. The plurality of dimensions include imaging, spectral sensing, and ranging at a range resolution that is orders of magnitude finer than the native time resolution of a detector used in the system.
FILED Thursday, February 24, 2022
APPL NO 17/680061
CURRENT CPC
Measurement of Intensity, Velocity, Spectral Content, Polarisation, Phase or Pulse Characteristics of Infra-Red, Visible or Ultra-violet Light; Colorimetry; Radiation Pyrometry
G01J 3/45 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/55 (20130101)

Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves
G01S 17/89 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276206 JAURIQUI et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Office of Scientific Research (AFOSR)
Air Force Research Laboratory (AFRL)
Materials and Manufacturing Directorate (MMD)
APPLICANT(S) Vibrant Corporation (Albuquerque, New Mexico)
ASSIGNEE(S)
INVENTOR(S) Leanne JAURIQUI (Albuquerque, New Mexico);  Thomas KOHLER (Diez, Germany);  Alexander J. MAYES (Albuquerque, New Mexico);  Julieanne HEFFERNAN (Albuquerque, New Mexico);  Richard LIVINGS (Albuquerque, New Mexico);  Eric BIEDERMANN (Albuquerque, New Mexico)
ABSTRACT Creation and use of a digital twin instance (DTI) for a physical instance of the part. The DTI may be created by a model inversion process such that model parameters are iterated until a convergence criterion related to a physical resonance inspection result and a digital resonance inspection result is satisfied. The DTI may then be used in relation to part evaluation including through simulated use of the part. The physical instance of the part may be evaluated by way of the DTI or the DTI may be used to generate maintenance schedules specific to the physical instance of the part.
FILED Wednesday, January 26, 2022
APPL NO 17/585343
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 29/04 (20130101)
G01N 29/52 (20130101)
G01N 29/4418 (20130101) Original (OR) Class

Electric Digital Data Processing
G06F 30/20 (20200101)
G06F 2119/18 (20200101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276316 NEMANICK et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
The Aerospace Corporation (AEROSPACE)
Federally Funded Research and Development Center (FFRDC)
Operated by The Aerospace Corporation (AEROSPACE) at El Segundo, CA
APPLICANT(S) The Aerospace Corporation (El Segundo, California)
ASSIGNEE(S) The Aerospace Corporation (, None)
INVENTOR(S) Eric Joseph NEMANICK (Santa Monica, California);  Robert G. WILL (Redondo Beach, California)
ABSTRACT An apparatus for monitoring health of one or more cells in a battery includes a health monitoring system configured to measure voltage on one or more cells when a waveform is injected into the one or more cells. The waveform is measured at an end of a pulse for each current.
FILED Friday, February 26, 2021
APPL NO 17/186449
CURRENT CPC
Measuring Electric Variables; Measuring Magnetic Variables
G01R 31/371 (20190101)
G01R 31/392 (20190101) Original (OR) Class
G01R 31/396 (20190101)

Circuit Arrangements or Systems for Supplying or Distributing Electric Power; Systems for Storing Electric Energy
H02J 7/005 (20200101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276325 Shi et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Office of Scientific Research (AFOSR)
APPLICANT(S) Sufei Shi (Albany, New York);  Tianmeng Wang (Troy, New York)
ASSIGNEE(S) Rensselaer Polytechnic Institute (Troy, New York)
INVENTOR(S) Sufei Shi (Albany, New York);  Tianmeng Wang (Troy, New York)
ABSTRACT A transition metal dichalcogenides device includes a substrate, a bottom layer of boron nitride, a tungsten diselenide monolayer on the bottom layer of boron nitride, a top layer of boron nitride on the tungsten diselenide monolayer such that the bottom and top layers of boron nitride at least partially encapsulate the tungsten diselenide monolayer, a source electrode on the substrate, a drain electrode on the substrate, and a top gate electrode on the top layer of boron nitride. The tungsten diselenide monolayer is configured to reveal excitons when at least one of a K valley and a K′ valley of the tungsten diselenide monolayer is exposed to excitation photon energy and an external magnetic field. The excitons are giant valley-polarized Rydberg excitons in excited states ranging from 2s to 11s when the external magnetic field is in the range of about −17 T to about 17 T.
FILED Thursday, December 30, 2021
APPL NO 17/565806
CURRENT CPC
Measurement of Intensity, Velocity, Spectral Content, Polarisation, Phase or Pulse Characteristics of Infra-Red, Visible or Ultra-violet Light; Colorimetry; Radiation Pyrometry
G01J 4/00 (20130101)

Measuring Electric Variables; Measuring Magnetic Variables
G01R 33/20 (20130101) Original (OR) Class

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 29/24 (20130101)
H01L 29/78696 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276340 Minkler et al.
FUNDED BY
Department of Defense (DOD)
Missile Defense Agency (MDA)
APPLICANT(S) Raytheon Company (Waltham, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Jing Q. Minkler (Tucson, Arizona);  Daniel Heacock (Arvada, Colorado)
ABSTRACT A follow-on object for use in a salvo mission in which one or more lead objects (LO) and a follow-on object track a target. A track state of a tracked object within a sensor field-of-view (FOV) of the follow-on object is initialized. Target-state estimator (TSE) processing based on sensor measurements from the sensor FOV is performed to maintain the track state of the tracked object. Kinematic characteristics of the tracked object are evaluated based on the sensor measurements to compute a probability that the tracked object is an LO based on the evaluated kinematic characteristics. If the probability is not greater than a threshold, the tracked object is designated as the target and TSE processing is resumed. Otherwise, the tracked object is designated as an LO and the track state is re-initialized and the track of the LO is excluded from some intercept task considerations.
FILED Friday, April 24, 2020
APPL NO 16/857820
CURRENT CPC
Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves
G01S 7/415 (20130101) Original (OR) Class
G01S 13/62 (20130101)
G01S 13/588 (20130101)
G01S 13/589 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276393 Yang et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
National Aeronautics and Space Administration (NASA)
APPLICANT(S) The Regents of the University of Colorado, a body corporate (Denver, Colorado)
ASSIGNEE(S)
INVENTOR(S) Rong Yang (Boulder, Colorado);  Yu Morton (Boulder, Colorado)
ABSTRACT Various embodiments of the present technology generally relate to multi-frequency satellite navigation receiver technology. More specifically, some embodiments relate to an inter-frequency signal aiding technique for multi-frequency signal tracking in a multi-frequency receiver. The present technology enables a satellite navigation receiver (such as GPS) to continue operation, or to have improved performance, in environments where signals on one or more frequency bands experience fading. Some embodiments can estimate parameters of signal channels that experience fading based on measurements obtained from all or other less compromised frequency bands in linear operation by the receiver. Some embodiments can optimally estimate carrier parameters of navigation signals with consideration of relative measurement qualities. These parameters are used to construct the local reference signals, maintain lock on the fading signals, and obtain accurate positioning solutions and remote sensing observations.
FILED Thursday, August 01, 2019
APPL NO 17/632088
CURRENT CPC
Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves
G01S 19/29 (20130101)
G01S 19/30 (20130101)
G01S 19/32 (20130101)
G01S 19/37 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277072 Austin et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan)
ASSIGNEE(S)
INVENTOR(S) Todd Austin (Ann Arbor, Michigan);  Valeria Bertacco (Ann Arbor, Michigan);  Mark Gallagher (Ann Arbor, Michigan);  Baris Kasikci (Ann Arbor, Michigan);  Lauren Biernacki (Ann Arbor, Michigan)
ABSTRACT A method of securing a virtual address space against unauthorized access from an unauthorized agent includes generating a superimposed address space corresponding to the virtual address space, dilating the superimposed address space by inserting dununy memory at a plurality of locations in the superimposed address space, and displacing the superimposed address space by shifting a segment of the superimposed address space by a d-bit key. A computer processor includes a memory and a dedicated functional unit in a stage of a pipeline of the computer processor, the computer processor including an instruction that when executed by the dedicated functional unit causes the computer processor to translate one or more pointers between displaced and dilated address spaces of the memory and virtual address spaces of the memory.
FILED Monday, August 17, 2020
APPL NO 17/635692
CURRENT CPC
Electric Digital Data Processing
G06F 21/54 (20130101) Original (OR) Class
G06F 21/71 (20130101)
G06F 21/554 (20130101)
G06F 21/577 (20130101)
G06F 21/602 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277254 Feeney et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
APPLICANT(S) Aptima, Inc. (Woburn, Massachusetts)
ASSIGNEE(S) Aptima, Inc. (Woburn, Massachusetts)
INVENTOR(S) John Feeney (Beavercreek, Ohio);  Kevin Durkee (Carmel, Indiana);  Zachary Kiehl (Dayton, Ohio);  William Depriest (Dayton, Ohio);  Matthew Ewer (Fairborn, Ohio)
ABSTRACT A contextualized sensor system is provided comprising one or more sensors, one or more memory elements, a library of alert rules stored in the one or more memory elements, one or more processors, and the one or more memory elements including instructions that, when executed, cause the one or more processors to perform operations comprising: receiving from one of the one or more sensors one or more sensor data, comparing the first sensor data to a library of alert rules to determine whether an alert situation has occurred, and communicating an alert if the alert situation has occurred. In some embodiments, the operations further comprise contextualizing an environmental data, a location data, a physiological data, a behavior data and an orientation data.
FILED Friday, December 27, 2019
APPL NO 16/728972
CURRENT CPC
Data Processing Systems or Methods, Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes; Systems or Methods Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes, Not Otherwise Provided for
G06Q 10/063114 (20130101) Original (OR) Class

Signalling or Calling Systems; Order Telegraphs; Alarm Systems
G08B 21/02 (20130101)
G08B 25/10 (20130101)

Wireless Communication Networks
H04W 4/38 (20180201)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277903 Cao et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Combat Capabilities Development Command (CCDC)
Army Research Laboratory (CCDC ARL)
Department of the Navy (DON)
Office of Naval Research (ONR)
APPLICANT(S) FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (Tallahassee, Florida);  GENERAL CAPACITOR, LLC (Tallahassee, None)
ASSIGNEE(S)
INVENTOR(S) Wanjun Ben Cao (Tallahassee, Florida);  Jin Yan (Tallahassee, Florida);  Xujie Chen (Tallahassee, Florida);  Jian-Ping Zheng (Tallahassee, Florida);  Annadanesh Shellikeri (Tallahassee, Florida);  Mark Andrew Hagen (Tallahassee, Florida)
ABSTRACT A hybrid lithium-ion battery-capacitor (H-LIBC) energy storage device includes a hybrid composite cathode electrode having a lithium ion battery (LIB) cathode active material and a lithium ion capacitor (LIC) cathode active material. An anode electrode having a surface is pre-loaded and pressed with a lithium (Li) thin film source. The anode electrode is pre-lithiated with the lithium film source by positioning the Li film source on the surface of anode electrode after electrolyte filling and soaking processes, a separator and an organic solvent electrolytic solution including a lithium salt electrolyte are also provided. A method of making a hybrid lithium-ion battery-capacitor and a method of making a hybrid composite cathode for a hybrid lithium-ion battery-capacitor are also disclosed.
FILED Thursday, December 16, 2021
APPL NO 17/552908
CURRENT CPC
Capacitors; Capacitors, Rectifiers, Detectors, Switching Devices or Light-sensitive Devices, of the Electrolytic Type
H01G 11/06 (20130101) Original (OR) Class
H01G 11/24 (20130101)
H01G 11/38 (20130101)
H01G 11/46 (20130101)
H01G 11/50 (20130101)
H01G 11/52 (20130101)
H01G 11/60 (20130101)
H01G 11/62 (20130101)
H01G 11/86 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277948 Cooks
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Army (DOA)
Combat Capabilities Development Command (CCDC)
Army Research Laboratory (CCDC ARL)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S)
INVENTOR(S) Robert Graham Cooks (West Lafayette, Indiana)
ABSTRACT The invention generally relates to systems and methods for conducting reactions and screening for reaction products.
FILED Monday, May 16, 2022
APPL NO 17/745209
CURRENT CPC
Electric Discharge Tubes or Discharge Lamps
H01J 49/0013 (20130101)
H01J 49/165 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220278746 AHADIAN et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Research Laboratory (AFRL)
APPLICANT(S) ULTRA COMMUNICATIONS, INC. (Vista, California)
ASSIGNEE(S)
INVENTOR(S) Joseph F. AHADIAN (San Marcos, California);  Vahid NAZER (San Marcos, California);  Sandra SKENDZIC (Vista, California);  Charles B. KUZNIA (Encinitas, California);  Richard J. WEISS (San Diego, California)
ABSTRACT Methods and systems for automated health assessment of fiber optic links of a fiber optic communication system are described. Tables are used to describe the fiber optic links, including access addresses to communication modules used in the links. Telemetry data representative of operation of the communication modules can be read via the access addresses into a central station. OTDR/OFDR measurement data of fiber optic segments used in the links can be read via the access addresses into the central station. The telemetry and/or OTDR/OFDR measurement data can be used by the central station for comparison against reference data to assess health of the links. The communication modules locally and continuously capture the telemetry data to detect transient events that may be the result of tampering of the links.
FILED Monday, May 16, 2022
APPL NO 17/663652
CURRENT CPC
Transmission
H04B 10/071 (20130101) Original (OR) Class
H04B 10/0793 (20130101)
H04B 10/07955 (20130101)
H04B 10/07957 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220278924 Brewer
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) Micron Technology, Inc. (Boise, Idaho)
ASSIGNEE(S)
INVENTOR(S) Tony Brewer (Plano, Texas)
ABSTRACT Implementations of the present disclosure are directed to systems and methods for flow control using a multiple flit interface. A credit return field is used in a credit-based flow control system to indicate that one or more credits are being returned to a sending device from a receiving device. Based on the number of credits available, the sending device determines whether to send device or wait until more credits are returned. The amount of buffer space used by the receiver to store the packet is determined by the number of transfer cycles used to receive the packet, not the number of flits comprising the packet. This is enabled by having the buffer be as wide as the bus. The receiver returns credits to the sender based on the number of buffer rows used to store the received packet, not the number of flits comprising the packet.
FILED Friday, May 13, 2022
APPL NO 17/744158
CURRENT CPC
Transmission of Digital Information, e.g Telegraphic Communication
H04L 45/38 (20130101) Original (OR) Class
H04L 45/74 (20130101)
H04L 45/586 (20130101)
H04L 49/3072 (20130101)
H04L 69/22 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220278998 STAVROU et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Army Materiel Command (AMC)
Combat Capabilities Development Command (CCDC)
Army Research Laboratory (CCDC ARL)
APPLICANT(S) George Mason Research Foundation, Inc. (Fairfax, Virginia)
ASSIGNEE(S) George Mason Research Foundation, Inc. (Fairfax, Virginia)
INVENTOR(S) Angelos STAVROU (Springfield, Virginia);  Sushil JAJODIA (Oakton, Virginia);  Anup K. GHOSH (Centreville, Virginia);  Rhandi MARTIN (St. James, Barbados);  Charalampos ANDRIANAKIS (Crete, Greece)
ABSTRACT A transparent proxy for malware detection includes a monitor module, a protocol determination module, a challenge generation module, a response determination module, and a data control module. The monitor module examines data originating from an application towards a remote server. The protocol determination module identifies the protocol type used for the data. The challenge generation module produces a challenge for the application based upon the protocol type, sends the challenge to the application, and maintains a state related to the data and the challenge. The response determination module makes a determination if an automatic non-interactive application response is received in response to the challenge from the application. The data control module allows the first data to continue to the remote server when the determination is valid. The data control module reports malware detection and blocks the data to continue to the remote server when the determination is invalid.
FILED Wednesday, May 04, 2022
APPL NO 17/736507
CURRENT CPC
Electric Digital Data Processing
G06F 21/566 (20130101)
G06F 2221/2103 (20130101)

Transmission of Digital Information, e.g Telegraphic Communication
H04L 63/08 (20130101)
H04L 63/145 (20130101)
H04L 63/0884 (20130101)
H04L 63/1416 (20130101) Original (OR) Class
H04L 67/02 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Energy (DOE) 

US 20220272942 Deng et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
Pacific Northwest National Laboratory (PNNL)
Federally Funded Research and Development Center (FFRDC)
Operated by Battelle Memorial Institute (BMI) at Richland, WA
APPLICANT(S) Battelle Memorial Institute (Richland, Washington)
ASSIGNEE(S) Battelle Memorial Institute (Richland, Washington)
INVENTOR(S) Z. Daniel Deng (Richland, Washington);  Jun Lu (Richland, Washington);  Huidong Li (Richland, Washington);  Jayson J. Martinez (Kennewick, Washington);  Mitchell J. Myjak (Richland, Washington)
ABSTRACT Organism monitoring devices and organism monitoring methods are described. According to one aspect, an organism monitoring device includes a housing configured to be physically associated with an organism to be monitored, an antenna, signal generation circuitry comprising an oscillator configured to generate an oscillation signal, and an output node configured to output the oscillation signal, impedance matching circuitry coupled with the housing, the antenna and the signal generation circuitry, and wherein the impedance matching circuitry is configured to match an impedance of the signal generation circuitry and an impedance of the antenna, and wherein the impedance matching circuitry is further configured to receive the oscillation signal and to provide the oscillation signal to the antenna, and wherein the antenna is configured to emit a wireless signal externally of the organism monitoring device as a result of the provision of the oscillation signal to the input of the antenna.
FILED Monday, March 01, 2021
APPL NO 17/189095
CURRENT CPC
Animal Husbandry; Care of Birds, Fishes, Insects; Fishing; Rearing or Breeding Animals, Not Otherwise Provided For; New Breeds of Animals
A01K 11/006 (20130101) Original (OR) Class

Antennas, i.e Radio Aerials
H01Q 1/50 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220272982 Monaco et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
Oak Ridge National Laboratory (ORNL)
Federally Funded Research and Development Center (FFRDC)
Operated by UT-Battelle, LLC (UTB) at Oak Ridge, TN
APPLICANT(S) RJ Lee Group, Inc. (Monroeville, Pennsylvania);  UT-BATTELLE, LLC (Oak Ridge, Tennessee);  IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (Ames, Iowa)
ASSIGNEE(S)
INVENTOR(S) Steven J. Monaco (Venetia, Pennsylvania);  Richard J. Lee (Murrysville, Pennsylvania);  Alan M. Levine (Monroeville, Pennsylvania);  Jonathan Lyle Wistrom (Maryville, Missouri);  Mariappan Parans Paranthaman (Knoxville, Tennessee);  Merlin Theodore (Knoxville, Tennessee);  Bryan Howard Bellaire (Ankeny, Iowa);  Nathan Drew Peroutka-Bigus (Ames, Iowa)
ABSTRACT Provided is a metal organic framework (MOF) comprising copper ions. Also provided are resin powders, granules or pellets comprising the MOF. In some embodiments, the resin powders, granules or pellets are antimicrobial. Also provided are fibers or sheets comprising the MOF. In some embodiments, the fibers or sheets are antimicrobial. Processes for preparing the MOF are also provided.
FILED Tuesday, February 15, 2022
APPL NO 17/651205
CURRENT CPC
Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators
A01N 25/10 (20130101)
A01N 25/34 (20130101)
A01N 59/20 (20130101) Original (OR) Class

Biocidal, Pest Repellant, Pest Attractant or Plant Growth Regulatory Activity of Chemical Compounds or Preparations
A01P 1/00 (20210801)

Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium
C07F 1/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273265 Lall et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
Brookhaven National Laboratory (BNL)
Federally Funded Research and Development Center (FFRDC)
Operated by Brookhaven Science Associates, LLC (BSA) at Upton, NY
APPLICANT(S) Hybridyne Imaging Technologies, Inc. (Toronto, Canada)
ASSIGNEE(S) Hybridyne Imaging Technologies, Inc. (Toronto, Canada)
INVENTOR(S) Terrence Lall (Toronto, Canada);  James A. Ionson (Lexington, Massachusetts)
ABSTRACT A dual modality endocavity imaging and treatment system for detection of cancer and targeted biopsy and treatment procedures, comprising: a housing; a nuclear detector system housed within the housing and configured for detecting nuclear radiation imaging data; an ultrasound detector system housed within the housing for detecting ultrasound imaging data; a needle associated with the housing and adjustably positionable relative thereto; and a data processing module configured to receive the nuclear radiation imaging data and the ultrasound imaging data and to generate and output an image showing the relative position of the needle and an endocavity object of interest. The needle may include a distinct radiation signature to facilitate imaging thereof.
FILED Friday, October 08, 2021
APPL NO 17/496854
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 6/12 (20130101)
A61B 6/037 (20130101)
A61B 6/481 (20130101)
A61B 6/482 (20130101)
A61B 6/5235 (20130101)
A61B 6/5247 (20130101)
A61B 8/12 (20130101)
A61B 8/465 (20130101)
A61B 8/0841 (20130101)
A61B 8/4416 (20130101) Original (OR) Class
A61B 8/5207 (20130101)
A61B 10/0233 (20130101)

Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 5/1001 (20130101)
A61N 5/1027 (20130101)
A61N 5/1049 (20130101)
A61N 5/1071 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274170 MANUEL et al.
FUNDED BY
Department of Energy (DOE)
Office of Fossil Energy and Carbon Management (FECM)
National Energy Technology Laboratory (NETL)
Office of Science (DOE-SC)
Oak Ridge National Laboratory (ORNL)
Federally Funded Research and Development Center (FFRDC)
Operated by UT-Battelle, LLC (UTB) at Oak Ridge, TN
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) University of Florida Research Foundation, Inc. (Gainesville, Florida);  UT BATTELLE, LLC (OAK RIDGE, Tennessee)
ASSIGNEE(S)
INVENTOR(S) MICHELE VIOLA MANUEL (GAINESVILLE, Florida);  HUNTER B. HENDERSON (GAINESVILLE, Florida);  ORLANDO RIOS (OAK RIDGE, Tennessee);  GERARD M. LUDTKA (OAK RIDGE, Tennessee)
ABSTRACT Disclosed herein is a method comprising disposing a container containing a metal and/or ferromagnetic solid and abrasive particles in a static magnetic field; where the container is surrounded by an induction coil; activating the induction coil with an electrical current, to heat up the metallic or ferromagnetic solid to form a fluid; generating sonic energy to produce acoustic cavitation and abrasion between the abrasive particles and the container; and producing nanoparticles that comprise elements from the container, the metal and/or the ferromagnetic solid and the abrasive particles. Disclosed herein too is a composition comprising first metal or a first ceramic; and particles comprising carbides and/or nitrides dispersed therein. Disclosed herein too is a composition comprising nanoparticles comprising chromium carbide, iron carbide, nickel carbide, γ-Fe and magnesium nitride.
FILED Thursday, May 19, 2022
APPL NO 17/664165
CURRENT CPC
Working Metallic Powder; Manufacture of Articles From Metallic Powder; Making Metallic Powder
B22F 1/00 (20130101)
B22F 1/07 (20220101)
B22F 1/054 (20220101)
B22F 9/06 (20130101) Original (OR) Class
B22F 2009/042 (20130101)

Alloys
C22C 1/1084 (20130101)

Processes for the Electrolytic or Electrophoretic Production of Coatings; Electroforming; Apparatus Therefor
C25D 1/00 (20130101)
C25D 15/00 (20130101)

Magnets; Inductances; Transformers; Selection of Materials for Their Magnetic Properties
H01F 1/047 (20130101)
H01F 1/442 (20130101)

Electric Heating; Electric Lighting Not Otherwise Provided for
H05B 6/367 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274202 Wilson et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
Oak Ridge National Laboratory (ORNL)
Federally Funded Research and Development Center (FFRDC)
Operated by UT-Battelle, LLC (UTB) at Oak Ridge, TN
APPLICANT(S) Mazak Corporation (Florence, Kentucky);  UT-Battelle, LLC (Oak Ridge, Tennessee)
ASSIGNEE(S)
INVENTOR(S) David A. Wilson (Knoxville, Tennessee);  Joseph C. McNay (Independence, Kentucky);  Adam M. McGrath (Erlanger, Kentucky);  Thomas J. Reckers (Florence, Kentucky);  Thomas A. Feldhausen (Knoxville, Tennessee);  Kyle S. Saleeby (Destin, Florida);  Seiichi Hattori (Florence, Kentucky);  Shunsuke Koike (Florence, Kentucky);  Masaharu Onji (Florence, Kentucky)
ABSTRACT An additive manufacturing machine that includes a wire supply including a wire drive configured to advance a wire at a wire feed rate and a wire heater configured to apply resistive heating to heat the wire. The additive manufacturing machine includes an additive head for emitting a laser beam to weld the wire to a substrate, a sensor configured to detect a weld parameter, and a controller operatively connected to the wire supply, additive head, and sensor. The controller is configured to determine a failure mode of the weld as the laser beam welds the wire to the substrate based at least in part upon the weld parameter. In response to determining the failure mode, the controller is configured to adjust at least one of the wire feed rate, the resistive heating, and a power of the laser beam as the laser beam welds the wire to stabilize the weld.
FILED Friday, February 25, 2022
APPL NO 17/681708
CURRENT CPC
Soldering or Unsoldering; Welding; Cladding or Plating by Soldering or Welding; Cutting by Applying Heat Locally, e.g Flame Cutting; Working by Laser Beam
B23K 9/125 (20130101)
B23K 9/1093 (20130101)
B23K 26/032 (20130101)
B23K 26/034 (20130101)
B23K 26/0093 (20130101)
B23K 26/211 (20151001)
B23K 26/342 (20151001) Original (OR) Class

Details, Components, or Accessories for Machine Tools, e.g Arrangements for Copying or Controlling; Machine Tools in General Characterised by the Construction of Particular Details or Components; Combinations or Associations of Metal-working Machines, Not Directed to a Particular Result
B23Q 5/04 (20130101)

Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 10/00 (20141201)
B33Y 30/00 (20141201)
B33Y 50/02 (20141201)

Image Data Processing or Generation, in General
G06T 7/0006 (20130101)
G06T 2207/30164 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274834 JENA et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
Lawrence Berkeley National Laboratory (LBNL)
Federally Funded Research and Development Center (FFRDC)
Operated by University of California (UC BERKELEY) at Berkeley, CA
APPLICANT(S) VIRGINIA COMMONWEALTH UNIVERSITY (Richmond, Virginia);  UNIVERSITY OF MASSACHUSETTS (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Puru JENA (Richmond, Virginia);  Hong FANG (Richmond, Virginia);  Joel THERRIEN (Boston, Massachusetts)
ABSTRACT A 3-dimensional crystalline carbon material that is magnetic and metallic under ambient conditions is provided. The material, denominated U-carbon, has been synthesized using the molecular precursor, 3, 3-dimethyl-1-butene (C6H12). Depending on the atomic connections made between the carbon atoms of the material, U-Carbon forms structures that exhibit semiconducting and nonmagnetic to metallic and ferromagnetic behaviors. The use of selected molecular precursors (such as 3, 3-dimethyl-1-butene C6H12) that support crystal growth based on clustered rather than individual atoms is a paradigm shift in materials development. Rationally designed metastable materials with desirable properties, including U-Carbon, can have many scientific and technological applications.
FILED Thursday, July 09, 2020
APPL NO 17/625511
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 23/50 (20130101)
B01J 23/52 (20130101)
B01J 23/72 (20130101)
B01J 23/755 (20130101)
B01J 27/24 (20130101)
B01J 37/0215 (20130101)

Non-metallic Elements; Compounds Thereof;
C01B 32/05 (20170801) Original (OR) Class

Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds
C01P 2006/40 (20130101)
C01P 2006/42 (20130101)

Coating Metallic Material; Coating Material With Metallic Material; Surface Treatment of Metallic Material by Diffusion into the Surface, by Chemical Conversion or Substitution; Coating by Vacuum Evaporation, by Sputtering, by Ion Implantation or by Chemical Vapour Deposition, in General
C23C 16/26 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274876 LI et al.
FUNDED BY
Department of Energy (DOE)
Office of Fossil Energy and Carbon Management (FECM)
APPLICANT(S) THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan)
ASSIGNEE(S) THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan)
INVENTOR(S) Victor C. LI (Ann Arbor, Michigan);  Brian R. ELLIS (Ann Arbor, Michigan);  Duo ZHANG (Ann Arbor, Michigan)
ABSTRACT Methods of preparing a cementitious structure for carbon dioxide (CO2) sequestration are provided. The cementitious structure may be a cast in a mold. First, a cementitious composite material comprising binder and water is conditioned, for example, in a mold by exposing the cementitious composite material to ≥about 50% to ≤about 80% relative humidity for ≥about 3 hours to ≤about 24 hours. The cementitious composite material is then dried to remove ≥about 10% by weight of initial water in the cementitious composite material. The cementitious structure formed is capable of a carbon dioxide uptake level of greater than or equal to about 6% by weight binder. The cementitious structure has a tensile strain capacity of ≥about 1% and a uniaxial tensile strength of ≥about 1 MPa. The method may also include carbonating the cementitious structure, following by an optional further hydration process.
FILED Friday, July 31, 2020
APPL NO 17/631408
CURRENT CPC
Separation
B01D 53/62 (20130101)
B01D 2251/404 (20130101)
B01D 2257/504 (20130101)

Shaping Clay or Other Ceramic Compositions; Shaping Slag; Shaping Mixtures Containing Cementitious Material, e.g Plaster
B28B 11/243 (20130101)

Lime, Magnesia; Slag; Cements; Compositions Thereof, e.g Mortars, Concrete or Like Building Materials; Artificial Stone; Ceramics; Refractories; Treatment of Natural Stone
C04B 14/06 (20130101)
C04B 16/0641 (20130101)
C04B 28/04 (20130101) Original (OR) Class
C04B 40/0236 (20130101)
C04B 40/0281 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274956 SESSLER et al.
FUNDED BY
Department of Energy (DOE)
APPLICANT(S) BOARD OF REGBTS, THE UNIVERSITY OF THE TEXAS SYSTEM (Austin, Texas);  GYEONGSANG NATIONAL UNIVERSITY (Jinju-si Jinju-daero, South Korea)
ASSIGNEE(S)
INVENTOR(S) Jonathan L. SESSLER (Austin, Texas);  Qing HE (Austin, Texas);  Sung Kuk KIM (Jinju-si, South Korea)
ABSTRACT The present disclosure relates to calixpyrrole compounds and compositions thereof. The calixpyrrole compounds are chemical groups which are located in such a manner so as to be useful for the selective extraction of specific salts. Also provided herein are compositions and methods of use thereof.
FILED Thursday, May 23, 2019
APPL NO 17/057713
CURRENT CPC
Separation
B01D 11/0492 (20130101)

Compounds of Alkali Metals, i.e Lithium, Sodium, Potassium, Rubidium, Caesium, or Francium
C01D 15/04 (20130101)

Heterocyclic Compounds
C07D 401/14 (20130101) Original (OR) Class
C07D 471/04 (20130101)

Production and Refining of Metals; Pretreatment of Raw Materials
C22B 3/36 (20210501)
C22B 3/1666 (20130101)
C22B 26/12 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275222 Sullivan et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
Lawrence Livermore National Laboratory (LLNL)
Federally Funded Research and Development Center (FFRDC)
Operated by Lawrence Livermore National Security LLC (LLNS) at Livermore, CA
APPLICANT(S) Lawrence Livermore National Security, LLC (Livemore, California)
ASSIGNEE(S)
INVENTOR(S) Kyle Sullivan (Pleasanton, California);  John M. Densmore (Livermore, California);  Eric Duoss (Dublin, California);  Alexander E. Gash (Brentwood, California);  Joshua Kuntz (Livermore, California);  John Vericella (Oakland, California)
ABSTRACT In one embodiment, a method includes depositing a material on a substrate. The material includes: a plurality of particles configured to complete a self-propagating and/or self-sustaining reaction upon initiation thereof, a solvent system, and one or more stabilizing agents.
FILED Friday, May 20, 2022
APPL NO 17/749920
CURRENT CPC
Shaping or Joining of Plastics; Shaping of Material in a Plastic State, Not Otherwise Provided For; After-treatment of the Shaped Products, e.g Repairing
B29C 64/118 (20170801)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 11/02 (20130101) Original (OR) Class
C09D 11/03 (20130101)

Technical Subjects Covered by Former US Classification
Y10T 428/24893 (20150115)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275253 Pagnotti et al.
FUNDED BY
Department of Energy (DOE)
Office of Energy Efficiency and Renewable Energy (EERE)
APPLICANT(S) PPG Industries Ohio, Inc. (Cleveland, Ohio)
ASSIGNEE(S) PPG Industries Ohio, Inc. (Cleveland, Ohio)
INVENTOR(S) Loubna Pagnotti (Wexford, Pennsylvania);  Masayuki Nakajima (Waxford, Pennsylvania);  Hongying Zhou (Allison Park, Pennsylvania);  Ying Zhou (Shanghai, China PRC);  Maria S. French (Canfield, Ohio);  Kar Tean Tan (Wexford, Pennsylvania);  Allison G. Condie (Valencia, Pennsylvania)
ABSTRACT Disclosed herein is an adhesive composition that includes a resin composition and an epoxy-containing compound. The resin composition includes an epoxidized polysulfide and an epoxidized oil. The epoxidized polysulfide is present in the adhesive composition in a weight ratio to the epoxidized oil of 20:1 to 1:1. Also disclosed is the adhesive composition in an at least partially cured state. Also disclosed is a method for treating a substrate comprising applying the adhesive composition to a surface of a substrate; and applying an external energy source to cure the composition. Also disclosed are substrates comprising the adhesive composition in an at least partially cured state.
FILED Friday, June 05, 2020
APPL NO 17/631628
CURRENT CPC
Adhesives; Non-mechanical Aspects of Adhesive Processes in General; Adhesive Processes Not Provided for Elsewhere; Use of Materials as Adhesives
C09J 7/383 (20180101) Original (OR) Class
C09J 109/00 (20130101)
C09J 163/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275268 Enick et al.
FUNDED BY
Department of Energy (DOE)
APPLICANT(S) University of Pittsburgh - Of the Commonwealth System of Higher Education (Pittsburgh, Pennsylvania);  THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF ENERGY (Washington, District of Columbia)
ASSIGNEE(S)
INVENTOR(S) Robert M. Enick (Bethel Park, Pennsylvania);  Deepak Tapriyal (Bethel Park, Pennsylvania);  Angela Goodman Hanson (Pittsburgh, Pennsylvania);  Dustin Crandall (Morgantown, West Virginia)
ABSTRACT A method of recovering hydrocarbons from a subterranean formation includes injecting into the subterranean formation a composition including carbon dioxide and at least one carbon-dioxide-soluble compound under conditions favorable to diffusion into and adsorption of the carbon-dioxide-soluble compound on the subterranean formation so that oil-wettability is decreased or water wettability or CO2-philicity is increased in at least a portion the subterranean formation.
FILED Thursday, July 09, 2020
APPL NO 17/625391
CURRENT CPC
Materials for Miscellaneous Applications, Not Provided for Elsewhere
C09K 8/584 (20130101)
C09K 8/594 (20130101) Original (OR) Class
C09K 8/602 (20130101)
C09K 8/604 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275405 Biggs et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
National Science Foundation (NSF)
APPLICANT(S) Northwestern University (Evanston, Illinois)
ASSIGNEE(S) Northwestern University (Evanston, Illinois)
INVENTOR(S) Bradley W. Biggs (Evanston, Illinois);  Keith E.J. Tyo (Evanston, Illinois)
ABSTRACT The present disclosure provides engineered bacteria for producing vanillin.
FILED Friday, February 25, 2022
APPL NO 17/681434
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 1/20 (20130101)
C12N 9/0008 (20130101)
C12N 15/113 (20130101)

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 7/24 (20130101) Original (OR) Class

Enzymes
C12Y 102/01067 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275408 Wendt et al.
FUNDED BY
Department of Energy (DOE)
Office of Nuclear Energy (DOE-NE)
Idaho National Laboratory (INL)
Federally Funded Research and Development Center (FFRDC)
Operated by Battelle Energy Alliance, LLC (BEA) at Idaho Falls, ID
APPLICANT(S) Battelle Energy Alliance, LLC (Idaho Falls, Idaho)
ASSIGNEE(S)
INVENTOR(S) Lynn M. Wendt (Idaho Falls, Idaho);  Bradley D. Wahlen (Rigby, Idaho);  Birendra Adhikari (Ammon, Idaho)
ABSTRACT A method of producing succinic acid from a biomass. The method comprises adding citric acid to a biomass comprising microalgae to form an acidified microalgae composition. The acidified microalgae biomass composition is stored under anaerobic conditions without inoculating the acidified microalgae composition with bacteria formulated to produce succinic acid. A coproduct comprising succinic acid is produced. Other methods of producing succinic acid from a biomass are also disclosed.
FILED Monday, February 28, 2022
APPL NO 17/652835
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 1/125 (20210501)

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 7/46 (20130101) Original (OR) Class
C12P 2203/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275483 McCall et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
Lawrence Livermore National Laboratory (LLNL)
Federally Funded Research and Development Center (FFRDC)
Operated by Lawrence Livermore National Security LLC (LLNS) at Livermore, CA
APPLICANT(S) Lawrence Livermore National Security, LLC (Livermore, California);  Eck Industries, Inc. (Manitowoc, Wisconsin);  Iowa State University Research Foundation, Inc. (Ames, Iowa);  University of Tennessee Research Foundation (Knoxville, Tennessee);  UT-Battelle, LLC (Oak Ridge, Tennessee)
ASSIGNEE(S)
INVENTOR(S) Scott K. McCall (Livermore, California);  Alexander Baker (Pleasanton, California);  Hunter B. Henderson (Livermore, California);  Tian Li (Pleasanton, California);  Aurelien Perron (Pleasanton, California);  Zachary Cole Sims (Knoxville, Tennessee);  David Weiss (Manitowoc, Wisconsin);  Ryan T. Ott (Ames, Iowa);  Orlando Rios (Knoxville, Tennessee);  Max Neveau (Knoxville, Tennessee)
ABSTRACT A product includes a material having: nickel and at least one rare earth element. The at least one rare earth element is present in the material in a weight percentage in a range of about 2% to about 20% relative to a total weight of the material. A method includes forming a material comprising an alloy of nickel and at least one rare earth element. The at least one rare earth element is present in the material in a weight percentage in a range of about 2% to about 20% relative to a total weight of the material.
FILED Friday, February 25, 2022
APPL NO 17/681424
CURRENT CPC
Alloys
C22C 1/023 (20130101)
C22C 19/055 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275818 Joshi et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
Pacific Northwest National Laboratory (PNNL)
Federally Funded Research and Development Center (FFRDC)
Operated by Battelle Memorial Institute (BMI) at Richland, WA
APPLICANT(S) BATTELLE MEMORIAL INSTITUTE (Richland, Washington)
ASSIGNEE(S) BATTELLE MEMORIAL INSTITUTE (Richland, Washington)
INVENTOR(S) Vineet V. Joshi (Richland, Washington);  Sina Shahrezaei (Richland, Washington);  Curt A. Lavender (Richland, Washington);  Rob J. Seffens (Kennewick, Washington);  Mark A. Rhodes (Kennewick, Washington);  Darrell R. Herling (Kennewick, Washington);  Aashish Rohatgi (Richland, Washington)
ABSTRACT Riveted assemblies are provided that can include: a first component having opposing first and second sidewalls; a second component having opposing third and fourth sidewalls, wherein the second sidewall of the first component abuts the third sidewall of the second component to bind and form an affixing interface comprising the second and third sidewall between the first component to the second component; and a rivet extending between a head along a shank to an end, the rivet piercing the first sidewall with the end of the rivet being between the first and fourth sidewalls. Methods for affixing at least two components using a rivet are also provided. The methods can include: providing a first component having opposing first and second sidewalls; providing a second component having opposing third and fourth sidewalls; abutting the second sidewall of the first component to the third sidewall of the second component; providing a rivet extending between a head along a shank to an end; projecting the rivet through at least the first sidewall of the first component to form an affixing interface comprising the second and third sidewalls.
FILED Thursday, May 12, 2022
APPL NO 17/743413
CURRENT CPC
Forging; Hammering; Pressing Metal; Riveting; Forge Furnaces
B21J 15/025 (20130101)

Devices for Fastening or Securing Constructional Elements or Machine Parts Together, e.g Nails, Bolts, Circlips, Clamps, Clips, Wedges, Joints or Jointing
F16B 5/04 (20130101) Original (OR) Class
F16B 19/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276179 Ohodnicki, JR. et al.
FUNDED BY
Department of Energy (DOE)
Office of Fossil Energy and Carbon Management (FECM)
National Energy Technology Laboratory (NETL)
APPLICANT(S) United States Department of Energy (Washington, District of Columbia)
ASSIGNEE(S)
INVENTOR(S) Paul R Ohodnicki, JR. (Allison Park, Pennsylvania);  Ping Lu (Library, Pennsylvania);  Ruishu Wright (Pittsburgh, Pennsylvania);  Jagannath Devkota (Pittsburgh, Pennsylvania)
ABSTRACT Materials, methods of making, and methods of sensing liquid droplets with high spatial resolution as a signature of the on-set of corrosion using a hierarchical sensor network A hierarchical sensor network for sensing liquid droplets with high spatial resolution as a signature of the on-set of corrosion, including an interrogation system; and an intermediate sensor array layer in communication with the interrogation system. The network includes an interrogation system and an intermediate sensor array layer in communication with the interrogation system.
FILED Tuesday, October 02, 2018
APPL NO 16/149774
CURRENT CPC
Pipe-line Systems; Pipe-lines
F17D 5/005 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/954 (20130101) Original (OR) Class
G01N 2021/9546 (20130101)
G01N 2201/0886 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276485 Pascall et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
Lawrence Livermore National Laboratory (LLNL)
Federally Funded Research and Development Center (FFRDC)
Operated by Lawrence Livermore National Security LLC (LLNS) at Livermore, CA
APPLICANT(S) LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (Livermore, California)
ASSIGNEE(S)
INVENTOR(S) Andrew J. Pascall (Livermore, California);  Kerry G. Krauter (Livermore, California)
ABSTRACT A deformable mirror has a mirror front face and a mirror back exposed surface. An elastomeric support structure is connected to the mirror back exposed surface. The elastomeric support structure includes a multitude of microchannels wherein the microchannels have a closed end located proximate the mirror back exposed surface and an open end located away from the mirror back exposed surface. A fluid pressure source is connected to the open end of the microchannels. A power source and control system are connected to the fluid pressure source.
FILED Thursday, May 12, 2022
APPL NO 17/743111
CURRENT CPC
Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 10/00 (20141201)
B33Y 80/00 (20141201)

Optical Elements, Systems, or Apparatus
G02B 26/0858 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276544 PANAS et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
Lawrence Livermore National Laboratory (LLNL)
Federally Funded Research and Development Center (FFRDC)
Operated by Lawrence Livermore National Security LLC (LLNS) at Livermore, CA
APPLICANT(S) Lawrence Livermore National Security, LLC (Livermore, California);  Bright Silicon Technology, Inc. (San Francisco, California)
ASSIGNEE(S)
INVENTOR(S) Robert Matthew PANAS (Dublin, California);  Frank RAVIZZA (Brentwood, California);  Robert MCHENRY (San Francisco, California)
ABSTRACT The present disclosure relates to a system for modifying temporal dispersion in an optical signal. The system makes use of a segmented array including a plurality of independently controllable, reflective optical elements. The optical elements are configured to segment a received input optical signal into a plurality of beamlets, and to reflect and steer selected ones of the plurality of beamlets in predetermined angular orientations therefrom. A variable optical dispersion subsystem is used which has a plurality of optical components configured to receive and impart different predetermined time delays to different ones of the received beamlets, and to output the plurality of beamlets therefrom.
FILED Monday, March 01, 2021
APPL NO 17/188656
CURRENT CPC
Optical Elements, Systems, or Apparatus
G02B 27/123 (20130101)

Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters
G02F 1/292 (20130101) Original (OR) Class

Devices Using the Process of Light Amplification by Stimulated Emission of Radiation [LASER] to Amplify or Generate Light; Devices Using Stimulated Emission of Electromagnetic Radiation in Wave Ranges Other Than Optical
H01S 3/0057 (20130101)
H01S 3/0071 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276924 Mills et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
Lawrence Livermore National Laboratory (LLNL)
Federally Funded Research and Development Center (FFRDC)
Operated by Lawrence Livermore National Security LLC (LLNS) at Livermore, CA
APPLICANT(S) Nvidia Corporation (Santa Clara, California)
ASSIGNEE(S)
INVENTOR(S) Peter Mills (Santa Clara, California);  Michael Sullivan (Santa Clara, California);  Nirmal Saxena (Santa Clara, California);  John Brooks (Santa Clara, California)
ABSTRACT Often there are errors when reading data from computer memory. To detect and correct these errors, there are multiple types of error correction codes. Disclosed is an error correction architecture that creates a codeword having a data portion and an error correction code portion. Swizzling rearranges the order of bits and distributes the bits among different codewords. Because the data is redistributed, a potential memory error of up to N contiguous bits, where N for example equals 2 times the number of codewords swizzled together, only affects up to, at most, two bits per swizzled codeword. This keeps the error within the error detecting capabilities of the error correction architecture. Furthermore, this can allow improved error correction and detection without requiring a change to error correcting code generators and checkers.
FILED Tuesday, May 17, 2022
APPL NO 17/746627
CURRENT CPC
Electric Digital Data Processing
G06F 3/0619 (20130101)
G06F 3/0659 (20130101)
G06F 3/0673 (20130101)
G06F 11/10 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277122 Miryala et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
Fermi National Accelerator Laboratory (FNAL)
Federally Funded Research and Development Center (FFRDC)
Operated by Fermi Research Alliance, LLC (FRA) at Batavia, IL
APPLICANT(S) Fermi Research Alliance, LLC (Batavia, Illinois)
ASSIGNEE(S) Fermi Research Alliance, LLC (Batavia, Illinois)
INVENTOR(S) Sandeep Miryala (Sound Beach, New York);  James Richard Hoff (Wheaton, Illinois);  Grzegorz W. Deptuch (Great Neck, New York)
ABSTRACT A soft error-mitigating semiconductor design system and associated methods that tailor circuit design steps to mitigate corruption of data in storage elements (e.g., flip flops) due to Single Events Effects (SEEs). Required storage elements are automatically mapped to triplicated redundant nodes controlled by a voting element that enforces majority-voting logic for fault-free output (i.e., Triple Modular Redundancy (TMR)). Storage elements are also optimally positioned for placement in keeping with SEE-tolerant spacing constraints. Additionally, clock delay insertion (employing either a single global clock or clock triplication) in the TMR specification may introduce useful skew that protects against glitch propagation through the designed device. The resultant layout generated from the TMR configuration may relax constraints imposed on register transfer level (RTL) engineers to make rad-hard designs, as automation introduces TMR storage registers, memory element spacing, and clock delay/triplication with minimal designer input.
FILED Friday, February 26, 2021
APPL NO 17/187516
CURRENT CPC
Electric Digital Data Processing
G06F 30/327 (20200101) Original (OR) Class
G06F 30/392 (20200101)
G06F 30/396 (20200101)
G06F 2119/02 (20200101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277865 Katalenich et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
Pacific Northwest National Laboratory (PNNL)
Federally Funded Research and Development Center (FFRDC)
Operated by Battelle Memorial Institute (BMI) at Richland, WA
APPLICANT(S) Battelle Memorial Institute (Richland, Washington)
ASSIGNEE(S) Battelle Memorial Institute (Richland, Washington)
INVENTOR(S) Jeffrey A. Katalenich (Richland, Washington);  Bruce D. Reid (Pasco, Washington);  Robert O. Gates (Kennewick, Washington);  Andrew W. Prichard (Pasco, Washington);  Bruce E. Schmitt (Kennewick, Washington);  Jim Livingston (Vienna, Virginia)
ABSTRACT Reactor target assemblies are provided that can include a housing defining a perimeter of at least one volume and Np or Am spheres within the one volume. Reactor assemblies are provided that can include a reactor vessel and a bundle of target assemblies within the reactor vessel, at least one of the target assemblies comprising a housing defining a volume with Np or Am spheres being within the volume. Irradiation methods are also provided that can include irradiating Np or Am spheres within a nuclear reactor, then removing the irradiated spheres from the reactor and treating the irradiated spheres.
FILED Wednesday, April 27, 2022
APPL NO 17/730203
CURRENT CPC
Nuclear Reactors
G21C 3/28 (20130101)
G21C 3/58 (20130101)

Conversion of Chemical Elements; Radioactive Sources
G21G 1/001 (20130101)
G21G 1/02 (20130101) Original (OR) Class
G21G 2001/0094 (20130101)

Plasma Technique; Production of Accelerated Electrically-charged Particles or of Neutrons; Production or Acceleration of Neutral Molecular or Atomic Beams
H05H 6/00 (20130101)

Reduction of Greenhouse Gas [GHG] Emissions, Related to Energy Generation, Transmission or Distribution
Y02E 30/30 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220278280 Forrest et al.
FUNDED BY
Department of Energy (DOE)
Office of Energy Efficiency and Renewable Energy (EERE)
APPLICANT(S) The Regents of the University of Michigan (Ann Arbor, Michigan)
ASSIGNEE(S)
INVENTOR(S) Stephen R. Forrest (Ann Arbor, Michigan);  Xinjing Huang (Ann Arbor, Michigan);  Dejiu Fan (Ann Arbor, Michigan)
ABSTRACT A method of fabricating an organic optoelectronic device comprises positioning a patterning layer over a substrate, etching the patterning layer using a photolithographic process to create an etched patterning layer, positioning a layer of an organic material over the etched patterning layer, and removing at least a portion of the etched patterning layer and at least a portion of the layer of the organic material to create a patterned organic layer over the substrate.
FILED Tuesday, March 01, 2022
APPL NO 17/684168
CURRENT CPC
Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 51/0018 (20130101) Original (OR) Class
H01L 51/424 (20130101)
H01L 51/441 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220278378 Friend et al.
FUNDED BY
Department of Energy (DOE)
APPLICANT(S) The Regents of the University of California (Oakland, California);  Technion Research and Development Foundation Ltd. (Haifa, Israel)
ASSIGNEE(S)
INVENTOR(S) James Friend (San Diego, California);  An Huang (San Diego, California);  Ping Liu (San Diego, California);  Haodong Liu (San Diego, California);  Ofer Manor (Haifa, Israel);  Viswanathan Krishnan (San Diego, California)
ABSTRACT A battery may include a first electrode, a second electrode, an electrolyte, and at least one acoustic device configured to generate acoustic streaming during a charging and/or a discharging of the battery. The charging of the battery may trigger cations from the first electrode to travel through the electrolyte and deposit on the second electrode while the discharging of the battery may trigger cations from the second electrode to travel through the electrolyte and deposit on the first electrode. The acoustic streaming may drive a mixing and/or a turbulent flow of the electrolyte, which may increase a charge rate and/or a discharge rate of the battery by increasing diffusion rate of cations and/or anions. The mixing and/or the turbulent flow may further prevent a formation of dendrites on the first electrode and/or the second electrode by at least homogenizing a distribution of the cations and/or anions in the electrolyte.
FILED Saturday, August 01, 2020
APPL NO 17/632036
CURRENT CPC
Mixing, e.g Dissolving, Emulsifying, Dispersing
B01F 31/80 (20220101)
B01F 2101/59 (20220101)

Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 10/44 (20130101)
H01M 10/425 (20130101)
H01M 10/4214 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220279653 Hatch et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
Kansas City National Security Campus (KCNSC)
NNSA Critical Mission Site
Operated by Honeywell Federal Manufacturing and Technologies, LLC (FM&T) at Kansas City, MO
APPLICANT(S) Honeywell Federal Manufacturing and Technologies, LLC (Kansas City, Missouri)
ASSIGNEE(S) Honeywell Federal Manufacturing and Technologies, LLC (Kansas City, Missouri)
INVENTOR(S) Stephen McGarry Hatch (Blue Springs, Missouri);  Jonathan Douglas Hatch (Cleveland, Missouri)
ABSTRACT A conductive trace interconnect tape for use with a printed circuit board or a flexible circuit substrate comprises a top insulating layer, an electrically conductive layer, and a bottom insulating layer. The top insulating layer is formed from electrically insulating material and is configured to provide electrical isolation from electrically conductive objects that are positioned on top of the conductive trace interconnect tape. The electrically conductive layer is positioned underneath the top insulating layer. The electrically conductive layer is formed from electrically conductive material and includes electrical interconnect traces, electrical component pads, or electrically conductive planar portions. The bottom insulating layer is positioned underneath the electrically conductive layer. The bottom insulating layer is formed from electrically insulating material and is configured to provide electrical isolation from electrically conductive objects that are positioned on the printed circuit board or flexible circuit substrate.
FILED Thursday, April 28, 2022
APPL NO 17/731621
CURRENT CPC
Printed Circuits; Casings or Constructional Details of Electric Apparatus; Manufacture of Assemblages of Electrical Components
H05K 1/09 (20130101) Original (OR) Class
H05K 1/118 (20130101)
H05K 1/189 (20130101)
H05K 3/103 (20130101)
H05K 2201/05 (20130101)
H05K 2201/0335 (20130101)
H05K 2201/1028 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220279681 COUSINEAU et al.
FUNDED BY
Department of Energy (DOE)
Office of Energy Efficiency and Renewable Energy (EERE)
National Renewable Energy Laboratory (NREL)
Federally Funded Research and Development Center (FFRDC)
Operated by Alliance for Sustainable Energy, LLC (ASE) at Golden, CO
APPLICANT(S) Deere and Company (Moline, Illinois);  Alliance for Sustainable Energy, LLC (Golden, Colorado)
ASSIGNEE(S) Deere and Company (Moline, Illinois);  Alliance for Sustainable Energy, LLC (Golden, Colorado)
INVENTOR(S) Emily COUSINEAU (Lakewood, Colorado);  Gilberto MORENO (Thornton, Colorado);  Kevin Scott BENNION (Littleton, Colorado);  Thomas ROAN (Fargo, North Dakota);  Brij N. SINGH (West Fargo, North Dakota)
ABSTRACT Provided is a condenser for use in an electronic assembly. The condenser includes a first vertical wall extending in a vertical direction, the first vertical wall defining a first plurality of vertical condensation channels within the first vertical wall, a second vertical wall extending in the vertical direction, the second vertical wall defining a second plurality of vertical condensation channels within the second vertical wall, and a first plurality of fins extending in the vertical direction, each of the first plurality of fins connected to the first vertical wall, the second vertical wall or both the first vertical wall and the second vertical wall.
FILED Monday, May 09, 2022
APPL NO 17/739348
CURRENT CPC
Refrigeration Machines, Plants or Systems; Combined Heating and Refrigeration Systems; Heat-pump Systems
F25B 39/04 (20130101)

Heat-exchange Apparatus, Not Provided for in Another Subclass, in Which the Heat-exchange Media Do Not Come into Direct Contact
F28D 15/0266 (20130101)

Details of Heat-exchange and Heat-transfer Apparatus, of General Application
F28F 1/022 (20130101)
F28F 2215/02 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 23/427 (20130101)

Printed Circuits; Casings or Constructional Details of Electric Apparatus; Manufacture of Assemblages of Electrical Components
H05K 7/20145 (20130101)
H05K 7/20172 (20130101)
H05K 7/20309 (20130101)
H05K 7/20318 (20130101) Original (OR) Class
H05K 7/20327 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

National Science Foundation (NSF) 

US 20220273187 Rutkove et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Science Foundation (NSF)
APPLICANT(S) Myolex Inc. (Brookline, Massachusetts)
ASSIGNEE(S) Myolex Inc. (Brookline, Massachusetts)
INVENTOR(S) Seward Rutkove (Brookline, Massachusetts);  Elmer C. Lupton (Charlestown, Massachusetts);  Jose L. Bohorquez (Burlingame, California);  Haydn Taylor (Windham, New Hampshire);  Gonzalo Cespedes (Daly City, California);  Cary Liberman (Oakland, California);  Dmitri Khrebtukov (San Francisco, California);  Claudio Cassina (Hollywood, Florida);  Yensy Hall (Pembroke Pines, Florida);  Stanislava Daraskevich (San Francisco, California);  Juan Jaramillo (San Francisco, California)
ABSTRACT A portable device for measuring a bioimpedance-related property of tissue includes a plurality of electrodes arranged in a pattern on a surface and associated software for measuring bio-impedance related data of localized regions of tissue and calculate health-related parameters based on the measured data. These calculated parameters may be representative of muscular health of the localized tissue region.
FILED Sunday, February 13, 2022
APPL NO 17/670478
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/0004 (20130101)
A61B 5/486 (20130101)
A61B 5/0537 (20130101) Original (OR) Class
A61B 5/742 (20130101)
A61B 5/4519 (20130101)
A61B 5/4872 (20130101)
A61B 5/7278 (20130101)
A61B 2560/0425 (20130101)
A61B 2562/043 (20130101)
A61B 2562/0214 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273711 BOYKEN et al.
FUNDED BY
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) University of Washington (Seattle, Washington)
ASSIGNEE(S)
INVENTOR(S) Scott BOYKEN (Seattle, Washington);  Marc Joseph LAJOIE (Seattle, Washington);  Robert A. LANGAN (Seattle, Washington);  David BAKER (Seattle, Washington);  Jilliane Ruth BRUFFEY (Seattle, Washington)
ABSTRACT Disclosed am protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called die key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain only when the protein switch components are co-localized when bound to their targets, components of such protein switches, and their use.
FILED Monday, May 18, 2020
APPL NO 17/609972
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101) Original (OR) Class

Peptides
C07K 16/18 (20130101)
C07K 2319/00 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/62 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273756 Baker et al.
FUNDED BY
National Science Foundation (NSF)
Directorate of Geosciences (GEO)
Office of Polar Programs (OPP)
APPLICANT(S) University of South Florida (Tampa, Florida)
ASSIGNEE(S) University of South Florida (Tampa, Florida)
INVENTOR(S) Bill J. Baker (Temple Terrace, Florida);  Nerida G. Wilson (Cottesloe, Australia);  John H. Adams (Tampa, Florida);  Matthew A. Knestrick (Washington, District of Columbia);  Alison Elizabeth Roth (North Bethesda, Maryland)
ABSTRACT Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as Plasmodium falciparum.
FILED Thursday, May 12, 2022
APPL NO 17/742640
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/4706 (20130101)
A61K 38/08 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 33/06 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274072 Weitz et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Biological Sciences (BIO)
Division of Biological Infrastructure (DBI)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) President and Fellows of Harvard College (Cambridge, Massachusetts)
ASSIGNEE(S) President and Fellows of Harvard College (Cambridge, Massachusetts)
INVENTOR(S) David A. Weitz (Cambridge, Massachusetts);  Adam R. Abate (Cambridge, Massachusetts);  Tony Hung (Cambridge, Massachusetts);  Pascaline Mary (Cambridge, Massachusetts)
ABSTRACT The present invention generally relates to systems and methods for the control of fluids and, in some cases, to systems and methods for flowing a fluid into and/or out of other fluids. As examples, fluid may be injected into a droplet contained within a fluidic channel, or a fluid may be injected into a fluidic channel to create a droplet. In some embodiments, electrodes may be used to apply an electric field to one or more fluidic channels, e.g., proximate an intersection of at least two fluidic channels. For instance, a first fluid may be urged into and/or out of a second fluid, facilitated by the electric field. The electric field, in some cases, may disrupt an interface between a first fluid and at least one other fluid. Properties such as the volume, flow rate, etc. of a first fluid being urged into and/or out of a second fluid can be controlled by controlling various properties of the fluid and/or a fluidic droplet, for example curvature of the fluidic droplet, and/or controlling the applied electric field.
FILED Monday, May 16, 2022
APPL NO 17/745711
CURRENT CPC
Mixing, e.g Dissolving, Emulsifying, Dispersing
B01F 25/314 (20220101) Original (OR) Class
B01F 33/3021 (20220101)
B01F 33/3022 (20220101)
B01F 33/3031 (20220101)

Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 19/0093 (20130101)

Chemical or Physical Laboratory Apparatus for General Use
B01L 3/50273 (20130101)
B01L 3/502784 (20130101)

Valves; Taps; Cocks; Actuating-floats; Devices for Venting or Aerating
F16K 99/0017 (20130101)
F16K 99/0051 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 27/44791 (20130101)

Technical Subjects Covered by Former US Classification
Y10T 137/206 (20150401)
Y10T 137/0391 (20150401)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274097 Do et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) University of Houston System (Houston, Texas)
ASSIGNEE(S) University of Houston System (Houston, Texas)
INVENTOR(S) Loi Hung Do (Manvel, Texas);  Zhongzheng Cai (Houston, Texas);  Thi Tran (Houston, Texas);  Dawei Xiao (Houston, Texas)
ABSTRACT Phosphine phosphonate and phenoxyphosphine ligands bearing polyethylene glycol (PEG) chains are used as described herein to produce heterobimetallic catalysts. The ligands can be metallated selectively with palladium or nickel and secondary metal ions to provide well-defined heterobimetallic compounds. These heterobimetallic complexes exhibit accelerated reaction rates and greater thermal stability in olefin polymerization compared to other catalysts.
FILED Friday, February 25, 2022
APPL NO 17/681073
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 31/2243 (20130101) Original (OR) Class
B01J 31/2247 (20130101)
B01J 2531/0205 (20130101)
B01J 2531/0297 (20130101)
B01J 2531/824 (20130101)
B01J 2531/847 (20130101)

Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 4/7014 (20130101)
C08F 10/02 (20130101)
C08F 2410/03 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274170 MANUEL et al.
FUNDED BY
Department of Energy (DOE)
Office of Fossil Energy and Carbon Management (FECM)
National Energy Technology Laboratory (NETL)
Office of Science (DOE-SC)
Oak Ridge National Laboratory (ORNL)
Federally Funded Research and Development Center (FFRDC)
Operated by UT-Battelle, LLC (UTB) at Oak Ridge, TN
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) University of Florida Research Foundation, Inc. (Gainesville, Florida);  UT BATTELLE, LLC (OAK RIDGE, Tennessee)
ASSIGNEE(S)
INVENTOR(S) MICHELE VIOLA MANUEL (GAINESVILLE, Florida);  HUNTER B. HENDERSON (GAINESVILLE, Florida);  ORLANDO RIOS (OAK RIDGE, Tennessee);  GERARD M. LUDTKA (OAK RIDGE, Tennessee)
ABSTRACT Disclosed herein is a method comprising disposing a container containing a metal and/or ferromagnetic solid and abrasive particles in a static magnetic field; where the container is surrounded by an induction coil; activating the induction coil with an electrical current, to heat up the metallic or ferromagnetic solid to form a fluid; generating sonic energy to produce acoustic cavitation and abrasion between the abrasive particles and the container; and producing nanoparticles that comprise elements from the container, the metal and/or the ferromagnetic solid and the abrasive particles. Disclosed herein too is a composition comprising first metal or a first ceramic; and particles comprising carbides and/or nitrides dispersed therein. Disclosed herein too is a composition comprising nanoparticles comprising chromium carbide, iron carbide, nickel carbide, γ-Fe and magnesium nitride.
FILED Thursday, May 19, 2022
APPL NO 17/664165
CURRENT CPC
Working Metallic Powder; Manufacture of Articles From Metallic Powder; Making Metallic Powder
B22F 1/00 (20130101)
B22F 1/07 (20220101)
B22F 1/054 (20220101)
B22F 9/06 (20130101) Original (OR) Class
B22F 2009/042 (20130101)

Alloys
C22C 1/1084 (20130101)

Processes for the Electrolytic or Electrophoretic Production of Coatings; Electroforming; Apparatus Therefor
C25D 1/00 (20130101)
C25D 15/00 (20130101)

Magnets; Inductances; Transformers; Selection of Materials for Their Magnetic Properties
H01F 1/047 (20130101)
H01F 1/442 (20130101)

Electric Heating; Electric Lighting Not Otherwise Provided for
H05B 6/367 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274268 Rucker et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) University of Tennessee Research Foundation (Knoxville, Tennessee)
ASSIGNEE(S)
INVENTOR(S) Daniel Caleb Rucker (Knoxville, Tennessee);  Jake A. Childs (Kingston, Tennessee)
ABSTRACT Mechanical bending actuators are provided including a first concentric, pre-curved bellows; and a second concentric, pre-curved bellows nested inside the first concentric, pre-curved bellows to provide a concentric, pre-curved bellows pair that when rotated axially at a base of the first and/or second concentric, pre-curved bellows provides independent control of a curvature and bending plane of the concentric, pre-curved bellows pair.
FILED Friday, August 14, 2020
APPL NO 17/627314
CURRENT CPC
Manipulators; Chambers Provided With Manipulation Devices
B25J 9/142 (20130101)
B25J 15/12 (20130101)
B25J 18/005 (20130101)
B25J 18/06 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274381 Singamaneni et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
APPLICANT(S) Washington University (St. Louis, Missouri)
ASSIGNEE(S)
INVENTOR(S) Srikanth Singamaneni (St. Louis, Missouri);  Jingyi Luan (St. Louis, Missouri);  Jeremiah Morrissey (St. Louis, Missouri);  Evan Kharasch (St. Louis, Missouri)
ABSTRACT Fluorescence-based techniques are the cornerstone of modern biomedical optics with applications ranging from bioimaging at various scales (organelle to organism) to detection and quantification of a wide variety of biological species of interest. However, feeble fluorescence signal remains a persistent challenge in meeting the ever-increasing demand to image, detect and quantify biological species of low abundance. Disclosed herein are simple and universal methods based on a flexible and conformal elastomeric film adsorbed with plasmonic nanostructures, referred to as “plasmonic skin” or “plasmonic patch”, that provide large and uniform enhancement of fluorescence on a variety of surfaces, through an “add-on-top” process. The novel fluorescence enhancement approach presented here represents a disease-, biomarker-, and application-agnostic ubiquitously-applicable fundamental and enabling technology to improve the sensitivity of existing analytical methodologies in an easy-to-handle and cost-effective manner, without changing and/or minimally altering the original procedures of the existing techniques.
FILED Friday, May 06, 2022
APPL NO 17/662293
CURRENT CPC
Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form
B32B 27/06 (20130101) Original (OR) Class
B32B 2307/422 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274698 Deng et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Office of Scientific Research (AFOSR)
National Science Foundation (NSF)
APPLICANT(S) PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana)
ASSIGNEE(S) PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana)
INVENTOR(S) Xinyan Deng (Lafayette, Indiana);  Jian Zhang (Lafayette, Indiana)
ABSTRACT Disclosed herein is a voice coil actuator direct-drive resonant flapper system for flapping wing micro air vehicles and flapping fin autonomous underwater vehicles.
FILED Monday, January 11, 2021
APPL NO 17/145398
CURRENT CPC
Aeroplanes; Helicopters
B64C 33/02 (20130101) Original (OR) Class
B64C 2201/025 (20130101)
B64C 2201/042 (20130101)

Dynamo-electric Machines
H02K 7/003 (20130101)
H02K 41/0354 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274843 JU et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Civil, Mechanical and Manufacturing Innovation (CMMI)
APPLICANT(S) PRINCETON UNIVERSITY (Princeton, New Jersey)
ASSIGNEE(S)
INVENTOR(S) Yiguang JU (Princeton, New Jersey);  Maksym MEZHERICHER (Princeton, New Jersey);  Christopher ABRAM (Princeton, New Jersey)
ABSTRACT A material synthesis method may comprise: adding at least one liquid precursor solution to an atomizer device; generating by the atomizer device an aerosol comprising liquid droplets; transporting the aerosol to a reactive zone for evaporating one or more solvents from the aerosol; and collecting particles synthesized from at least evaporating the aerosol.
FILED Wednesday, May 18, 2022
APPL NO 17/747660
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 23/002 (20130101)
B01J 23/83 (20130101)

Non-metallic Elements; Compounds Thereof;
C01B 13/34 (20130101)
C01B 2203/0238 (20130101)

Compounds of the Metals Beryllium, Magnesium, Aluminium, Calcium, Strontium, Barium, Radium, Thorium, or of the Rare-earth Metals
C01F 7/16 (20130101)
C01F 17/34 (20200101)
C01F 17/218 (20200101) Original (OR) Class

Compounds Containing Metals Not Covered by Subclasses C01D or C01F
C01G 45/1242 (20130101)
C01G 53/50 (20130101)

Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds
C01P 2002/70 (20130101)
C01P 2002/72 (20130101)
C01P 2004/03 (20130101)
C01P 2004/04 (20130101)
C01P 2004/34 (20130101)
C01P 2004/51 (20130101)
C01P 2004/53 (20130101)
C01P 2004/61 (20130101)
C01P 2004/62 (20130101)
C01P 2004/64 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274930 LOPCHUK et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, Florida)
ASSIGNEE(S)
INVENTOR(S) Justin M. LOPCHUK (Tampa, Florida);  Preeti P. CHANDRACHUD (Tampa, Florida)
ABSTRACT The invention described herein relates generally to processes for the synthesis of amine-containing organic compounds. More specifically, described herein relates to processes for the decarboxylative amination of redox-active esters with diazirines and the products formed thereof. Compounds for use in the above processes are also described.
FILED Monday, June 15, 2020
APPL NO 17/617973
CURRENT CPC
Heterocyclic Compounds
C07D 211/96 (20130101)
C07D 229/02 (20130101) Original (OR) Class
C07D 401/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274931 Jewett et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (Tucson, Arizona)
ASSIGNEE(S)
INVENTOR(S) John C. Jewett (Tucson, Arizona);  Natasha Cornejo (Tucson, Arizona);  Bismark Amofah (Tucson, Arizona);  Lindsay E. Guzman (Tucson, Arizona);  W Mudiyanselage Anjalee Wijetunge (Tucson, Arizona);  Abigail Shepard (Tucson, Arizona);  Danielle Johnson (Tucson, Arizona)
ABSTRACT Protected triazabutadiene molecules, such as those according to Formula D or variations thereof, as probes for cellular studies in intact biological systems. The protected triazabutadiene probes selectively release benzene diazonium ions (BDIs) intracellularly, providing a tool for accessing and/or labeling intracellular proteins or molecules prior to cell lysis. The present invention also includes methods for synthesizing the protected triazabutadienes, the protected triazabutadienes themselves, and methods of use.
FILED Monday, May 23, 2022
APPL NO 17/751474
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/545 (20170801)
A61K 49/0021 (20130101)

Heterocyclic Compounds
C07D 233/88 (20130101) Original (OR) Class
C07D 403/12 (20130101)
C07D 405/12 (20130101)
C07D 413/14 (20130101)

Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids
C07H 21/00 (20130101)

Organic Dyes or Closely-related Compounds for Producing Dyes; Mordants; Lakes
C09B 26/06 (20130101)
C09B 55/003 (20130101)

Adhesives; Non-mechanical Aspects of Adhesive Processes in General; Adhesive Processes Not Provided for Elsewhere; Use of Materials as Adhesives
C09J 163/00 (20130101)

Materials for Miscellaneous Applications, Not Provided for Elsewhere
C09K 11/06 (20130101)
C09K 2211/1048 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6845 (20130101)
G01N 33/56983 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220274963 Huang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Lan Huang (Irvine, California);  Scott D. Rychnovsky (Irvine, California)
ABSTRACT The disclosure provides for mass spectrometry (MS)-cleavable heterobifunctional photoactivated cross-linkers. The MS-cleavable heterobifunctional photoactivated cross-linkers can be used in mass spectrometry to facilitate structural analysis of intra-protein interactions in proteins and inter-protein interactions in protein complexes.
FILED Thursday, February 24, 2022
APPL NO 17/680236
CURRENT CPC
Heterocyclic Compounds
C07D 403/12 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 30/7233 (20130101)
G01N 33/6845 (20130101)
G01N 33/6848 (20130101)
G01N 2030/027 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275390 Jonikas et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Biological Sciences (BIO)
Division of Molecular and Cellular Biosciences (MCB)
APPLICANT(S) The Trustees of Princeton University (Princeton, New Jersey);  The Board of Trustees of the Leland Stanford Junior University (Stanford, California);  University of York (Heslington, York, United Kingdom);  Howard Hughes Medical Institute (Chevy Chase, Maryland)
ASSIGNEE(S) The Trustees of Princeton University (Princeton, New Jersey);  The Board of Trustees of the Leland Stanford Junior University (Stanford, California);  University of York (Heslington, York, United Kingdom);  Howard Hughes Medical Institute (Chevy Chase, Maryland)
INVENTOR(S) Martin C. Jonikas (Princeton, New Jersey);  Moritz Meyer (Esch-sur-Alzette, Luxembourg);  Shan He (Princeton, New Jersey);  Alan Itakura (Stanford, California);  Vivian Chen Wong (San Jose, California);  Luke Colin Martin Mackinder (Norton, Malton, North Yorkshire, United Kingdom);  Zhiheng Yu (Ashburn, Virginia);  Doreen Matthies (Sterling, Virginia);  Hui-Ting Chou (San Mateo, California)
ABSTRACT Described herein are chimeric polypeptides that include one or more Rubisco-binding motifs (RBMs) and a heterologous polypeptide. Additional aspects of the present disclosure provide genetically altered plants having a chimeric polypeptide including one or more Rubisco-binding motifs (RBMs) and a heterologous polypeptide. Further aspects of the present disclosure relate to genetically altered plants having a stabilized polypeptide including two or more RBMs and one or both of an algal Rubisco-binding membrane protein (RBMP) and a Rubisco small subunit (SSU) protein. Other aspects of the present disclosure relate to methods of making such chimeric polypeptides and plants, as well as cultivating these genetically altered plants.
FILED Thursday, July 30, 2020
APPL NO 17/631427
CURRENT CPC
Peptides
C07K 14/405 (20130101)
C07K 2319/03 (20130101)
C07K 2319/08 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/8269 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220275405 Biggs et al.
FUNDED BY
Department of Energy (DOE)
Office of Science (DOE-SC)
National Science Foundation (NSF)
APPLICANT(S) Northwestern University (Evanston, Illinois)
ASSIGNEE(S) Northwestern University (Evanston, Illinois)
INVENTOR(S) Bradley W. Biggs (Evanston, Illinois);  Keith E.J. Tyo (Evanston, Illinois)
ABSTRACT The present disclosure provides engineered bacteria for producing vanillin.
FILED Friday, February 25, 2022
APPL NO 17/681434
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 1/20 (20130101)
C12N 9/0008 (20130101)
C12N 15/113 (20130101)

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 7/24 (20130101) Original (OR) Class

Enzymes
C12Y 102/01067 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276103 Merrell et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Civil, Mechanical and Manufacturing Innovation (CMMI)
APPLICANT(S) Nano Composite Products, Inc. (Orem, Utah)
ASSIGNEE(S)
INVENTOR(S) Aaron Jake Merrell (Orem, Utah);  David T. Fullwood (Provo, Utah);  Anton E. Bowden (Lindon, Utah);  Taylor D. Remington (Provo, Utah)
ABSTRACT In one general aspect, a composite foam comprises a non-layered mixture of a polymeric foam with a plurality of voids; and a plurality of conductive fillers disposed in the polymeric foam. The conductive fillers are disposed in an even manner from outer surface to outer surface. In some implementations, the conductive fillers are up to 25% by weight of the composite foam. In some implementations, the composite foam may be used as padding. In some implementations, the composite foam may be used as a strain gauge. In some implementations, the foam may be in contact with a voltage detector.
FILED Monday, May 09, 2022
APPL NO 17/662607
CURRENT CPC
Measuring Force, Stress, Torque, Work, Mechanical Power, Mechanical Efficiency, or Fluid Pressure
G01L 1/04 (20130101) Original (OR) Class
G01L 1/06 (20130101)
G01L 1/16 (20130101)
G01L 1/18 (20130101)
G01L 1/20 (20130101)
G01L 5/0052 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 41/37 (20130101)
H01L 41/183 (20130101)

Technical Subjects Covered by Former US Classification
Y10T 29/49117 (20150115)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277404 Marculescu et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Computer and Information Science and Engineering (CISE)
Division of Computing and Communication Foundations (CCF)
APPLICANT(S) Carnegie Mellon University (Pittsburgh, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Radu Marculescu (Pittsburgh, Pennsylvania);  Huan-Kai Peng (Pittsburgh, Pennsylvania)
ABSTRACT In some aspects, computer-implemented methods of identifying patterns in time-series social-media data. In an embodiment, the method includes applying a deep-learning methodology to the time-series social-media data at a plurality of temporal resolutions to identify patterns that may exist at and across ones of the temporal resolutions. A particular deep-learning methodology that can be used is a recursive convolutional Bayesian model (RCBM) utilizing a special convolutional operator. In some aspects, computer-implemented methods of engineering outcome-dynamics of a dynamic system. In an embodiment, the method includes training a generative model using one or more sets of time-series data and solving an optimization problem composed of a likelihood function of the generative model and a score function reflecting a utility of the dynamic system. A result of the solution is an influence indicator corresponding to intervention dynamics that can be applied to the dynamic system to influence outcome dynamics of the system.
FILED Thursday, May 19, 2022
APPL NO 17/748173
CURRENT CPC
Computer Systems Based on Specific Computational Models
G06N 7/005 (20130101)
G06N 20/00 (20190101)
G06N 20/10 (20190101)

Data Processing Systems or Methods, Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes; Systems or Methods Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes, Not Otherwise Provided for
G06Q 50/01 (20130101) Original (OR) Class

Transmission of Digital Information, e.g Telegraphic Communication
H04L 51/52 (20220501)
H04L 51/216 (20220501)
H04L 67/535 (20220501)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277804 WEI et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
APPLICANT(S) BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (East Lansing, Michigan)
ASSIGNEE(S)
INVENTOR(S) Guowei WEI (Haslett, Michigan);  Zixuan CANG (Irvine, California);  Jiahui CHEN (Dallas, Texas);  Weihua GENG (Dallas, Texas)
ABSTRACT Systems and methods are described relating to a Poisson Boltzmann machine learning model, which may be executed to predict electrostatic solvation free energy for molecular compounds, such as proteins. Feature data input to the Poisson Boltzmann machine learning model may include multi-weighted colored subgraph centralities, which may be calculated based on edge definitions of pairwise atomic interactions between atoms of a given protein using a generalized exponential function and/or a generalized Lorentz function, either or both of which may be weighted based on atomic rigidity or atomic charge. Predictions of electrostatic solvation free energy performed by the Poisson Boltzmann machine learning model may be used as a basis for ranking candidate compounds for a defined target clinical application.
FILED Tuesday, May 05, 2020
APPL NO 17/637440
CURRENT CPC
Electric Digital Data Processing
G06F 17/13 (20130101)

Computer Systems Based on Specific Computational Models
G06N 7/08 (20130101)

Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology
G16B 15/30 (20190201) Original (OR) Class
G16B 40/00 (20190201)
G16B 45/00 (20190201)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277814 Nivala
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) University of Washington (Seattle, Washington)
ASSIGNEE(S) University of Washington (Seattle, Washington)
INVENTOR(S) Jeffrey Matthew Nivala (Seattle, Washington)
ABSTRACT The disclosure provides compositions, systems, and related method for using nanopore-based detection of nucleic acid displacement circuits. In some embodiments, output strands contain orthogonal barcode sequences that are captured by nanopore systems to produce a unique and recognizable current signal. Machine learning models can be used to differentiate a plurality of current signals and, therefore, monitor detection and quantification of multiple nucleic acid displacement circuits in a single pot reaction.
FILED Friday, July 24, 2020
APPL NO 17/630135
CURRENT CPC
Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 15/00 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6825 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 27/44791 (20130101)
G01N 33/48721 (20130101)

Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology
G16B 30/00 (20190201)
G16B 50/30 (20190201) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277896 Arnold et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Engineering Education and Centers (EEC)
Division of Industrial Innovation and Partnerships (IIP)
APPLICANT(S) University of Florida Research Foundation, Inc. (Gainesville, Florida)
ASSIGNEE(S)
INVENTOR(S) David P. Arnold (Gainesville, Florida);  Ololade D. Oniku (Gainesville, Florida)
ABSTRACT Various embodiments to mitigate the contamination of electroplated cobalt-platinum films on substrates are described. In one embodiment, a method of manufacture of a device includes depositing a diffusion barrier over a substrate, depositing a seed layer upon the diffusion barrier, and depositing a cobalt-platinum magnetic layer upon the seed layer. In a second embodiment, a method of manufacture of a device may include depositing a diffusion barrier over a substrate and depositing a cobalt-platinum magnetic layer upon the diffusion barrier. In a third embodiment, a method of manufacture of a device may include depositing an adhesion layer over a substrate, depositing a seed layer upon the adhesion layer, and depositing a cobalt-platinum magnetic layer over the seed layer. Based in part on these methods of manufacture, improvements in the interfaces between the layers can be achieved after annealing with substantial improvements in the magnetic properties of the cobalt-platinum magnetic layer.
FILED Tuesday, May 17, 2022
APPL NO 17/663737
CURRENT CPC
Processes or Apparatus Specially Adapted for the Manufacture or Treatment of Microstructural Devices or Systems
B81C 1/0038 (20130101)

Magnets; Inductances; Transformers; Selection of Materials for Their Magnetic Properties
H01F 10/30 (20130101)
H01F 10/123 (20130101)
H01F 41/32 (20130101) Original (OR) Class
H01F 41/309 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220278152 Xu
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Electrical, Communications and Cyber Systems (ECCS)
APPLICANT(S) UNIVERSITY OF MASSACHUSETTS (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Guangyu Xu (Amherst, Massachusetts)
ABSTRACT A spectrally filtered photodiode pair includes a substrate having a first photodiode and a second photodiode, wherein the first photodiode is positioned adjacent to the second photodiode. The spectrally filtered photodiode pair further includes a first spectral filter positioned over the first photodiode and a second spectral filter positioned over the second photodiode. The first and second spectral filters comprise particular absorbing dye compositions described herein, selected to filter preselected wavelengths of light. The spectrally filtered photodiode pair can be useful in sensors, particularly when rapid and low-concentration detection is needed.
FILED Wednesday, February 23, 2022
APPL NO 17/678259
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/115 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/582 (20130101)
G01N 33/6863 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 27/14621 (20130101) Original (OR) Class
H01L 27/14645 (20130101)
H01L 27/14685 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220278394 Bolton
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) Onas Bolton (Pepper Pike, Ohio)
ASSIGNEE(S)
INVENTOR(S) Onas Bolton (Pepper Pike, Ohio)
ABSTRACT An electrolyte additive is provided. The additive is a quaternary ammonium or phosphonium salt effective to suppress hydrogen evolution and metal dendrite formation during operation of a zinc electrochemical cell such as a zinc-air battery. A zinc battery cell is also provided, which contains an effective amount of the electrolyte additive.
FILED Tuesday, May 17, 2022
APPL NO 17/746432
CURRENT CPC
Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 12/02 (20130101)
H01M 12/06 (20130101) Original (OR) Class
H01M 2300/0014 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220278523 Wang et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) University of Tennessee Research Foundation (Knoxville, Tennessee)
ASSIGNEE(S)
INVENTOR(S) Fei Wang (Knoxville, Tennessee);  Edward A. Jones (Knoxville, Tennessee)
ABSTRACT A power converter circuit includes a switch including a field effect transistor, the field effect transistor being a wide bandgap field effect transistor and being configured to maintain an on operational state responsive to a maintenance signal received through a gate terminal, a current sensing circuit that is configured to estimate a drain terminal current of the field effect transistor responsive to a voltage between the gate terminal of the field effect transistor and a source terminal of the field effect transistor, and a gate driving circuit that is configured to generate the maintenance signal responsive to the estimate of the drain terminal current.
FILED Thursday, May 19, 2022
APPL NO 17/664163
CURRENT CPC
Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 29/2003 (20130101)
H01L 29/7787 (20130101)

Emergency Protective Circuit Arrangements
H02H 1/0007 (20130101)
H02H 7/122 (20130101)
H02H 7/125 (20130101)
H02H 7/1213 (20130101) Original (OR) Class

Apparatus for Conversion Between AC and AC, Between AC and DC, or Between DC and DC, and for Use With Mains or Similar Power Supply Systems; Conversion of DC or AC Input Power into Surge Output Power; Control or Regulation Thereof
H02M 1/08 (20130101)
H02M 1/32 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220279119 Alshurafa et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Science Foundation (NSF)
Directorate for Computer and Information Science and Engineering (CISE)
Division of Computer and Network Systems (CNS)
APPLICANT(S) Northwestern University (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Nabil I. Alshurafa (Chicago, Illinois);  Josiah D. Hester (Evanston, Illinois)
ABSTRACT A camera system includes a camera configured to capture first video of a scene in the form of first image frames. The camera system also includes an infrared sensor configured to capture second video of the scene in the form of second image frames. The system also includes a processor in communication with the camera and the infrared sensor. The processor is configured to obfuscate one or more portions of the scene.
FILED Wednesday, April 27, 2022
APPL NO 17/730858
CURRENT CPC
Image Data Processing or Generation, in General
G06T 5/003 (20130101)
G06T 5/50 (20130101)
G06T 7/194 (20170101)
G06T 2207/10024 (20130101)
G06T 2207/10048 (20130101)
G06T 2207/20221 (20130101)

Pictorial Communication, e.g Television
H04N 5/76 (20130101)
H04N 5/247 (20130101)
H04N 5/272 (20130101)
H04N 5/2252 (20130101)
H04N 5/2253 (20130101)
H04N 5/23229 (20130101) Original (OR) Class
H04N 7/18 (20130101)
H04N 9/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220279337 Edalat et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Yalda Edalat (Santa Cruz, California);  Katia Obraczka (Santa Cruz, California)
ABSTRACT Techniques for avoiding packet collision in wireless communications networks include initializing a first data indicating a plurality of fixed delay values in a range from a minimum delay to a maximum delay and indicating a corresponding plurality of adjustable weights. A first applied delay for a first packet is determined based on the first data. The first packet if transmitted at a time based on the first applied delay. Based on whether transmission of the first packet was successful the first data is adjusted by reducing a first weight of the plurality of adjustable weights for a corresponding first fixed delay value greater than the first applied delay, or by increasing a second weight of the plurality of adjustable weights for a corresponding second fixed delay value smaller than the first applied delay, or both.
FILED Tuesday, May 17, 2022
APPL NO 17/746618
CURRENT CPC
Transmission of Digital Information, e.g Telegraphic Communication
H04L 43/0852 (20130101)
H04L 47/32 (20130101)
H04L 47/283 (20130101)
H04L 47/2416 (20130101)

Wireless Communication Networks
H04W 8/04 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 

National Aeronautics and Space Administration (NASA) 

US 20220274077 Brewer et al.
FUNDED BY
National Aeronautics and Space Administration (NASA)
APPLICANT(S) Blueshift, LLC dba Outward Technologies (Broomfield, Colorado)
ASSIGNEE(S) Blueshift, LLC dba Outward Technologies (Broomfield, Colorado)
INVENTOR(S) Andrew Timon Brewer (Wheat Ridge, Colorado);  Ryan Garvey (Lafayette, Colorado)
ABSTRACT A solar concentrator reactor system and method of use for high temperature thermochemical processes. In one embodiment, the solar concentrator reactor system produces a thermochemical reaction of irradiated particles within an enclosed vessel volume of a solar concentrator reactor. In one aspect, the solar concentrator reactor system uses a solar concentrator to irradiate particles of a particle stream within an enclosed vessel volume of a solar concentrator reactor. The thermochemical reaction yields a chemical change of the feedstock and/or phase transition of the feedstock such as the production of a molten reacted material from a solid particulate feed. In one embodiment, the particles are a lunar regolith and the thermochemical reaction yields oxygen.
FILED Wednesday, February 09, 2022
APPL NO 17/668206
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 6/008 (20130101) Original (OR) Class
B01J 19/127 (20130101)
B01J 2219/0801 (20130101)
B01J 2219/0879 (20130101)
B01J 2219/1203 (20130101)

Non-metallic Elements; Compounds Thereof;
C01B 5/00 (20130101)
C01B 13/0203 (20130101)
C01B 32/40 (20170801)
C01B 32/50 (20170801)

Solar Heat Collectors; Solar Heat Systems
F24S 20/20 (20180501)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276291 ARUMUGAM
FUNDED BY
National Aeronautics and Space Administration (NASA)
Jet Propulsion Laboratory (JPL)
Federally Funded Research and Development Center (FFRDC)
Operated by California Institute of Technology (CALTECH) at Pasadena, CA
APPLICANT(S) California Institute of Technology (Pasadena, California)
ASSIGNEE(S)
INVENTOR(S) Darmindra D. ARUMUGAM (Pasadena, California)
ABSTRACT Orientation and position sensing methods and devices are disclosed. The described methods and devices are based on implementing magneto-electric-quasi-static fields for position and orientation sensing in lossy-dielectric, conducting, or metallic non-line-of-sight environments, where obstructions or occlusions or nearby objects exists that are lossy in nature and that typically perturb radio or electromagnetic wave signaling. Detailed experimental results highlighting the performance of the disclosed methods are also presented.
FILED Monday, March 21, 2022
APPL NO 17/700116
CURRENT CPC
Measuring Electric Variables; Measuring Magnetic Variables
G01R 29/14 (20130101)
G01R 29/0814 (20130101) Original (OR) Class
G01R 29/0878 (20130101)
G01R 29/0892 (20130101)

Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves
G01S 1/70 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276393 Yang et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
National Aeronautics and Space Administration (NASA)
APPLICANT(S) The Regents of the University of Colorado, a body corporate (Denver, Colorado)
ASSIGNEE(S)
INVENTOR(S) Rong Yang (Boulder, Colorado);  Yu Morton (Boulder, Colorado)
ABSTRACT Various embodiments of the present technology generally relate to multi-frequency satellite navigation receiver technology. More specifically, some embodiments relate to an inter-frequency signal aiding technique for multi-frequency signal tracking in a multi-frequency receiver. The present technology enables a satellite navigation receiver (such as GPS) to continue operation, or to have improved performance, in environments where signals on one or more frequency bands experience fading. Some embodiments can estimate parameters of signal channels that experience fading based on measurements obtained from all or other less compromised frequency bands in linear operation by the receiver. Some embodiments can optimally estimate carrier parameters of navigation signals with consideration of relative measurement qualities. These parameters are used to construct the local reference signals, maintain lock on the fading signals, and obtain accurate positioning solutions and remote sensing observations.
FILED Thursday, August 01, 2019
APPL NO 17/632088
CURRENT CPC
Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves
G01S 19/29 (20130101)
G01S 19/30 (20130101)
G01S 19/32 (20130101)
G01S 19/37 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220277190 Song et al.
FUNDED BY
National Aeronautics and Space Administration (NASA)
APPLICANT(S) ANAFLASH INC. (SUNNYVALE, California)
ASSIGNEE(S)
INVENTOR(S) Seung-Hwan Song (Palo Alto, California);  Sihwan Kim (San Francisco, California)
ABSTRACT A neural network engine configured to perform neural network computations. The neural network engine includes a first memory block configured to provide a first operand; a second memory block configured to provide a second operand; a synapse array configured to produce partial products of the first and second operands, wherein the synapse array is located outside of the first and second memory blocks; and, an accumulator array to perform summation of the partial products produced by the synapse array.
FILED Tuesday, February 22, 2022
APPL NO 17/677772
CURRENT CPC
Electric Digital Data Processing
G06F 7/50 (20130101)

Computer Systems Based on Specific Computational Models
G06N 3/063 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 

Small Business Administration (SBA) 

US 20220273810 Lu et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) IMCARE BIOTECH, LLC (Doylestown, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Xuanyong Lu (Horsham, Pennsylvania);  Felix Lu (Burbank, California)
ABSTRACT Anti-AS-SPIK antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to diagnose and/or treat disorders characterized by the expression of AS-SPIK (e.g., liver cancer). Diagnostic methods and kits comprising the anti-AS-SPIK antibodies are also disclosed.
FILED Wednesday, July 08, 2020
APPL NO 17/625693
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/542 (20170801)
A61K 47/6817 (20170801)
A61K 47/6843 (20170801) Original (OR) Class

Peptides
C07K 16/38 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6893 (20130101)
G01N 2333/811 (20130101)
G01N 2800/50 (20130101)
G01N 2800/085 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220273828 Frank et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) IGL Pharma Inc. (Angleton, Texas)
ASSIGNEE(S) IGL Pharma Inc. (Angelton, Texas)
INVENTOR(S) R. Keith Frank (Lake Jackson, Texas);  Jaime Simon (Angleton, Texas);  Kelli R. Jay (Brazoria, Texas)
ABSTRACT This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.
FILED Saturday, May 21, 2022
APPL NO 17/750333
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/19 (20130101)
A61K 47/02 (20130101)
A61K 51/0482 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20220276265 Kim
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Hyesook Kim (Bloomfield Hills, Michigan)
ASSIGNEE(S) Detroit R and D, Inc. (Bloomfield Hills, Michigan)
INVENTOR(S) Hyesook Kim (Bloomfield Hills, Michigan)
ABSTRACT This invention discloses diagnosis of risk of chemotherapy-induced cardiotoxicity by measurement of increased expression of soluble epoxide hydrolase in vitro and in vivo in cells, tissues or animals including measurement of increased levels of soluble epoxide hydrolase metabolites, e.g., 14,15-DHET and 11,12-DHET, in biological fluids. This invention also includes diagnosis of risk of chemotherapy-induced cardiotoxicity by measuring increased levels of oxidative stress in cells, tissues or animals including measurement of increased levels of oxidative stress biomarkers, e.g., 8-isoprostane, in biological fluids. Fatty acid and protein biomarkers to diagnose the risk of chemotherapy-induced cardiotoxicity are detected using various detection methods including mass spectrometry and immunoassay such as ELISA, Western blot analysis or label-free microwell and nanowell technologies. This invention discloses targeted medical intervention for a subject who is at risk or with chemotherapy-induced cardiotoxicity by treating with soluble epoxide hydrolase inhibitor(s) with or without antioxidants to prevent or ameliorate the chemotherapy-induced cardiotoxicity.
FILED Monday, January 28, 2019
APPL NO 16/259499
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/92 (20130101) Original (OR) Class
G01N 33/573 (20130101)
G01N 33/6887 (20130101)
G01N 2405/00 (20130101)
G01N 2560/00 (20130101)
G01N 2800/32 (20130101)
G01N 2800/42 (20130101)
G01N 2800/50 (20130101)
G01N 2800/52 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Agriculture (USDA) 

US 20220274918 LEW et al.
FUNDED BY
Department of Agriculture (USDA)
APPLICANT(S) The United States of America, as represented by the Secretary of Agriculture (Washington, District of Columbia)
ASSIGNEE(S)
INVENTOR(S) HELEN N. LEW (WYNNEWOOD, Pennsylvania);  XUETONG FAN (NORTH WALES, Pennsylvania);  KUN HUANG (CONSHOHOCKEN, Pennsylvania);  JIANWEI ZHANG (GUANGDONG PROVINCE, Switzerland)
ABSTRACT A biobased fatty acid arginate may be synthesized according to the disclosed process by combining arginine and a fatty acid. The fatty acid arginate may have certain beneficial properties, such as surfactant properties or acting as an antimicrobial agent.
FILED Friday, February 26, 2021
APPL NO 17/186958
CURRENT CPC
Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators
A01N 47/44 (20130101)

Acyclic or Carbocyclic Compounds
C07C 279/14 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Homeland Security (DHS) 

US 20220275978 Jacobs
FUNDED BY
Department of Homeland Security (DHS)
APPLICANT(S) The Government of the United States of America, as represented by the Secretary of Homeland Security (Washington, District of Columbia)
ASSIGNEE(S) The Government of the United States of America, as represented by the Secretary of Homeland Security (Washington, District of Columbia)
INVENTOR(S) Bryson Jacobs (Quaker Hill, Connecticut)
ABSTRACT A thermoacoustic refrigeration assembly includes a resonating tube having a first end and a second end; a first mechanical oscillator at the first end; a second mechanical oscillator at the second end; and a thermoacoustic stack sandwich disposed along a length of the resonating tube through which gas travels. The stack sandwich includes a first outboard heat exchanger on a first side of the stack sandwich facing the first mechanical oscillator, a second outboard heat exchanger on a second side of the stack sandwich facing the second mechanical oscillator, and a center heat exchanger disposed between the first outboard heat exchanger and the second outboard heat exchanger.
FILED Thursday, May 05, 2022
APPL NO 17/737063
CURRENT CPC
Refrigeration Machines, Plants or Systems; Combined Heating and Refrigeration Systems; Heat-pump Systems
F25B 9/145 (20130101) Original (OR) Class
F25B 2309/1407 (20130101)
F25B 2309/1412 (20130101)
F25B 2309/1413 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Veterans Affairs (DVA) 

US 20220273845 Nikkhah et al.
FUNDED BY
Department of Veterans Affairs (DVA)
APPLICANT(S) Arizona Board of Regents on Behalf of Arizona State University (Scottsdale, Arizona);  The United States of America as Represented by The Department of Veterans Affairs (Washington, District of Columbia)
ASSIGNEE(S) Arizona Board of Regents on Behalf of Arizona State University (Scottsdale, Arizona);  The United States of America as Represented by The Department of Veterans Affairs (Washington, District of Columbia)
INVENTOR(S) Mehdi Nikkhah (Scottsdale, Arizona);  Ali Navaei (Tempe, Arizona);  Raymond Migrino (Phoenix, Arizona)
ABSTRACT A method for regeneration or repair of an infarcted myocardium including an infarcted region in an animal comprising injecting into the animal a composition including one or more gold nanostructures is disclosed.
FILED Monday, May 09, 2022
APPL NO 17/740071
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 27/22 (20130101) Original (OR) Class
A61L 27/26 (20130101)
A61L 27/047 (20130101)
A61L 27/54 (20130101)
A61L 27/3604 (20130101)
A61L 27/3804 (20130101)
A61L 27/3821 (20130101)
A61L 27/3826 (20130101)
A61L 27/3873 (20130101)
A61L 27/3886 (20130101)
A61L 27/3895 (20130101)
A61L 2430/20 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0656 (20130101)
C12N 5/0658 (20130101)
C12N 2501/165 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Non-Profit Organization (NPO) 

US 20220273655 SHI et al.
FUNDED BY
Non-Profit Organization (NPO)
California Institute for Regenerative Medicine (CIRM)
APPLICANT(S) CITY OF HOPE (Duarte, California)
ASSIGNEE(S) CITY OF HOPE (Duarte, California)
INVENTOR(S) Yanhong SHI (Arcadia, California);  E. TIAN (Monrovia, California)
ABSTRACT Disclosed herein are methods of reprograming autologous tissues or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds only without any transgenes. Also disclosed are methods of preventing or treating neurodegenerative diseases or neurological disorders associated with dysfunction of astrocytes, such as Alzheimer's Disease, by transplanting the astrocytes or astroglial progenitor cells produced by the methods disclosed herein into the brain of a subject suffering from the neurodegenerative disease or neurological disorder.
FILED Tuesday, March 29, 2022
APPL NO 17/656999
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/19 (20130101)
A61K 31/135 (20130101)
A61K 31/437 (20130101)
A61K 31/444 (20130101)
A61K 31/506 (20130101) Original (OR) Class
A61K 31/4439 (20130101)
A61K 35/30 (20130101)
A61K 38/18 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0622 (20130101)
C12N 2501/01 (20130101)
C12N 2501/15 (20130101)
C12N 2501/065 (20130101)
C12N 2501/115 (20130101)
C12N 2501/603 (20130101)
C12N 2501/727 (20130101)
C12N 2501/999 (20130101)
C12N 2506/1307 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

Government Rights Acknowledged 

US 20220275032 Poznansky et al.
FUNDED BY
APPLICANT(S) The General Hospital Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Mark C. Poznansky (Newton, Massachusetts);  Jeffrey A. Gelfand (Cambridge, Massachusetts)
ABSTRACT This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.
FILED Monday, May 09, 2022
APPL NO 17/739444
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0019 (20130101)

Peptides
C07K 14/35 (20130101) Original (OR) Class
C07K 14/7051 (20130101)
C07K 14/70517 (20130101)
C07K 16/30 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 

How To Use This Page 

THE FEDINVENT PATENT APPLICATION DETAILS PAGE

Each week, FedInvent analyzes newly granted patents and published patent applications whose origins lead back to funding by the US Federal Government. The FedInvent Patent Details page is a companion to the weekly FedInvents Patents Report.

This week's information is published in the FedInvent Patents report for Thursday, September 01, 2022.

The FedInvent Weekly Patent Details Page contains a subset of patent information to provide a deeper dive into the week's taxpayer-funded patents to help the reader better understand where a patent fits in the federal innovation ecosphere.

HOW IS THE INFORMATION ORGANIZED?

Patents are organized by the funding agency. Within each group, the patents are organized in numeric order. A patent funded by more than one agency will appear in the section of each of the agencies that funded the research and development that resulted in the invention. This approach gives the reader a complete view of the department or agency activity for the week.

WHAT INFORMATION WILL I FIND?

THE PANEL
There is a panel for each patent that contains the patent number and the title of the patent. When you click the panel, it opens to reveal the following information:

FUNDED BY
The agencies that funded the grants, contracts, or other research agreements that resulted in the patent. FedInvent includes as much information on the source of the funding as possible. The information is presented in a hierarchy going from the Federal Department down to the agencies, subagencies, and offices that funded the work. Here are two examples:

Department of Health and Human Services (HHS)
     National Institutes of Health (NIH)
         National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Department of Defense (DOD)
     Defense Advanced Research Projects Agency (DARPA)
         Army Research Office (ARO)

We do our best to provide detailed information about the funding. In some cases, the patent only reports limited information on the origins of the funding. FedInvents presents what it can confirm. We add the patents without the information required by the Bayh-Dole Act to our list of patents worthy of further investigation.

APPLICANT(S) and ASSIGNEES
FedInvent includes both the Applicants and the Assignees because having both provides more information about where the inventive work was done and by what organizations. Many organizations — universities, corporations, and federal agencies — standardize the Assignee/Owner information by the time a patent is granted. In the case of federal patents, many of the patents use the agency headquarters information for patent assignment.

Showing just the headquarters address would make Washington, DC the epicenter of all taxpayer-funded research and development. Providing both the applicant information and the assignee information provides a more accurate picture of where important taxpayer-funded innovation is happening in America. Here are two examples from two different patents:

APPLICANT: U.S. Army Research Laboratory, Adelphi, MD
ASSIGNEE: The United States of America as represented by the Secretary of the Army Washington, DC

APPLICANT: Optech Ventures, LLC (Torrance, California)
ASSIGNEE(S): The Regents of the University of California (Oakland, California); Optech Ventures, LLC (Torrance, California)

INVENTOR(S)
The inventors appear in the same order as they appear on the patent. FedInvents presents the names in first name/last name order because they are easier to read than the last name/first name order of the names on the USPTO patent documents.

ABSTRACT
The abstract is presented as it appears on the patent.

FILED
The date the patent application including the day of the week.

APPL NO
This is the patent application serial number. If you’d like to learn more about how application serial numbers work you can go to the Lists Page.

ART UNIT
Patent data includes the Art Unit where a patent was examined. (The Art Unit isn’t available for published patent applications.) The Art Unit provides insight into what group of patent examiners prosecuted the patent application and the subject matter that the examiners work on. For example:

3793 — Medical Instruments, Diagnostic Equipment, and Treatment Devices

You can learn more about ART UNITS on the FedInvent Patents Weekly panel called About Tech Center or you can find information on the FedInvent Lists Page.

CURRENT CPC
Current CPC provides a list of the Cooperative Patent Classification symbols assigned to the patent. These are the CPC symbols assigned at the time the patent was granted.

The FedInvent Project is a patent classification maximalist endeavor or put another way, we believe that the more you understand about patent classification the more you'll learn about the nature of the invention and the types of work that the federal government is funding.

The symbol presented in BOLD is the symbol identified as the "first" classification which is the most relevant classification on the patent. The date that follows the symbol is the date of the most recent revision to the art classed there.

  • A61B 1/149 (20130101)
  • A61B 1/71 (20130101)
  • A61B 1/105 (20130101)

The CPC symbols match the classifications found on the PDF version of the patent. Over time, the classifications on the full text version of the patent change to reflect how USPTO organizes patent art to support its examiners. The two sets of CPCs don’t always match.

VIEW PATENT
As of June 2021, we include two ways to view a patent at USPTO. FedInvent provides a link to the Full-Text Version of the patent and a link to the PDF version of the patent.

HOW DO I FIND A SPECIFIC PATENT ON A PAGE?

You can use the Command F or Control F to find a specific patent you are interested in.

HOW DO I GET HERE?

You navigate to the details of a patent by clicking the information icon that follows a patent on the FedInvent Patents Weekly Report.

You can also reach this page using the weekly page link that looks like this:

https://wayfinder.digital/fedinvent/patents-2022/fedinvent-applications-20220901.html

Just update the date portion of the URL. Tuesdays for patents. Thursdays for pre-grant publication of patent applications.

Download a copy of the How To Use This Page

HAVE MORE QUESTIONS?

info@wayfinder.digital